US 20170202939A1

(19) **United States**

(12) **Patent Application Publication** (10) **Pub. No.: US 2017/0202939 A1**

CARRENO et al. (43) **Pub. Date: Jul. 20, 2017**

(54) **PERSONALIZED CANCER VACCINES AND METHODS THEREFOR**

(71) Applicant: **Washington University**, Saint Louis, MO (US)

(72) Inventors: **Beatriz CARRENO**, Philadelphia, PA (US); **Gerald LINETTE**, Philadelphia, PA (US); **Elaine MARDIS**, Troy, IL (US); **Vincent MAGRINI**, Saint Louis, MO (US)

(21) Appl. No.: **15/458,149**

(22) Filed: **Mar. 14, 2017**

Related U.S. Application Data

(63) Continuation of application No. PCT/US15/49836, filed on Sep. 11, 2015.

(60) Provisional application No. 62/141,602, filed on Apr. 1, 2015, provisional application No. 62/050,195, filed on Sep. 14, 2014.

Publication Classification

(51) **Int. Cl.**

A61K 39/00	(2006.01)
G01N 33/569	(2006.01)
C12N 5/0784	(2006.01)
C12Q 1/68	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 39/0011*** (2013.01); ***C12Q 1/6881*** (2013.01); ***G01N 33/56977*** (2013.01); ***C12N 5/0639*** (2013.01); *A61K 2039/5154* (2013.01); *A61K 2039/572* (2013.01); *C12N 2501/998* (2013.01)

(57) **ABSTRACT**

Methods of cane r treatment based, on personalized vaccines are disclosed. Individual amino acid substitutions from tumors are revealed using whole genome sequencing, and identified as neoantigens silico. Peptide sequences are then tested in vitro for ability to bind HLA molecules and to be presented to CD8+ T-cells. A vaccine is formed using neoantigen peptides and an adjuvant or dendritic cells (DC) autologous to a subject. In the latter, autologous DC are matured and contacted with the neoantigen peptides. The DC are then administered to the subject. PBMC are then obtained from the subject, and CD8+ T cells specific to the neoantigens are cultured and enriched. Enriched T-cells are then administered to the subject to treat cancer. Treatment resulted in tumor regression in mice bearing human melanomas, and complete or partial responses were observed in human patients.

FIG. 1


Identification of patient-specific mutation-directed tumor neo-antigens
Tissue procurement
PBMC/ TUMOR matched sets
EXOME
identification tumor-specific missense mutations
MHC class I binding affinity prediction analysis for candidate neo-antigen identification
TRANSCRIPTOME
identification of expressed candidate neo-antigen
Neo-Antigen Selection
In vitro peptide binding and presentation assays
Personalized patient therapy
Mature DC vaccination
3 vaccine doses using optimal length peptides encoding neo-antigen
T cell expansion
Use a 2 step procedure for antigen-specific expansion of neo-antigen specific T cells
Adoptive T cell therapy
infuse neo-antigen specific T cells in pre-conditioned patients

FIG. 2


TUMOR
PBMC
Tumor somatic mutations n=838
Exome
Missense mutations n=515
Prediction Algorithms
Candidates epitopes
HLA-A2 n=96
Transcriptome
Expressed Candidates
25

FIG. 3


Mean Flourescence Index (MFI)
MFBB7.2 PE
6000
5000
4000
3000
2000
1000
0
100
20
4
0
no pep
FluM1
G280-9V
G17
NP265
AKAP13
ARFGEF
CPNE3
DICER1
GLYR1
HSD17B
IL17RA
IL17RA
MED13L
PRKCD
SEC24A
TAOK1
UTRN
ZYX
ORBB3

FIG. 4


Identification of patient-specific mutation-directed tumor neo-antigens
Tissue procurement
PBMC/ TUMOR matched sets
EXOME
identification tumor-specific missense mutations
MHC class I binding affinity prediction analysis for candidate neo-antigen identification
TRANSCRIPTOME
identification of expressed candidate neo-antigen
Neo-Antigen Selection
In vitro peptide binding and presentation assays
DC generation
Ex vivo differentiation of monocytes into DC
Mutation-specific T cell immunity
ex vivo monitoring to evaluate generation of cytotoxic effectors
DC maturation
Ex vivo instruction to generate appropriate cytotoxic effectors
DC targeting
Loading with selected Missense-encoding peptides
Infusion of DC vaccine


ARFGEF1
CDKN2A
GPX8
KDM1B
PHKA2
TKT
TMEM48
AKAP13
ARFGEF1
HSD17B7
OR8B3
PRKCDBP
SEC24A
UTRN
EXOC8
LARP7
MRPS5
MRPS17
PABPC1
SRP9
SMOX
Pre-Vacc
Post-Vacc
MEL21
MEL38
MEL218
HLA/Ag Dextramer
CD8

FIG. 5

FIG. 6


MUT
WT
Affinity (nM)
100000
10000
1000
100
10
1
ARFGEF1-21
CDKN2A
GPX8
KDM1B
PHKA2
TKT
TMEM48
AKAP13
ARFGEF1-38
HSD17B7
OR6B3
PRKCDBP
SEC24A
UTRN
EXOC8
LARP7
MRPS5
MRPS17
PABPC1
SRP9
SMOX
Stability (h)
100
10
1
0.1
ARFGEF1-21
CDKN2A
GPX8
KDM1B
PHKA2
TKT
TMEM48
AKAP13
ARFGEF1-38
HSD17B7
OR6B3
PRKCDBP
SEC24A
UTRN
EXOC8
LARP7
MRPS5
MRPS17
PABPC1
SRP9
SMOX


AKAP13
OR8B3
SEC24A
Blood (Day 0)
Expanded (Day 20)
HLA/Ag Dextramer
AKAP13 Dex
OR8B3 Dex
SEC24A Dex
CD8
0.11
100
0.12
100
0.62
99
79
0.022
6.1e-3
21
70
30
6.2e-3
0.025
39
61

FIG. 7

Day 0
Day 20
Antigen-Specific T cell Yields (x10⁶)
1000
100
10
1
0.1
0.01
0.001
AKAP13
OR8B3
SEC24A
Ag-Specific T cell Fold (x10³)
200
150
100
50
0
AKAP13
OR8B3
SEC24A

FIG. 8

FIG. 9


pMXsig
Ub-signal
Minigene 1
AKAP13
TGPIFKLMNIQQKLMKTNLN
Minigene 2
Minigene 3
Minigene 4
Minigene 5
Minigene 6
Up to Minigene 14
G280
SVG-9
HA
pMXsig

FIG. 10


AKAP13
IFN-g (ng/ml)
15
10
5
0
media
MUT
WT

FIG. 11


AKAP13
SEC24A
MUT
WT
% Specific Lysis
100
80
60
40
20
0
0.001
0.01
0.1
1
10
100
1000
10000
100000
[Peptide] nM

FIG. 12


OR8B
% Specific Lysis
100
80
60
40
20
0
0.001
0.01
0.1
1
10
100
1000
10000
100000
[Peptide] nM

FIG. 13


AKAP13
Cytokine Production (ng/ml)
40
30
20
10
0
IFN-g
IL-13
IL-5
IL-4
AKAP13
Cytokine Ratio
8
6
4
2
0
IFN-g/IL-13
IFN-g/IL-5
IFN-g/IL-4

FIG. 14


Photon Flux (photon x 10^7/sec)
100000
10000
1000
100
10
1
0.1
0.01
0.001
0 5 10 15 20 25 30 35 40 45 50
Days after tumor inoculation
No T cells
10^6 T cells
10^7 T cells
10^8 T cells

FIG. 15


Days post tumor
0
10
13
26
40
50
No T cells
10^7 T cells
20
15
10
5
x10^5
Photons/sec/cm^2/sr

FIG. 16


untreated
10^6
10^7
10^8
Percent survival
150
100
50
0
p=0.007
0
50
100
150
Day

FIG. 17
(PRIOR ART)
Immunological and Clinical Outcomes



Patient	Sex	Age*	Stage**	Site of metastasis	Clinical Status#	Time of progression^
P1	M	47	4 (M1a)	Subcutaneous (multiple), lymph node	CR	9/23/08; >1416 days
P2	M	70	4 (M1b)	Lung (multiple)	PD	1/16/19; 131 days
P3	M	53	4 (M1a)	Lymph node	PD	5/29/09; 81 days
P4	F	50	4 (M1a)	Subcutaneous (solitary)	PD	1/15/10; 74 days
P5	M	53	4 (M1b)	Lung (multiple)	PR	4/9/10; 352 days
P6	M	38	4 (M1c)	Liver (multiple)	PR	4/13/10; 444 days
P7	M	36	4 (M1b)	Lung (multiple) subcutaneous (multiple)	PD	3/15/11; 63 days



FIG. 18
(PRIOR ART)

Ex-vivo DC IL-12 production and Tc1 profile correlates with clinical outcome (TTP)





FIG. 19
(PRIOR ART)

Weak p35 transcription accounts for the IL-12p70 defect in non-responder patients



FIG. 20

Impaired IL-12p70 production by patient's DC is rescued by a combination of innate and adaptive signals



FIG. 21


A combination of innate and adaptive signals for DC maturation enhances kinetic of response
P2
Maturation signal: CD40L + IFN-γ
G209-2M
G280-9V
% Antigen-specific T cells/CD8
Pre-Vaccine
Post-Vaccine
G209-2M
G280-9V
CD8
P9
Maturation signal: CD40L + IFN-γ + Poly I:C + R848
G209-2M
G280-9V
% Antigen-specific T cells/CD8
Pre-Vaccine
Post-Vaccine
G209-2M
G280-9V
CD8

FIG. 22

A combination of innate and adaptive signals for DC maturation promotes Tc1-polarized immunity



FIG. 23


Cutaneous melanoma harbor a significant mutation burden
Clinical Data
Gender
Age at Diagnosis
Tissue
Survival
Vital Status
MEL1 MEL2 MEL3 MEL4 MEL5 lung MEL5 pancreas MEL6 MEL7 MEL8 MEL9 MEL10 MEL11 MEL12 MEL13 lung MEL13 chest wall
Male Female Male Male Female Male Female Female Male Male Male Female Female
66 47 53 66 64 60 62 55 . 39 53 38 39
Brain Chest wall S. Intestine Stomach Lung Pancreas Lung Lymphnode Brain Adrenal Gl Chest wall Brain Chest wall Lung Chest wall
3 4 16 7+ 9+ 9+ 1+ 8 . 12 17 1 1+
Deceased Deceased Deceased Alive Alive Alive Alive Deceased Deceased Deceased Deceased Deceased Alive
Synonymous & Nonsynonymous Mutations
8000
7000
6000
5000
4000
3000
2000
1000
0
Synonymous
Nonsynonymous
Mutation Frequency
100%
50%
0
C-T
C-G
C-A
A-T
A-G
A-C

FIG. 24


Translating tumor missense mutations into patient-specific vaccines
Exome (missense)
HLA-A2 candidates
Expressed candidates
247
48
15
AKAP13
ARFGEF1
HSD17B7
OR8B3
PRKCDBP
SEC24A
UTRN
Pre-Vaccine
Post-Vaccine
HLA/Ag Dextramer
CD8

FIG. 25


Do Vaccine-Induced Mutation-Specific T cells: Discriminate between MUT and WT sequences? Recognized processed and presented Antigen?
Endogenous Ag
IFN-g (ng/mL)
media
MUT
WT
Stimuli
Peptide
% Specific Lysis
AKAP13
SEC24A
Peptide [nM]

FIG. 26A



FIG. 26B



FIG. 27


MEL21
MEL38
MEL218
LN (1/30/2011)
SKIN (5/10/2012)
SKIN (6/06/2013)
AXILLA (4/19/2012)
BREAST (2/14/2013)
Ab wall (4/16/2013)
LN (4/04/2005)
Missense mutations (all exomic mutations)
Predicted HLA-A*02:01 candidates
Expressed HLA-A*02:01 candidates
HLA-A*02:01 VACCINE NEOANTIGENS
443 (702)
515 (838)
598 (1099)
219 (359)
247 (402)
238 (385)
437 (695)
79
96
111
52
48
46
93
11
11
12
14
16
16
24
7
1
3
2
2
1
2
1
TKT R438W
CDKN2A E153K
TMEM48 F169L
AKAP13 Q285K
SEC24A P469L
OR8B3 T190I
EXOC8 Q656P
MRPS P59L
PABPC1 R520Q

FIG. 28


EXOME
Mutation Calling
CRITERIA
Missense mutations
In silico Epitope Prediction
(NetMHC3.4 algorithm)
9-mer AAS-peptides
with IC50 < 500 nM
cDNA CAPTURE
Transcriptional Expression
CANDIDATE SELECTION
for experimental validation
MANUFACTURE PEPTIDES
Synthesis / Solubility
HLA-A*02:01 Binding Confirmation
(T2 assay, Fluorescence polarization assay)
VACCINE FORMULATION
(≥7 Experimentally Validated Peptides)

FIG. 29


MEL21
Fold
G269-9V
NP265
ARFGEF1 F1637L
CDKN2A E153K
PHDC1 A426V
GPX8 L27P
KDM1B G349E
LRP1B L297F
PCDHB11 P143S
PHKA2 S264F
PTPRK P137S
TKT R436W
TMEM45 P169L
MEL38
Fold
G269-9V
NP265
AKAP13 G285K
ARFGEF1 R762C
CPNE3 P446L
DICER1 Y153C
GLYR1 P366L
HSD17B7 H108Y
IL17RA T326M
MED13L G2045W
ORBB3 T198I
PRKCDBP S153F
SEC24A P469L
TAOK1 A196V
UTRN G1658R
ZYX P315S
MEL218
Fold
G269-9V
NP265
ABCD1 P508L
ALMS1 S934L
CDC14B K253R
DNAL2 D662V
EXOC8 Q658P
FBXO7 P160L
HLA-DRB5 K14E
LARP7 N515D
MRPS5 P55L
MRPS17 P167L
PABPC1 R529Q
RNASEK P10L
SMOX K499N
SRP9 I64M
TPP2 W1168L

FIG. 30A


CDKN2A E153K
TMEM48 F169L
TKT R438W
MEL21
Dextramer/CD8 T cells x10^4
AKAP13 Q285K
OR8B3 T190I
SEC24A P469L
MEL38
EXOC8 Q656P
MRPS5 P59L
PABPC1 R520Q
MEL218
Weeks of Treatment

FIG. 30B


Pre-Vaccine
Post-Vaccine
MEL21
Blood
Ex-vivo expanded
TMEM48 F169L
TMEM48 Dex
0.4
2.6
TMEM48 F169L
TKT R438W
CDKN2A E153K
TKT Dex
CDKN2A Dex
0.1
0.9
0.06
75
33
91
MEL38
SEC24A P469L
SEC24A Dex
0.1
3.3
SEC24A P469L
AKAP13 Q285K
OR8B3 T190I
AKAP13 Dex
OR8B3 Dex
0.6
0.1
0.1
39
56
70
MEL218
EXOC8 Q656P
EXOC8 Dex
0.03
24
EXOC8 Q656P
PABPC1 R520Q
MRPS5 P59L
OR8B3 Dex
PABPC1 Dex
MRPS5 Dex
PABPC1
0.1
0.09
0.1
30
90
72
HLA-A*A02:01/AAS-peptide dextramer
CD8

FIG. 30C


IFN-g Production (pg/ml)
2500
2000
1500
1000
500
0
TMEM48 F169L
SEC24A P469L
EXOC8 Q656P


MEL21
ARFGEF1 F1637L
CDKN2A E153K
GPX8 L27P
KDM1B G394E
PHKA2 S264F
TKT R438W
TMEM48 F169L
Pre-Vaccine
Post-Vaccine
MEL38
AKAP13 Q285K
ARFGEF1 R782C
HSD17B7 H108Y
OR8B3 T190I
PRKCDBP S153F
SEC24A P469L
UTRN Q1058K
Pre-Vaccine
Post-Vaccine
MEL218
EXOC8 Q656P
LARP7 N515D
MRPS5 P59L
MRPS17 P167L
PABPC1 R520Q
SRP9 I64M
SMOX K499N
Pre-Vaccine
Post-Vaccine
HLA-A*A02:01/AAS-peptide dextramer
CD8

FIG. 31

FIG. 32


Pre-Vaccine
Post-Vaccine
G209-2M
G280-9V
G209-2M
G280-9V
MEL21
Blood
0.07
0.1
0.2
0.1
Ex-vivo expanded
26
24
54
54
MEL38
Blood
0.03
0.03
0.1
0.1
Ex-vivo expanded
0.2
0.5
65
59
MEL218
Blood
0.03
0.03
0.1
0.1
Ex-vivo expanded
47
2
84
65
HLA-A*A02:01/AAS-peptide dextramer
CD8

FIG. 33


MEL21
G209-2M
G280-9V
Dextramer/CD8 T cells x10⁴
400
350
300
200
150
100
50
0
0
5
10
15
20
MEL38
Dextramer/CD8 T cells x10⁴
200
150
100
50
0
0
5
10
15
20
MEL218
Dextramer/CD8 T cells x10⁴
400
300
200
100
50
0
0
5
10
15
20
Weeks of Treatment

FIG. 34


MEL 21
MEL 38
MEL 218
% Specific Lysis
[Peptide] nM
TMEM48 F169L
TKT R438W
CDKN2A E153K
SEC24A P469L
AKAP13 Q285K
OR8B3 T190I
EXOC8 Q656P
PABC1 R520Q
MRPS5 P59L

FIG. 35


MEL21
TMEM48 F169L
TKT R438W
CDKN2A E153K
MEL38
SEC24A P469L
AKAP13 Q285K
OR8B3 T190I
MEL218
EXOC8 Q656P
PABPC1 R520Q
MRPS5 P59L
Cytokine Production (pg/ml)
100000
10000
1000
100
10
1
IFN-g
IL-13
IL-5
IL-4

FIG. 36


MEL21
TMEM48 F169L
TKT R438W
CDKN2A E153K
MEL38
SEC24A P469L
AKAP13 Q285K
OR8B3 T190I
MEL218
EXOC8 Q656P
PABPC1 R520Q
MRPS5 P59L
Cytokine Ratio
IGN-g/IL-13
IGN-g/IL-5
IGN-g/IL-4

FIG. 37A



FIG. 37B



FIG. 38


MEL 21
TMEM48 F169L
TKT R438W
CDKN2A E153K
MEL 38
SEC24A P469L
AKAP13 Q285K
OR8B3 T190I
MEL 218
EXOC8 Q656P
PABC1 R520Q
MRPS5 P59L
E:T Ratio
15:1 7.5:1 3.75:1 1.8:1
60:1 30:1 15:1 7.5:1 3.75:1
30:1 15:1 7.5:1 3.25:1 1.1:1
30:1 15:1 7.5:1 3.25:1 1.8:1
30:1 15:1 7.5:1 3.25:1 0.9:1

FIG. 39


MEL 21
MEL 38
MEL 218
TMEM48 F169L
TKT R438W
CDKN2A E153K
SEC24A P469L
AKAP13 Q285K
OR8B3 T190I
EXOC8 Q656P
PABC1 R520Q
MRPS5 P59L
IFN-g (ng/mL)
media
AAS
WT
Stimuli

FIG. 40A



FIG. 40B



FIG. 40C



FIG. 40D



FIG. 40E



FIG. 40G



FIG. 40F



FIG. 40H



FIG. 41A



FIG. 41C



FIG. 41B

FIG. 41D

FIG. 42


Neoantigen-specific CD8+ T cell TCRβ CDR3 Reference Library
Purified (post-vaccine) CD8+ T cells + AAS-peptide
Neo-antigen-specific CD8+ T cell lines (HLA-A*02:01/AAS-peptide dextramer+)
cell sorting (97-99% dextramer+)
Next-generation sequencing (NGS)
Neoantigen-specific TCRβ CDR3 LIBRARY
Select Neoantigen TCRβ clonotypes, frequency > 0.1%
Pre-vaccine PBMC
Post-vaccine PBMC
Purified CD8+ T cells
Purified CD8+ T cells
PROBE
CD8+ T cell TCRβ CDR3 clonotypes
CD8+ T cell TCRβ CDR3 clonotypes
IDENTIFY
Neoantigen-specific TCRβ repertoire
Neoantigen-specific TCRβ repertoire

FIG. 43A


A
TMEM48 F169L
0.065
97
0.26
2.6
TKT R438W
0.12
99
0.11
1.2
SEC24A P469L
0.062
99
0.26
1
AKAP13 Q285K
0.031
99
0.38
0.11
EXOC8 Q656P
0.04
98
0.27
1.4
PABPC1 R520Q
0.071
97
0.69
2.5
HLA-A*02:01/AAS-peptide dextramer
CD8
0 10^1 10^2 10^3 10^4

FIG. 43B


TMEM48 F169L (n=10)
TKT R438W (n=84)
SEC24A P469L (n=60)
AKAP1 Q285K (n=19)
EXOC8 Q656P (n=13)
PABPC1 R520Q (n=12)
Reads (%)
Reads (%)

FIG. 44A


MEL21
MEL38
MEL218
Frequency (%)
Pre
Post
p=0.002
p<0.0001
p<0.001
p<0.005
TMEM48 F169L
TKT R438W
SEC24A P469L
AKAP Q285K
EXOC8 Q656P
PABPC1 R520Q

FIG. 44B


MEL21 TKT R438W
MEL218 EXOC8 Q656P
MEL38 SEC24A P469L
Frequency (%)
10^0
10^-1
10^-2
10^-3
10^-4
<1

FIG. 45


HLA-A*02:01
HLA-B*08:01
Axilla (07/18/2013)
Limb (10/29/2013)
Axilla (07/18/2013)
Limb (10/29/2013)
Missense mutations (all exomic mutations)
2182 (3442)
1858 (2873)
2182 (3442)
1858 (2873)
Predicted HLA-class I candidates
432
377
185
152
Expressed HLA-class I candidates
220
204
92
79
HLA-class I VACCINE NEOANTIGENS
GCN1L1 P274L
ZDBF2 S2228L
AKAP9 L974F
ATP2B4 L934F
SOCS6 P134L
TLE2 E288K
66
154
49
36
56
23

FIG. 46


HLA-A*02:01
HLA-A*11:01
Skin/Limb (11/22/2013)
Skin/Scalp (11/22/2013)
Skin/Limb (11/22/2013)
Skin/Scalp (11/22/2013)
Missense mutations (all exomic mutations)
141 (256)
162 (282)
141 (256)
162 (282)
Predicted HLA-class I candidates
25
34
25
31
Expressed HLA-class I candidates
6
12
7
11
HLA-class I VACCINE NEOANTIGENS
MPV17 R75G
RUFY1 K225N
6
6
SIPA1L3 S893F
ERCC6L V476I
SMARCC2 S624F
7
4

FIG. 47

Patient	MEL66	MEL69
HLA restriction	HLA-B*08:01	HLA-A*11:01
Neoantigen ID	SOCS6 *P134L*	ERCC6L *V476I*
AA sequence	SLRSHHYSL	KIYRRQIFK



PERSONALIZED CANCER VACCINES AND METHODS THEREFOR

REFERENCE TO PRIOR APPLICATIONS

[0001] This application claims the benefit of and priority to PCT application PCT/US15/49836, filed Sep. 11, 2015. which claims benefit of and priority to U.S. Provisional Application 62/050,195 filed on Sep. 14, 2014. PCT/US15/49836 also claims the benefit of and priority to U.S. Provisional Application 62/141,602 filed Apr. 1, 2015. Each of these applications are hereby incorporated by reference, each in their entirety.

STATEMENT OF GOVERNMENT SUPPORT

[0002] This invention was made with government support under CA179695 awarded by the National Institutes of Health. The government has certain rights in the invention.

REFERENCE TO A SEQUENCE LISTING

[0003] The Sequence Listing, which is a part of the present disclosure, includes a text file comprising primer nucleotide and/or amino acid sequences of the present invention. The subject matter of the Sequence Listing is incorporated herein by reference in its entirety. The information recorded in computer readable form is identical to the written sequence listing.

INTRODUCTION

[0004] The incidence of malignant melanoma continues to rise worldwide. The number of new cases, in the US for 2012 is estimated to be 76,250 (8.6% increase compared to 2011) (Siegel, R., et al., Cancer statistics, 62, 10-29 2012). Despite recent advances in the treatment of metastatic melanoma with ipilimumab (anti-CTLA-4 antibody) and vemurafenib (BRAF V600E inhibitor), this disease remains an incurable malignancy with an expected survival of 12-14 months (Hodi, F. S., et al., N. Engl. J. Med. 363, 711-723, 2010; Chapman, P. B., et al., N. Engl. J. Med. 364, 2507-2516, 2011). Thus, metastatic melanoma represents a disease area of unmet medical need. Melanoma is distinguished for its association with early in life UV-light exposure, high mutational rate, and the ability to induce spontaneous antitumor immunity (Lennerz, V., et al., Proc. Nat'l. Acad. Sci. USA 102, 16013-16018, 2005; Garibyan, L., et al., Curr. Oncol. Rep. 12, 319-326, 2010; Pleasance, E. D. et al., Nature 463, 191-196, 2010; Berger, M. F., et al., Nature 485, 502-506, 2012; Hodis, E., et al., Cell 150, 251-263, 2012). The modest, yet reproducible, clinical activity of ipilimumab seen in patients with advanced melanoma provides strong evidence that immune targeting confers therapeutic benefit in this disease. Investigational cancer vaccines as well as adoptive T cell therapies while more technically demanding are now beginning to show efficacy in early phase clinical trials (Rosenberg, S. A. Science Translational Medicine 4, 127ps128, 2012).

[0005] However, a critical barrier facing investigators developing these cellular therapies is the paucity of validated melanoma antigens. New strategies are needed to identify patient-specific (unique) tumor antigens, which can serve as targets for immune intervention. Identification of the entire spectrum of unique antigens at the single tumor/patient level has been viewed historically as an unattainable goal.

SUMMARY

[0006] The present inventors have developed anti-cancer vaccines, methods of constructing vaccines, methods of their use, and methods of identifying neoantigens create personalized vaccines to treat cancer. In various embodiments, the present teachings provide methods for identification of tumor-specific neoantigens and their incorporation in a vaccine, and adoptive T cell therapy for the treatment of cancers such as, without limitation, melanoma and lung cancer. Various embodiments involve patient-specific identification of tumor neo-antigens. In various configurations, such tumor neo-antigens, such as those arising during neoplastic transformation, can elicit T cell immunity capable of protecting the host from cancer progression. In various embodiments, the present teachings make use of next-generation sequencing technology, human leukocyte antigens (HLA) class I binding/stability prediction algorithms and in vitro assays to identify personalized tumor neoantigens. In various embodiments, these technologies can be incorporated into a vaccine/adoptive T cell therapy for treatment of cancer.

[0007] In some embodiments, the present teachings include strategies for personalized neoantigen-specific adoptive T cell therapy. In various aspects, DNA isolated from tumor and matched peripheral blood mononuclear cells (PBMC) can be subjected to exome sequencing to identify tumor somatic missense mutations. In some embodiments, RNA isolated from a tumor can be used for transcriptome analysis to identify those somatic mutations that are expressed. In some aspects, results can show that in cancers such as melanoma and lung cancer, a high number of missense mutations (>200) can be identified per tumor genome. In some embodiments, a combination of major histocompatibility complex (MHC) class I binding and stability prediction algorithms can be used to identify candidate neo-antigens among missense mutations, and expressed candidate neo-antigens can be selected for, peptide manufacturing. Biochemical and cellular assays can be performed to established binding and presentation of neo antigen-encoding peptides. Experimentally validated peptides can be selected for incorporation in a dendritic cell (DC) vaccine as described in Carreno, B. M., et al., J. Clin. Invest. 123, 3383-3394, 2013; after 3 vaccine doses patients can be subjected to apheresis and CD8+ T cells can be isolated from PBMC. These T cells can be expanded in an antigen-specific manner using a 2 step procedure as described in Carreno, B. M., et al., J. Immunology 188, 5839-5849, 2012. In various configurations, the 2 step procedure can take 10-30 days, such as, without limitation, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days or 30 days for completion and can yield>10^4 fold antigen-specific T cell expansions. In various configurations, expanded neo-antigen specific T cells, can be infused into pre-conditioned patients as adoptive T cell therapy, by, for example, methods described by Linette, G. P. et al., Clin. Cancer Res. 11, 7692-7699, 2005.

[0008] In various configurations, the present teachings include a series of analytical steps for identification of neo-antigens from somatic tumor missense mutations, as illustrated in FIG. **1**. In various embodiments, DNA isolated from tumor and matched PBMC can be subjected to exome sequencing in order to identify tumor somatic missense

mutations. For example, in melanoma and lung cancer high number of missense mutations (>200) can be identified per tumor genome. Prediction algorithms such as, without limitation, PePSSI (Bui, H. H., et al., Proteins 63, 43-52, 2006) can be used for the identification of candidate tumor neoantigen epitopes presented in the context of the patient's HLA class I molecules. In various configurations, analysis of tumor transcriptome data can be used for the selection, among predicted candidates, of those epitopes that are expressed by the tumor.

[0009] Various embodiments of the present teachings include the following aspects: In some embodiments, a method of treating a cancer in a subject in need thereof can comprise: providing a neoantigen peptide encoded in DNA of a tumor of the subject, wherein the neoantigen peptide can consist of from 8 to 13 amino acids; transfecting at least one HLA class I positive cell with at least one tandem minigene construct that can comprise at least one sequence that can encode the at least one neoantigen; identifying a complex that can comprise the at least one HLA molecule and the at least one neoantigen peptide produced by the at least one HLA class I positive cell; forming a vaccine that can comprise the at least one neoantigen; and administering the vaccine to the subject, wherein at least one tumor cell of the cancer can comprise at least one polypeptide which can comprise at least one amino acid substitution. In some configurations, the at least one neoantigen peptide can consist of from 9 to 11 amino acids. In some configurations, the at least one neoantigen peptide can consist of 9 amino acids. In various configurations, the at least one neoantigen peptide can consist of 8, 9, 10, 11, 12, or 13 amino acids. In some configurations, the at least one neoantigen peptide can bind in silico to an HLA class I molecule with a stability>2 h. In some configurations, the at least one neoantigen peptide can bind in silico to an HLA class I molecule an affinity of <500 nM. In some configurations, the at least one neoantigen peptide can bind in silico to an HLA class I molecule with an affinity of <250 nM. In various configurations, the at least one neoantigen peptide can bind in silico to an HLA Class I molecule with an affinity of <550 nM, <500 nM, <450 nM, <400 nM, <350 nM, <300 nM, <250 nM, or <200 nM. In various configurations, the at least one neoantigen peptide can bind in vitro to an HLA class I molecule with an affinity of <4.7 log (IC_{50}, nM), <4.6 log (IC_{50}, nM), <4.5 log (IC_{50}, nM), <4.4 log (IC_{50}, nM), <4.3 log (IC_{50}, nM), <4.2 log (IC_{50}, nM), <4.1 log (IC_{50}, nM), <4.0 log nM), <3.9 log (IC_{50}, nM), <3.8 log (IC_{50}, nM), or <3.7 log (IC_{50}, nM). In some configurations, the at least one neoantigen peptide can bind in vitro to an HLA class I molecule with an affinity of <4.7 log (IC_{50}, nM). In some configurations, the at least one neoantigen peptide can bind in vitro to an HLA class I molecule with an affinity of <3.8 log (IC_{50}, nM). In some configurations, the at least one neoantigen peptide can bind in vitro to an HLA class I molecule with an affinity of <3.7 log (IC_{50}, nM). In some configurations, the at least one neoantigen peptide can bind in vitro to an HLA class I molecule with an affinity of <3.2 log (IC_{50}, nM). In some configurations, the vaccine can comprise at least seven neoantigen peptides. In various configurations, the HLA class I molecules can be selected from the group consisting of HLA-A*01:01, HLA-B*07:02, HLA-A*02:01, HLA-B*07:03, HLA-A*02:02, HLA-B*08:01, HLA-A*02:03, HLA-B*15:01, HLA-A*02:05, HLA-B*15:02, HLA-A*02:06, HLA-B*15:03, HLA-A*02:07, HLA-B*15:08, HLA-A*03:01, HLA-B*15:12, HLA-A*11:01, HLA-B*15:16, HLA-A*11:02, HLA-B*15:18, HLA-A*24:02, HLA-B*27:03, HLA-A*29:01, HLA-B*27:05, HLA-A*29:02, HLA-B*27:08, HLA-A*34:02, HLA-B*35:01, HLA-A*36:01, HLA-B*35:08, HLA-B*42:01, HLA-B*53:01, HLA-B*54:01, HLA-B*56:01, HLA-B*56:02, HLA-B*57:01, HLA-B*57:02, HLA-B*57:03, HLA-B*58:01, HLA-B*67:01, and HLA-B*81:01. In some configurations, the HLA class I molecules can be HLA-A*02:01 molecules. In some configurations, the HLA class I molecules can be HLA-A*11:01 molecules. In some configurations, the HLA class I molecules can be HLA-B*08:01 molecules. In some configurations, the at least one HLA class I positive cell can be at least one melanoma cell. In various configurations, the at least one melanoma cell can be selected from the group consisting of DM6 cell and an A375 cell. In some configurations, the tandem minigene can further comprise a ubiquitination signal and two mini-gene controls. In configurations where the neoantigens bind HLA-A*2:01 molecules, the tandem minigene can further comprise a ubiquitination signal and two mini-gene controls that encode HLA-A*02:01 peptides G280 and WNV SVG9. In various configurations, the cancer can be selected from the group consisting of skin cancer, lung cancer, bladder cancer, colorectal cancer, gastrointestinal cancer, esophageal cancer, gastric cancer, intestinal cancer, breast cancer, and a cancer caused by a mismatch repair deficiency. In various configurations, the skin cancer can be selected from the group consisting of basal cell carcinoma, squamous cell carcinoma, merkel cell carcinoma, and melanoma. In some configurations, the cancer can be a melanoma. In some configurations, the forming a vaccine can comprise: providing a culture comprising dendritic cells obtained from the subject; and contacting the dendritic cells with the at least one neoantigen peptide, thereby forming dendritic cells comprising the at least one neoantigen peptide. In some configurations, the forming a vaccine can further comprise maturing the dendritic cells. In some configurations, the maturing the dendritic cells can comprise administering CD40L and IFNγ. In various configurations, the maturing the dendritic cells can further comprise administering TLR agonist. In various configurations, the maturing the dendritic cells can further comprise administering a TLR3 agonist. In various configurations, the maturing the dendritic cells can further comprise administering a TLR8 agonist. In various configurations, the maturing the dendritic cells can further comprise administering TLR3 and TLR8 agonists. In various configurations, the maturing the dendritic cells can further comprise administering poly I:C and R848. In some configurations, the forming a vaccine can further comprise: administering to the subject the dendritic cells comprising the at least one neoantigen peptide; obtaining a population of CD8+ T cells from a peripheral blood sample from the subject, wherein the CD8+ cells recognize the at least one neoantigen; and expanding the population of CD8+ T cells that recognize the neoantigen. In some configurations, the forming a vaccine can further comprise administering to the subject the expanded CD8+ T cells. In various configurations, the forming a vaccine can comprise combining the neoantigen peptide with a pharmaceutically acceptable adjuvant.

[0010] In some embodiments, a method of treating a cancer in a subject in need thereof, can comprise: a) providing a sample of a tumor from a subject; b) performing

exome sequencing on the sample to identify one or more amino acid substitutions comprised by the tumor exome; c) performing transcriptome sequencing on the sample to verify expression of the amino acid substitutions identified in b); and d) selecting at least one candidate neoantigen peptide sequence from amongst the amino acid substitutions identified in c) according to the following criteria: i) Exome VAF>10%; ii) Transcription VAF>10%; iii) Alternate reads>5; iv) FPKM>1. v) binds in silico to an HLA class I molecule with an affinity of <500 nM and a stability>2 h; e) performing an in vitro HLA class I binding assay; f) selecting at least one candidate neoantigen peptide sequence from amongst the amino acid substitutions identified in d) that bind HLA class one molecules with an affinity of <4.7 log (IC_{50}, nM) in the assay performed in e); g) transfecting at least one HLA class I positive cell with at least one tandem minigene construct which can comprise at least one sequence encoding the at least one neoantigen; identifying a complex comprising the at least one HLA molecule and the at least one neoantigen peptide produced by the at least one HLA class I positive cell; i) forming a vaccine that can comprise the at least one neoantigen; and j) administering the vaccine to the subject, wherein at least one tumor cell of the cancer can comprise at least one polypeptide comprising the one or more amino acid substitutions. In some configurations, the Exome VAF can be ≥30%. In some configurations, the Exome VAF can be ≥40%. In some configurations, the Exome VAF can be ≥50%. In various configurations, the in vitro HLA class I binding assay can be selected from the group consisting of a T2 assay and a fluorescence polarization assay.

[0011] In some embodiments, a method of treating cancer in a subject in need thereof can comprise: a) providing a sample of a tumor from a subject; b) performing exome sequencing on the sample to identify amino acid substitutions comprised by the tumor exome; c) performing transcriptome sequencing on the sample to verify expression of the amino acid substitutions identified in b); d) performing a fluorescence polarization binding assay or a T2 assay of amino acid substitutions identified in c) to an HLA class I molecule; e) selecting at least one candidate neoantigen from amongst the amino acid substitutions identified in d) according to the following criteria: i) Exome variant allele fraction (VAF)>10%; ii) Transcriptome (seq capture data) VAF>10%; is iii) Alternate reads>5; iv) fragments per kilobase of exon per million fragments mapped (FPKM) (>1; v) Peptides comprise 9-11 amino acids; vi) Peptides are predicted in silico to bind to any HLA class I allele that meet the following criteria: A) Predicted MHC binding<250 nM; B) Predicted MHC stability>2 h; vii) MHC binding<3.2 log [IC_{50}, nM] in fluorescence polarization binding assay; f) transfecting at least one HLA class I positive cell line such as a melanoma cell line with at least one tandem minigene construct comprising at least one sequence encoding the at least one candidate neoantigen identified in e); g) extracting from the at least one HLA class I positive cell line one or more HLA class I complexes comprising a HLA class I molecule and the one or more neoantigen peptides; h) identifying the sequence of at least one neoantigen peptide comprised by the soluble HLA class I complex using reverse phase HPLC and LC/MS; i) contacting dendritic cells obtained from the subject with the at least one neoantigen peptide of sequence identified in h), thereby forming dendritic cells comprising the at least one neoantigen peptide; j) administering to the subject the dendritic cells comprising the at least one neoantigen peptide; k) obtaining CD8+ T cells from a peripheral blood sample from the subject; l) enriching the CD8+ T cells that recognize the at least one neoantigen; m) administering to the subject the enriched CD8+ T cells. In some configurations of the present teachings, the HLA class I molecules can be selected from the group consisting of HLA-A*01:01, HLA-B*07:02, HLA-A*02:01, HLA-B*07:03, HLA-A*02:02, HLA-B*08:01, HLA-A*02:03, HLA-B*15:01, HLA-A*02:05, HLA-B*15:02, HLA-A*02:06, HLA-B*15:03, HLA-A*02:07, HLA-B*15:08, HLA-A*03:01, HLA-B*15:12, HLA-A*11:01, HLA-B*15:16, HLA-A*11:02, HLA-B*15:18, HLA-A*24:02, HLA-B*27:03, HLA-A*29:01, HLA-B*27:05, HLA-A*29:02, HLA-B*27:08, HLA-A*34:02, HLA-B*35:01, HLA-A*36:01, HLA-B*35:08, HLA-B*42:01, HLA-B*53:01, HLA-B*54:01, HLA-B*56:01, HLA-B*56:02, HLA-B*57:01, HLA-B*57:02, HLA-B*57:03, HLA-B*58:01, HLA-B*67:01, and HLA-B*81:01. In some configurations, the HLA class I molecules can be HLA-A*02:01 molecules. In some configurations, the HLA class I molecules can be HLA-A*11:01 molecules. In some configurations, the HLA class I molecules can be HLA-B*08:01 molecules. In various configurations, the melanoma cell line can be selected from the group consisting of DM6 and A375. In some configurations, the tandem minigene can further comprise a ubiquitination signal and two mini-gene controls. In configurations where the HLA-A molecules are HLA-A*02:01 molecules, the two mini-gene controls can encode G280 and WNV SVG9 peptides. In some configurations, the cancer can be a melanoma. In various configurations, the melanoma is a metastatic melanoma.

[0012] In some configurations, as many as 600 amino acid substitutions can be identified from any given tumor. In some configurations, each of these amino acid substitutions can be analyzed for predicted binding to HLA-A class I molecules. In various configurations, at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 11, at least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, at least 40, at least 41, at least 42, at least 43, at least 44, at least 45, at least 46, at least 47, at least 48, at least 49 or at least 50 candidate neoantigens can be expressed in a tumor. In some configurations, at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 31, at least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, at least 40, at least 41, at least 42, at least 43, at least 44, at least 45, at least 46, at least 47, at least 48, at least 49 or at least 50 candidate neoantigens can be selected to test their presentation to T cells. In some configurations, at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 31, at least 32, at least 33, at least 34, at least

35, at least 36, at least 37, at least 38, at least 39, at least 40, at least 41, at least 42, at least 43, at least 44, at least 45, at least 46, at least 47, at least 48, at least 49 or at least 50 candidate neoantigens can be selected for incorporation into a vaccine. In some configurations, the tandem minigenes can comprise at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 31, at least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, at least 40, at least 41, at least 42, at least 43, at least 44, at least 45, at least 46, at least 47, at least 48, at least 49 or at least 50 candidate neoantigen sequences. In some configurations, the dendritic cells can comprise at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 31, at least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, at least 40, at least 41, at least 42, at least 43, at least 44, at least 45, at least 46, at least 47, at least 48, at least 49 or at least 50 neoantigen peptides. In some embodiments, the personalized neoantigen therapy can be paired with other forms of cancer therapy such as, but without limitation, chemotherapy. In some configurations, the chemotherapy can comprise ipilimumab and/or vemurafenib.

[0013] In some embodiments, the present teachings include a neoantigen peptide encoded in DNA of a tumor of the subject for use in the treatment of a cancer, wherein the neoantigen peptide consists of from 8 to 13 amino acids, binds in silico to an HLA class I molecule with an affinity of <500 nM and a stability>2 h and binds in vitro to an HLA class I molecule with an affinity of <4.7 log (IC_{50}, nM).

[0014] In various embodiments of the invention, it includes the following aspects;

[0015] 1. A method of treating a cancer in a subject in need thereof, comprising: providing a neoantigen peptide encoded in DNA of a tumor of the subject, wherein the neoantigen peptide consists of from 8 to 13 amino acids, binds in silico to an HLA class I molecule with an affinity of <500 nM and a stability>2 h and binds in vitro to an HLA class I molecule with an affinity of <4.7 log (IC50, nM); transfecting at least one HLA class I positive cell with at least one tandem minigene construct comprising at least one sequence encoding the at least one neoantigen; identifying a complex comprising the at least one HLA molecule and the at least one neoantigen peptide produced by the at least one HLA class I positive cell; forming a vaccine comprising the at least one neoantigen; and administering the vaccine to the subject, wherein at least one tumor cell of the cancer comprises at least one polypeptide comprising at least one amino acid substitution.

[0016] 2. A method in accordance with aspect 1, wherein the at least one neoantigen peptide consists of from 9 to 11 amino acids.

[0017] 3. A method in accordance with aspect 1, wherein the at least one neoantigen peptide consists of 9 amino acids.

[0018] 4. A method in accordance with aspect 1, wherein the at least one neoantigen binds in silico to an HLA class I molecule with an affinity of <250 nM.

[0019] 5. A method in accordance with aspect 1, wherein the at least one neoantigen binds in vitro to an class I molecule with an affinity of <3.8 log (IC50, nM).

[0020] 6. A method in accordance with aspect 1, wherein the at least one neoantigen binds in vitro to an HLA class I molecule with an affinity of <3.7 log (IC50, nM).

[0021] 7. A method in accordance with aspect 1, wherein the at least one neoantigen binds in vitro to an HLA class I molecule with an affinity of <3.2 log (IC50, nM).

[0022] 8. A method in accordance with aspect 1, wherein the vaccine comprises at least seven neoantigen peptides.

[0023] 9. A method in accordance with aspect 1, wherein the HLA class I molecule is selected from the group consisting of HLA-A*01:01, HLA-B*07:02, HLA-A*02:01, HLA-B*07:03, HLA-A*02:02, HLA-B*08:01, HLA-A*02:03, HLA-B*15:01, HLA-A*02:05, HLA-B*15:02, HLA-A*02:06, HLA-B*15:03, HLA-A*02:07, HLA-B*15:08, HLA-*03:01, HLA-B*15:12, HLA-A*11:01, HLA-B*15:16, HLA-A*11:02, HLA-B*15:18, HLA-A*24:02, HLA-B*27:03, HLA-A*29:01, HLA-B*27:05, HLA-A*29:02, HLA-B*27:08, HLA-A34:02, HLA-B*35:01, HLA-A*36:01, HLA-B*35:08, HLA-B*42:01, HLA-B*53:01, HLA-B*54:01, HLA-B*56:01, HLA-B*56:02, HLA-B*57:01, HLA-B*57:02, HLA-B*57:03, HLA-B*58:01, HLA-B*67:01 and HLA-B*81:01.

[0024] 10. A method in accordance with aspect 1, wherein the HLA class I molecule is an HLA-A*02:01 molecule.

[0025] 11. A method in accordance with aspect 1, wherein the HLA class I molecule is an HLA-A*11:01 molecule.

[0026] 12. A method in accordance with aspect 1, wherein the HLA class I molecule is an HLA-B*08:01 molecule.

[0027] 13. A method in accordance with aspect 1, wherein the at least one HLA class I positive cell is at least one HLA class I positive melanoma cell.

[0028] 14. A method in accordance with aspect 13, wherein the at least one HLA class I positive melanoma cell is selected from the group consisting of a DM6 cell and an A375 cell.

[0029] 15. A method in accordance with aspect 1, wherein the tandem minigene further comprises a ubiquitination signal and two mini-gene controls.

[0030] 16. A method in accordance with aspect 10, wherein the tandem minigene further comprises a ubiquitination signal and two mini-gene controls that encode HLA-A*02:01 peptides G280 and WNV SVG9.

[0031] 17. A method in accordance with aspect 1, wherein the cancer is selected from the group consisting of skin cancer, lung cancer, bladder cancer, colorectal cancer, gastrointestinal cancer, esophageal cancer, gastric cancer, intestinal cancer, breast cancer, and a mismatch air deficiency cancer.

[0032] 18. A method in accordance with aspect 17, wherein the skin cancer is selected from the group consisting of basal cell carcinoma, squamous cell carcinoma, merkel cell carcinoma, and melanoma.

[0033] 19. A method in accordance with aspect 1, wherein the cancer is a melanoma.

[0034] 20. A method in accordance with aspect 1, wherein the forming a vaccine comprises: providing a culture comprising dendritic cells obtained from the subject; and contacting the dendritic cells with the at least one neoan-

tigen peptide, thereby forming dendritic cells comprising the at least one neoantigen peptide.

[0035] 21. A method in accordance with aspect 20, further comprising: administering to the subject the dendritic cells comprising the at least one neoantigen peptide; obtaining a population of CD8+ T cells from a peripheral blood sample from the subject, wherein the CD8+ cells recognize the at least one neoantigen; and expanding the population of CD8+ T cells that recognizes the neoantigen.

[0036] 22. A method in accordance with aspect 21, comprising administering to the subject the expanded population of CD8+ T cells.

[0037] 23. A method in accordance with aspect 1, wherein the forming a vaccine comprises combining the neoantigen peptide with a pharmaceutically acceptable adjuvant.

[0038] 24. A method in accordance with aspect 1, wherein the identifying a complex comprises a LC/MS assay.

[0039] 25. A method in accordance with aspect 1, wherein the identifying a complex comprises a reverse phase HPLC assay.

[0040] 26. A method of treating a cancer in a subject in need thereof, comprising: a) providing a sample of a tumor from a subject; b) performing exome sequencing on the sample to identify one or more amino acid substitutions comprised by the tumor exome; c) performing transcriptome sequencing on the sample to verify expression of the amino acid substitutions identified in b); and d) selecting at least one candidate neoantigen peptide sequence from amongst the amino acid substitutions identified in c) according to the following criteria; i) Exome VAF>10%; ii) Transcription VAF>10%; iii) Alternate reads>5; iv) FPKM>1; v) binds in silico to an HLA class I molecule with an affinity of <500 nM and a stability>2 h; e) performing an in vitro HLA class I binding assay; f) selecting at least one candidate neoantigen peptide sequence from amongst the amino acid substitutions identified in d) that bind HLA class one molecules with an affinity of <4.7 log (IC50, nM) in the assay performed in e); g) transfecting at least one HLA class I positive cell with at least one tandem minigene construct comprising at least one sequence encoding the at least one neoantigen; h) identifying a complex comprising the at least one HLA molecule and the at least one neoantigen peptide produced by the at least one HLA class I positive cell; i) forming a vaccine comprising the at least one neoantigen; and j) administering the vaccine to the subject, wherein, at least one tumor cell of the cancer comprises at least one polypeptide comprising the one or more amino acid substitutions.

[0041] 27. A method in accordance with aspect 26, wherein the Exome VAF is ≥30%

[0042] 28. A method in accordance with aspect 26, wherein the Exome VAF is ≥40%.

[0043] 29. A method in accordance with aspect 26, wherein the Exome VAF is ≥50%.

[0044] 30. A method in accordance with aspect 26, wherein the in vitro HLA class I binding assay is selected from the group consisting of a T2 assay and a fluorescence polarization assay.

[0045] 31. A method in accordance with aspect 26, wherein the forming a vaccine comprises: providing a culture comprising dendritic cells obtained from the subject; and contacting the dendritic cells with the at least one neoantigen peptide, thereby forming dendritic cells comprising the at least one neoantigen peptide.

[0046] 32. A method in accordance with aspect 31, further comprising; administering to the subject the dendritic cells comprising the at least one neoantigen peptide; obtaining a population of CD8+ T cells from a peripheral blood sample from the subject, wherein the CD8+ cells recognize the at least one neoantigen; and expanding the population of CD8+ T cells that recognizes the neoantigen.

[0047] 33. A method in accordance with aspect 32, comprising administering to the subject cells of the expanded population of CD8+ T cells.

[0048] 34. A method in accordance with aspect 26, wherein the forming a vaccine comprises combining the neoantigen peptide with a pharmaceutically acceptable adjuvant.

[0049] 35. A method in accordance with aspect 26, wherein the identifying a complex comprising the at least one HLA molecule and the at least one neoantigen peptide comprises a LC/MS assay.

[0050] 36. A method in accordance with aspect 26, wherein the identifying a complex comprising the at least one HLA molecule and the at least one neoantigen peptide comprises a reverse phase HPLC assay.

[0051] 37. A method of treating a cancer in a subject in need thereof, comprising: providing a neoantigen peptide encoded in DNA of a tumor of the subject, wherein the neoantigen peptide consists of from 8 to 13 amino acids, binds in silico to an HLA class I molecule with an affinity of <500 nM and a stability>2 h, performing an in vitro HLA class I molecule binding assay to identify at least one neoantigen peptide which binds in vitro to an HLA class I molecule with an affinity of <4.7 log (IC50, nM); transfecting at least one HLA class positive cell with at least one tandem minigene construct comprising at least one sequence encoding the at least one neoantigen; identifying a complex comprising the at least one HLA molecule and the at least one neoantigen peptide produced by the at least one HLA class I positive cell; forming a vaccine comprising the at least one neoantigen; and administering the vaccine to the subject, wherein at least one tumor cell of the cancer comprises at least one polypeptide comprising at least one amino acid substitution.

[0052] 38. A method in accordance with aspect 37, wherein the in vitro HLA class I binding assay is selected from the group consisting of a T2 assay and a fluorescence polarization assay.

[0053] 39. A method in accordance with aspect 37, wherein the identifying a complex comprising the at least one HLA molecule and the at least one neoantigen peptide comprises a LC/MS assay.

[0054] 40. A method in accordance with aspect 37, wherein the identifying a complex comprising the at least one HLA molecule and the at least one neoantigen peptide comprises a reverse phase HPLC assay.

[0055] 41. A method in accordance with aspect 37, wherein the forming a vaccine comprises; providing a culture comprising dendritic cells obtained from the subject; and contacting the dendritic cells with the at least one neoantigen peptide, thereby forming dendritic cells comprising the at least one neoantigen peptide.

[0056] 42. A method in accordance with aspect 41, further comprising; administering to the subject the dendritic cells comprising the at least one neoantigen peptide; obtaining a population of CD8+ T cells from a peripheral blood sample from the subject, wherein the CD8+ cells recognize the at least one neoantigen; and expanding the population of CD8+ T cells that recognizes the neoantigen.

[0057] 43. A method in accordance with aspect 42, comprising administering to the subject the expanded population of CD8+ T cells.

[0058] 44. A neoantigen peptide encoded in DNA of a tumor of the subject for use in the treatment of a cancer, wherein the neoantigen peptide consists of from 8 to 13 amino acids, binds in silico to an HLA class I molecule with an affinity of <500 nM and a stability>2 h and binds in vitro to an HLA class I molecule with an affinity of <4.7 log (IC50, nM), wherein the treatment comprises: transfecting at least one HLA class I positive cell with at least one tandem minigene construct comprising at least one sequence encoding the at least one neoantigen; identifying a complex comprising the at least one HLA molecule and the at least one neoantigen peptide produced by the at least one HLA class I positive cell; forming a vaccine comprising the at least one neoantigen; and administering the vaccine to the subject, wherein at least one tumor cell of the cancer comprises at least one polypeptide comprising at least one amino acid substitution.

[0059] 45. A neoantigen peptide in accordance with aspect 44, wherein the forming a vaccine comprises: providing a culture comprising dendritic cells obtained from the subject; and contacting the dendritic cells with the at least one neoantigen peptide, thereby forming dendritic cells comprising the at least one neoantigen peptide.

[0060] 46. A neoantigen peptide in accordance with aspect 45, wherein the treatment of a cancer further comprises: administering to the subject the dendritic cells comprising the at least one neoantigen peptide; obtaining a population of CD8+ T cells from a peripheral blood sample from the subject, wherein the CD8+ cells recognize the at least one neoantigen; expanding the population of CD8+ T cells that recognizes the neoantigen; and administering the expanded population of CD8+ cells to the subject.

BRIEF DESCRIPTION OF THE DRAWINGS

[0061] FIG. **1** illustrates a work flow for identifying candidate neo-antigens and preparing a dendritic cell vaccine comprising the neo-antigens.

[0062] FIG. **2** illustrates the analytical steps and specific neo-antigen analysis for a melanoma patient.

[0063] FIG. **3** illustrates HLA binding on T-cell surfaces to various neo-antigens.

[0064] FIG. **4** illustrates a schematic representation of the steps for creating a dendritic cell based vaccine of the present teachings.

[0065] FIG. **5** illustrates T cell response in vaccinated patients for the listed neo-antigens using a dextramer assay.

[0066] FIG. **6** illustrates the in silico binding affinity (top) and stability (bottom) of peptides to T-cell HLA.

[0067] FIG. **7** illustrates the binding of immunogenic peptides to blood CD8 T cells following vaccination.

[0068] FIG. **8** illustrates antigen-specific T cell yields following vaccination.

[0069] FIG. **9** is a schematic diagram of a tandem minigene construct.

[0070] FIG. **10** illustrates ELISA-measured production of IFN-γ by T cells.

[0071] FIG. **11** illustrates that T cell specificity can detect a single amino acid change for AKAP13 and Sec24A.

[0072] FIG. **12** illustrates that T cells cannot discriminate between peptides with a single amino acid change for OR8B3.

[0073] FIG. **13** illustrates that vaccine-induced T cells produce large amounts of IFN-γ relative to IL-4, -5 and -13.

[0074] FIG. **14** illustrates tumor regression monitored by luciferase (photon flux).

[0075] FIG. **15** illustrates disease progression of mice inoculated with a luciferase expressing melanoma.

[0076] FIG. **16** illustrates the relationship between tumor regression and survival.

[0077] FIG. **17** illustrates immunological and clinical outcomes for patients treated with G209-2M and G2880-9V specific CD8+ T cells.

[0078] FIG. **18** illustrates ex-vivo IL-12 production and that Tc1 profile correlates with clinical outcome (TPP)

[0079] FIG. **19** illustrates that weak p35 transcription accounts for the IL-12p70 defect in non-responder patients.

[0080] FIG. **20** illustrates that impaired IL-12p70 production by a patient's dendritic cells is rescued by a combination of innate and adaptive signals.

[0081] FIG. **21** illustrates that a combination of innate and adaptive signals for dendritic cell maturation enhances the kinetics of the response.

[0082] FIG. **22** illustrates that a combination of innate and adaptive signals for dendritic cell maturation promotes Tc1 -polarized immunity.

[0083] FIG. **23** illustrates that cutaneous melanoma harbor a significant mutation burden.

[0084] FIG. **24** illustrates the translation of tumor missense mutations into patient-specific vaccines.

[0085] FIG. **25** illustrates discrimination between mutation and wild-type sequences and discrimination between antigens that are and are not presented to T-cells.

[0086] FIG. **26**A-B illustrates clinical trial schema and ex-vivo IL-12p70 levels produced by mature DC.

[0087] FIG. **27** is a schematic representation of the selection of AAS peptides for use in experiments and vaccines.

[0088] FIG. **28** is a schematic representation of a strategy for neoantigen selection.

[0089] FIG. **29** illustrates AAS-comprising peptide binding to HLA-A*02:01.

[0090] FIG. **30**A-C illustrate immune response to neoantigens.

[0091] FIG. **31** illustrates immune-monitoring of neoantigen-specific CD8+ T cell responses

[0092] FIG. **32** illustrates frequency of G209-2M- and G280-9V-specific T cells in CD8+ populations isolated directly from PBMC samples and after ex-vivo expansion using autologous DC and artificial antigen presenting cells.

[0093] FIG. **33** illustrates kinetics of immune responses to G209-2M and G280-9V peptides.

[0094] FIG. **34** illustrates antigenic determinants recognized by vaccine-induced T-cells

[0095] FIG. **35** illustrates cytokine production in neoantigen-specific T cells that were stimulated with artificial antigen presenting cells in the presence (open bar) or absence (close bar) of AAS-peptide.

[0096] FIG. **36** illustrates the Type 1/Type 2 phenotype of neoantigen-specific CD8+ T cells.

[0097] FIG. **37**A-B illustrates the structure (A) and expression (B) of tandem mini-gene constructs (TMC) used for evaluating processing and presentation of neoantigens.

[0098] FIG. **38** illustrates neoantigen processing and presentation.

[0099] FIG. **39** illustrates interferon production in neoantigen-specific CD8 T cells cultured with neoantigen expressing DM6 cells.

[0100] FIG. **40**A-H illustrates processing and presentation of tumor neoantigens.

[0101] FIG. **41**A-D illustrates processing and presentation of to G280 and WNV SVG9 peptide controls.

[0102] FIG. **42** is a schematic diagram for analysis and identification of neoantigen-specific TCRβ clonotypes in CD8+ T cell populations isolated from PBMC samples obtained Pre- and Post-vaccination.

[0103] FIG. **43**A-B illustrates profiles of purified neoantigen-specific CD8+ T cells used for the generation of TCRβ CDR3 reference libraries.

[0104] FIG. **44**A-B illustrate that vaccination promotes a diverse neoantigen-specific T cell repertoire.

[0105] FIG. **45** depicts schematic diagrams of HLA-A*02:01 and HLA-B*08:01 neoantigen identification for patient MEL66.

[0106] FIG. **46** depicts schematic diagrams of HLA-A*02:01 and HLA-A*11:01 neoantigen identification for patient MEL69.

[0107] FIG. **47** depicts results of a dextramer assay to illustrate neoantigen response in T cells following administration of a vaccine in accordance with the present teachings.

DETAILED DESCRIPTION

[0108] The present teachings describe methods of creating vaccines for personalized cancer treatment. As used herein, "a vaccine" is a preparation that induces a T-cell mediated immune response. As used in the present description and the appended claims, the singular forms "a", "an" and "the" are intended to include the plural forms as well, unless the context indicates otherwise.

[0109] In some embodiments, methods of the present teachings can comprise sequencing DNA from excised tumor tissue of a subject to identify amino acid substitutions, performing sequence capture to confirm the expression of the amino acid substitutions, selecting amino acid substitutions that bind or are likely to bind HLA molecules, transfecting nucleic acids encoding the selected amino acid substitutions into an HLA positive melanoma cell line, extracting HLA class I complexes from the transfected cells, identifying the sequence of neoantigens bound to the extracted HLA class one complexes, contacting dendritic cells obtained from the subject with the identified neoantigen peptides, thereby forming a dendritic cell vaccine, administering to the subject the dendritic cell vaccine, obtaining and enriching CD8+ T cells from the subject, and administering the enriched CD8+ T cells to the subject. In some embodiments, the neoantigen binding T cells can be used for adaptive T cell therapy. In some embodiments, a fluorescence polarization binding assay can be used to confirm the binding of neoantigen peptides to HLA molecules prior to selection for transfection.

[0110] In some configurations, the following criteria can be used to select the neoantigens for transfection into HLA class I positive cells; in the exome sequencing, the variant allele fraction of the neoantigen greater than 10%; in the transcript sequencing results the VAF greater than 10%, the alternate read counts greater than 5, and the FPKM greater than 1; the encoded peptides can be 9-11 amino acids in length; the predicted binding to any HLA class I allele can have following characteristics; the predicted MHC binding <250 nM (NetMHC3.4 algorithm), the predicted MHC stability>2 h (NetMHCStab, algorithm); the experimental MHC binding<3.2 log [IC_{50}, nM] in the fluorescence polarization binding assay. In some embodiments, a personalized immunotherapy of the present teachings can be used in conjunction with check point inhibitors, such as but without limitation ipiplimumab therapy. In some configurations, a cancer vaccine can be generated by contacting dendritic cells obtained from the patient with at least one neoantigen peptide of the present teachings. In some configurations, the dendritic cell vaccine can then be administered to the subject. In some configurations, CD8+ T cells be obtained from PBMC samples from the subject, and CD8+ T cells that recognize the at least one neoantigen are isolated using cell sorting. In various configurations, the cell sorting can comprise using an affinity column or affinity beads. In some configurations, sorted CD8 + T cells that recognize neoantigens can be expanded using methods as described herein. In some configurations, the expanded T cells can then be administered to the subject.

[0111] In various configurations, the present teachings include a series of analytical steps for identification of neo-antigens from somatic tumor missense mutations, as illustrated in FIG. **2**. In various embodiments, DNA isolated from tumor and matched PBMC can be subjected to exome sequencing in order to identify tumor somatic missense mutations. For example, in melanoma and lung cancer high number of missense mutations (>200) can be identified per tumor genome. Prediction algorithms such as, without limitation, PePSSI (Bui, H. H., et al., Proteins 63, 43-52, 2006) can be used for the identification of candidate tumor neoantigen epitopes presented in the context of the patient's HLA class I molecules. In various configurations, analysis of tumor transcriptome data can used for the identification and selection, among predicted candidates, of those epitopes that are expressed by the tumor.

Methods

[0112] The methods and compositions described herein utilize laboratory techniques well known to skilled artisans, and can be found in laboratory manuals such as Sambrook, J., et al., Molecular Cloning: A Laboratory Manual, 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 2001; Methods In Molecular Biology, ed. Richard, Humana Press, NJ, 1995; Spector, D. L. et al, Cells: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1998; and Harlow, E., Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1999. Methods also are as described herein and in publications such as Linette, G. P. et al., Clin. Cancer Res. 11, 7692-7699, 2005; Carreno, B. M. et al., J. Immunol. 188, 5839-5849, 2012; and Carreno, B. M., et al., J. Clin. Invest. 123, 3383-3394, 2013.

[0113] In order to determine the safety, tolerability and immunological responses to Amino Acid Substitutions (AAS)-peptides formulated in an mDC vaccine, the following protocols were followed.

Human Subjects

EXAMPLES 1-10

[0114] Human subjects, Eligible adult patients with newly diagnosed treatment naïve (ECOG performance status 0) stage IV cutaneous melanoma are enrolled in this clinical trial. All subjects are HLA-A*0201*, had $gp100^{+}$ biopsy-proven ($HMB45^{+}$, immunohistochemistry) melanoma metastases, have no evidence of autoimmune disorder, and are negative for HIV, HBV, and HCV. Leukapheresis was performed to obtain PBMCs from patients and healthy donors through the Barnes Jewish Hospital blood bank. For trial patients, leukapheresis is performed prior to treatment and after D3 and D6. Patients are not prescreened for IL-12p70 DC production prior to treatment. Prior to treatment, baseline imaging is performed by MRI scan of brain and CT scan of the chest/abdomen/pelvis with i.v. contrast.

EXAMPLES 11-15

[0115] All patients were enrolled in clinical trial (NCT00683670, BB-IND 13590) and signed informed consents that had been approved by the Institutional Review Board of Washington University. All subjects were HLA-A*02:01*, had no evidence of autoimmune disorder and were negative for HIV, HBV, and HCV. Leukapheresis was performed, prior to treatment and after the 3rd mature dendritic cell (DC) vaccination, at Barnes Jewish Hospital blood bank (Saint Louis, Mo.). Patients were not prescreened for interleukin (IL)-12p70 DC production prior to treatment. Prior to treatment, baseline imaging was performed by MRI scan of brain and CT scan of the chest, abdomen and pelvis with i.v. contrast. Toxicities and adverse effects were graded according to the National Cancer Institute Common Toxicity Scale (version 3.0). Informed consent for genome sequencing was obtained for all patients on protocols approved by the Institutional Review Board of Washington University.

Patient Information

[0116] Patient MEL21 was a 54-year-old man diagnosed with stage 3C cutaneous melanoma of the right lower extremity in 2010. The BRAF V600E mutation was detected. Surgery was performed to excise 2 cm inguinal lymph node and numerous in transit metastases. He developed recurrent in transit metastases and deep pelvic adenopathy in May 2012 and was given ipilimumab (3 mg/kg×4 doses) with stable disease until late 2013. Disease progression was noted with increasing 2 cm external iliac, 1.2 cm inguinal, and 7 mm retrocrural adenopathy. Three surgically resected melanoma lesions (inguinal lymph node Jan. 30, 2011, leg skin May 10, 2012, leg skin Jun. 6, 2013) and PBMC were submitted for genomic analysis in order to identity somatic missense mutations. The patient provided written'informed consent for the study and underwent apheresis, and received cyclophosphamide 4 days prior to administration of the first vaccine dose. He received a <total of three vaccine doses without side effect or toxicity. Re-staging CT showed stable disease and be remains in follow up 9 months later.

[0117] Patient MEL38 was a 47-year-old woman diagnosed with stage 3C cutaneous flank melanoma and underwent surgical resection of an axillary lymph node in 2012. The BRAF V600E mutation was detected. She developed recurrent disease in the skin and axilla that was surgically resected. A few months later, CT imaging confirmed metastatic disease in the right lung and axilla and she was given ipilimumab (3 mg/kg×4 doses) in May 2012 with complications of grade 2 autoimmune colitis requiring prednisone taper and later, grade 3 hypophysitis requiring replacement therapy with levothyroxine and hydrocortisone. Disease progression was noted 12 months later with new lung and skin metastases. Vemurafenib was administered for two months with no response in August 2013. Three surgically resected melanoma lesions (axilla lymph node Apr. 19, 2012, skin breast Feb. 14, 2013, skin abdominal wall Apr. 16, 2013) and PBMC were submitted for genomic analysis in order to identify somatic missense mutations. Further disease progression was evident with 3 lung nodules measuring 12 mm, 5 mm, and 5 mm in diameter. The patient provided written informed consent for the study and underwent apheresis, and received cyclophosphamide 4 days prior to the first vaccine dose. She received a total of three vaccine doses without side effect or toxicity. Re-staging CT showed 30% tumor reduction; however, the following CT examination 12 weeks later showed interval increase of tumor size back to baseline dimensions with no new sites of disease. The patient remains with stable disease for the past 8 months.

[0118] Patient MEL218 was a 52-year-old man diagnosed with stage 3C cutaneous melanoma on the left lower extremity in 2005. The BRAF mutation V600E mutation was detected when tested later on archived tumor. He underwent surgical resection and received adjuvant interferon for 6 months but had disease recurrence that was surgically resected on several occasions. In 2008, he developed disease progression with extensive in transit and subcutaneous metastases on the left leg with bulky inguinal nodal metastasis deemed unresectable. He received ipilimumab (10 mg/kg×14 doses) on clinical trial from 2008-2012 with complete response. One surgical specimen (inguinal lymph node Apr. 4, 2005) and PBMC were submitted for genomic analysis to identify somatic missense mutations. The patient provided written informed consent for the study and underwent apheresis, and received cyclophosphamide 4 days prior to the first vaccine dose. He received a total of three vaccine doses administered in the adjuvant setting without side effect or toxicity. Re-staging PET-CT imaging confirms no evidence of recurrent or metastatic disease. The patient remains in complete remission and continues in follow up.

[0119] Patient MEL69 was a 61-year-old man diagnosed with stage 3C cutaneous melanoma in 2012. Surgery was performed to excise the primary site and the axillary adenopathy. A total of 3 lymph nodes contained metastatic melanoma. The BRAF V600E mutation was detected. The patient received adjuvant Interferon for 5 months but this was discontinued after progression and development of metastatic disease. The patient was given vemurafenib for 10 months but progressed with new sites of disease. Dabrafenib and trametinib combination systemic therapy was administered for 7 additional months until progression.

Several new sites of metastatic disease including a solitary brain lesion were resected. His subsequent course was complicated by malignant pericardial effusion and deep venous thrombosis. After appropriate treatment, he improved. Two surgically resected melanoma lesions (MEL69A2, limb and MEL69B2, scalp) and PBMC were submitted for genomic analysis in order to identify somatic missense mutations. The patient provided written informed consent, underwent apheresis, and then received cyclophosphamide 4 d prior to the first vaccine dose. He received a total of 2 vaccines doses without side effect or toxicity. Re-staging CT examination confirmed disease progression and the patient was removed from the study and enrolled in hospice care.

[0120] Patient MEL66 was a 43-year-old female diagnosed initially with stage 3B cutaneous melanoma in 2013. Surgery was performed to excise in transit metastases and the BRAF V600E mutation was detected. Subsequent imaging confirmed metastatic disease in the lung and retroperitoneal cavity deemed unresectable. She received several doses of ipilimumab and developed grade 3 autoimmune colitis treated with corticosteroids. After her recovery, disease progression was noted and combination therapy with dabrafenib/trametinib was begun. Disease progression was noted after 6 months of treatment. Surgical resection of several metastatic lesions was performed to render the patient disease-free. Two surgically resected melanoma lesions (ME1-66A, skin and. MEL66D, soft tissue) and PBMC were submitted for genomic analysis in order to identify somatic missense mutations. The patient provided written informed consent, underwent apheresis, and then received cyclophosphamide 4 d prior to the first vaccine dose. She received a total of 3 vaccine doses without side effect or toxicity. Re-staging Ct confirmed no evidence of disease recurrence and the patient remains in remission with no evidence of disease 4 months in follow up with no additional therapy.

Cyclophosphamide Treatment and DC Preparation (Examples 1-10)

[0121] Cyclophosphamide (300 mg/m^2) was given 72 hours prior to D1 with the intention of eliminating Tregs (Hoons, D. S., et al., Cancer Res., 50, 5358-5364, 1990). All mature dendritic cell (mDC) vaccine doses were prepared at the time of immunization from either freshly isolated (D1) or cryopreserved (D2-D6) PBMCs (all derived from the same leukapheresis collection). A GMP-grade CD40Lexpressing K562 cell line (referred to as K463H), used for maturation of DCs, is generated, selected, and maintained under serum-free (Stemline, S1694 media) conditions. For each vaccine dose, monocyte-derived immature dendridic cells (iDCs) were generated as described previously (Linette, G. P., et al., Clin. Cancer Res., 11, 7692-7699, 2005) by culturing the PBMC adherent fraction in RPMI 1640 with 1% human AB-serum (DC media) supplemented with 100 ng/ml GM-CSF (Berlex) and 20 ng/ml IL-4 (CellGenix). 6 days after culture initiation, iDCs were harvested, washed in PBS, and cultured for an additional 24 hours in DC media (iDC control) or DC media with irradiated (100 Gy) K463H (5:1 DC/K463H ratio) and 100 U/ml IFN-γ (Actimmune; InterMune Inc.) to generate mDCs. 2 hours prior to infusion, mDCs were pulsed with (50 μg/10^6 cells/ml) peptide. For infusion, mDCs were resuspended in 50 ml normal saline supplemented with 5% human serum albumin and administered over 30 minutes by i.v. infusion after premedication with 650 mg acetaminophen.

DC Immunizations (Examples 1-10)

[0122] mDC infusions were given i.v. every 3 weeks for 6 doses in the outpatient clinic. A restaging CT scan of the chest/abdomen/pelvis with i.v. contrast was performed after D3 and D6 and then every 2 months thereafter until disease progression. If clinical or radiographic disease progression was evident, the patient was removed from the study. For D1, patients received 1.5+10^7 DCs per peptide (6×10^7 DCs total); for D2-D6, patients received 5×10^6 DCs per peptide (2×10^7 DCs total). Patients underwent clinical evaluation prior to each mDC infusion. Toxicities and adverse effects were graded according to the National Cancer Institute Common Toxicity Scale (version 3.0). Clinical response was assessed by measurement of assessable metastatic deposits by CT scan, MRI scan, or direct measure of cutaneous deposits. The RECIST (v1.0) group system was used (Therasse, P., et al., J. Nat'l. Cancer Inst., 92, 205-216, 2000).

[0123] Immunologic monitoring (Examples 1-10). Immunologic analysis to evaluate the kinetics and magnitude of T cell response to gp100 peptides was performed using PBMCs collected weekly (prior to vaccination and until week 21. Fresh PBMCs obtained by Ficoll-Hypaque gradient centrifugation were adjusted to 2×10^6 cells/ml in Stemline media (Sigma-Aldrich) containing 5% human AB-serum, and dispersed at 1 ml/well in 24-well plates. Cultures were set up for the gp100 peptides and the CMV pp65 peptide (positive peptide control). Cultures were pulsed with 40 μg/ml peptide and 50 U/ml IL-2 fed starting at 48 hours and every other day thereafter. On day 12 (peak of response; the inventors' unpublished observation), cultures were harvested, counted, and stained for flow cytometry analysis. To assess the antigen-specific T cell frequency, cells were stained with HLAA*0201/peptide tetramers (Beckman Coulter) for 30 minutes at room temperature, followed by addition of FITC-conjugated CD4, CD14, CD19, and CD56 and allophycocyanin-conjugated CD8 (Invitrogen) for 15 minutes at 4° C. Cells were washed and resuspended in FACS buffer, and 7AAD was added 5 minutes before analysis. Control CMV pp65-specific CD8+ T cells were detected in all CMV-seropositive patients before and after immunization. A negative HLA-A*0201/HIV gag peptide tetramer control was included. 25,000 events in the CD8+ gate were collected using a hierarchical gating strategy that included FSC/SSC and excluded 7AAD+ (dead) cells and CD4+CD14+CD19+CD56+ cells. Data were acquired and analyzed using Flow-Jo software.

DC Manufacturing and Vaccine (Examples 11-15)

[0124] Cyclophosphamide (300 mg/m^2) was given 96 h prior to the first DC dose with the intention of eliminating Tregs. All mature DC (mDC) vaccine doses were prepared at time of immunization from either freshly isolated (D1) or cryopreserved (D2-3) PBMC (all derived from same leukapheresis collection). For each vaccine, dose, monocyte-derived immature DCs were generated in 100 ng/mL granulocyte-macrophage colony-stimulating factor (GM-CSF, Berlex) and 20 ng/mL IL-4 (Miltenyi Biotec) as described (Carreno, B. M., et al., J. Clin. Invest. 123, 3383-3394, 2013; Linette G P, et al., Clin. Cancer Res 11, 7692-7699, 2005) by culturing the PBMC adherent fraction in RPMI 1640 with

1% human AB-serum (DC media) supplemented with 100 ng/ml GM-CSF (Berlex) and 20 ng/ml IL-4 (CellGenix). Six days after culture initiation, immature DCs were cultured with irradiated (10,000 rad) GMP-grade CD40L-expressing K562 cells (Carreno, B. M., et al., J. Clin. Invest., 123, 3383-3394, 2013), 100 u/mL IFN-γ (Actimmune, InterMune Inc.), poly I:C (Invivogen, Inc) and R848 (Invivogen, Inc.) for 16 h to generate mDC. Two hours prior to infusion, mDC were pulsed (50 μg/10^6 cells/mL) separately with each peptide (7 AAS-peptides and 2 gp100 peptides, G209-2M and G280-9V) and, for dose 1 only, influenza virus vaccine (Fluvirin Novartis) was added to provide a source of recall antigen for CD4+ T cells. IL-12p70 production by vaccine DC was measured by ELISA (eBioscience) in accordance to the manufacturer's instructions. The initial priming dose was 1.5×10^7 DC per peptide (1.35×10^8 DC total), in remaining doses, patients received 5×10^6 DC per peptide (4.5×10^7 DC total). mDC were resuspended in 50 mL normal saline supplemented with 5% human serum albumin and administered over 30 min by intravenous infusion after premedication with acetaminophen 650 mg. Patients underwent clinical evaluation prior to each mDC infusion.

[0125] Cytokine Production

[0126] DC IL-12p70 and IL-12p40 production is measured by ELISA (eBioscience) according to the manufacturer's instructions. Production of additional cytokines and chemokines by DCs is determined using MILLIPLEX map Human Cytokine Panels I and II (EMD Millipore). For production of cytokines by T cells, G280-9V-specific T cells are expanded using mDCs and AT-SCT as described previously (infra and Carreno, B. M., et al., J. Immunol. 188, 5839-5849, 2012). The frequency of antigen-specific T cells after secondary stimulation is 2%-52%, as determined by HLA-A*0201/peptide tetramers (NIH tetramers Facility or Beckman Coulter). T cells are restimulated as described infra (Carreno, B. M., et al., J. Immunol. 188, 5839-5849, 2012), supernatants are collected at 24 hours, and production of cytokines is determined using MILLIPLEX® map Human Cytokine Panel I (EMD Millipore).

Generation and Expansion of Ag-Specific T Cells

[0127] CD8+ T cells were isolated from PBMCs using a CD82 negative-selection kit (Miltenyi Biotec, Auburn, Calif.). Purified CD8+ T cells were cultured at a 20:1 ratio with irradiated (2500 rad) autologous mature DC (mDC) pulsed with peptide in Stemline media (S1694; Sigma-Aldrich, St. Louis, Mo.) supplemented with pooled human sera (Stemline-5), Human IL-2 (10-50 U/ml; Chiron, Emeryville, Calif.) was added every 2 d starting 48 h after culture initiation. Fourteen days after DC stimulation, T cell cultures were harvested, characterized for neo-antigen specific frequencies using HLA/peptide tetramers (see below), and restimulated with irradiated (10,000 rad) Single Chain Trimers (SCT; U.S. Pat. No. 8,518,697; U.S. Pat. No. 8,895,020; Carreno, B. M., et al., J. Immunol., 188, 5839-5849, 2012) or amino-terminal extended peptide MHC class I single-chain trimer (AT-SCT)-expressing K562 cells at a 1:1 ratio. Cultures were initiated in either six-well plates (10^6 each T and SCT or AT-SCT) or T25 flask (5×10^6 each) using Stemline-5. Twenty-four hours after stimulation, cultures were supplemented with IL-2 (500 U/ml), and viable cell counts were performed daily.

[0128] Cell concentrations were maintained at 5×10^5/ml throughout the culture period. For large-scale expansion, T cells were cultured in gas-permeable Lifecell bags (Nexell Therapeutics, Emeryville, Calif.). On days 10-14 of secondary stimulation, the percentage of tetramer+ cells and the number of viable cells were used to determine tetramer yields and tetramer folds.

[0129] For analysis of cytokines secreted by T cells upon SCT activation, cultures were activated 14 d after SCT or AT-SCT stimulation, T cells were restimulated with SCT at 1:1 ratio in RPMI 1640 supplemented with 5% pooled human sera (RPMI-5), supernatants were collected 24 h after activation and characterized using a MILLIPLEX® cytokine kit (Millipore, Billerica, Mass.), per the manufacturer's instructions.

qRT-PCR

[0130] qRT-PCR was performed as described previously (Carreno, B. M., et al., Immunol. Cell Biol. 87: 167-177, 2009). cDNAs were prepared (2 μg total RNA), and cDNA samples were amplified in triplicate using a GeneAmp 5700 sequencer detector (Applied Biosystems). Primers used are IL-12p35 (Hs00168405_m1) and ITGAX (integrin alpha X, referred to herein as CD11c; Hs01015070_m1). Transcript levels were calculated using the relative standard curve method, using CD11c transcript levels to normalize values.

^{51}Cr Release and T2 Assays

[0131] ^{51}Cr release assays to measure specific lysis have been described previously (Carreno, B. M., et al., Immunol. Cell Biol., 87: 167-177, 2009; Linette, G. P. et al., Clin. Cancer Res. 11, 7692-7699, 2005). Melanoma cell lines DM6 (HLAA2+ gp100+) and A375 (HLA-A2+gp100−) were labeled with 25 μCi ^{51}Cr for 1 hour, washed, and tested as targets in a standard 4-hour assay. Effectors were generated using PBMCs collected after D3 and cultured for 12 days in the presence of peptide (40 μg/ml) and IL2 (50 U/ml every other day). Vaccine-induced antigen-specific T cells were characterized using HLAA*0201/peptide dextramers (Immudex). To determine the avidity (effective concentration at 50% maximal lysis) of vaccine-induced T cells for antigen, T2 cells were pulsed with titrated G209-2M or G280-9V peptide concentrations for 1 hour in serum-free media followed by 51Cr (25 μCi) labeling for 1 hour, washed twice, and tested using vaccine-induced gp100-specific T cells in a standard 4-hour assay.

Statistics

[0132] Student's t tests are 2-tailed (GraphPad Prism software, version 5.0). Data are presented as mean±1 SD, unless otherwise indicated. Cox regression analysis followed by likelihood-ratio test is used to evaluate whether (loge) IL-12p70 (sum) production added statistically significant information to a model of time to progression (TTP). Kaplan-Meier TTP model is used to test whether cytokine ratios added statistically significant information to a model of TTP. Wilcoxon matched-pairs analysis is used to compare IL-12p70 production between patients and healthy donors (GraphPad Prism software, version 5.0). All P values less than 0.05 were considered significant, except the Cox proportional hazard model, which used a lower threshold of significance ($P<0.048$) to adjust for 1 interim analysis of this endpoint.

Peptides

[0133] Peptides were obtained lyophilized from American Peptide Company (>95% purity), dissolved in 10% DMSO

in sterile water and tested for sterility, purity, endotoxin and residual organics. Peptide binding to HLA-A*02:01 was determined by T2 assay (Elvin et al. 1993 J. Immunol. Methods 158, 161) or using a fluorescence polarization assay (Pure Protein, L.L.C.) (Buchli, R., et al., Biochemistry 44, 12491-12507, 2005). The affinity scale of this latter assay is: high binders: log (IC_{50} nM)<3.7; intermediate binders: log (IC_{50} nM) 3.7-4.7; low binders: log (IC_{50} nM) 4.7-5.5; and very low binders: log (IC_{50} nM)≥6.0 (11).

Computer Algorithm

[0134] Burrows-Wheeler Aligner (BWA; Li, H. and Durbin R., Bioinformatics 25, 1754-1760, 2009) is a reference-directed aligner that is used for mapping low-divergent sequences against a large reference genome, and consists of separate algorithms designed for handling short query sequences up to 100 bp, as well as longer sequences ranged from 70 bp to 1 Mbp.

[0135] Picard (Broad Institute, Cambridge, Mass.) is a set of Java-based command-line tools for processing and analyzing high-throughput sequencing data in both Sequence Alignment/Map (SAM) text format and SAM binary (BAM) format. The 'MarkDuplicates' utility within Picard examines aligned records in the supplied SAM or BAM file to locate duplicate molecule and can be used to flag and/or remove the duplicate records.

[0136] SAMtools (Li, H., et al., Bioinformatics, 25, 2078-2079, 2009) is a suite of programs for interacting with and post-processing alignments in the SAM/BAM format to perform a variety of functions like variant calling and alignment viewing as well as sorting, indexing, data extraction and format conversion.

[0137] Somatic Sniper (Larson, D. E., et al., Bioinformatics, 28, 311-317) is used to identify single nucleotide positions that are different between tumor and normal BAM files. It employs a Bayesian comparison of the genotype likelihoods in the tumor and normal, as determined by the germline genotyping algorithm implemented in the MAQ and then calculates the probability that the tumor and normal genotypes are different.

[0138] VarScan (Koboldt D. C., et al., Genome Research, 22, 568-576, 2012; Koboldt, D. C., et al., Bioinformatics 25, 2283-2285, 2009,) is a software program that detects somatic variants (SNPs and indels) using a heuristic method and a statistical test based on the number of aligned reads supporting each allele using an input SAMtools pileup/mpileup file. For tumor-normal pairs, it further classifies each variant as Germline, Somatic, or LOH, and also detects somatic copy number changes.

[0139] Strelka (Saunders, C. T., et al., Bioinformatics 28, 1811-1817, 2012) is an analysis package designed to detect SNVs and small indels from the sequencing data of matched tumor-normal samples. It is specifically designed to detect somatic variants at lower frequencies typically encountered in tumors due to high sample impurity or sub-clone variation, while maintaining sensitivity.

[0140] TopHat (Trapnell. C., et al., Bioinformatics, 25, 1105-1111, 2009; Kim, D., et al., Genome Biol., 14, R36, 2013) is a fast splice junction mapper for RNA-Seq reads that aligns reads to mammalian-sized genomes in order to identify exon-exon splice junctions. It uses the ultra high-throughput short read aligner Bowtie, and then analyzes the mapping results to identify splice junctions between exons.

[0141] Cufflinks (Trapnell, C., et al., Nat. Protoc., 7, 562-578, 2012) is a software program for transcriptome assembly and differential expression analysis for RNA-Seq data. It assembles transcripts from aligned RNA-Seq reads, estimates their abundances based on how many reads support each one, taking into account biases in library preparation protocols, and then tests for differential expression and regulation in RNA-Seq samples.

[0142] Flexbar (Dodt, M., et al., Biology (Basel), 1, 895-905, 2012) is a software package that preprocesses high-throughput sequencing data efficiently by demultiplexing barcoded runs and removing adapter sequences. Additionally, it supports trimming as well as filtering features; thereby aiming to increase read mapping rates and improve genome and transcriptome assemblies.

[0143] NetMHC 3.4 server (Nielsen, M., et al., Protein Sci., 12, 1007-1017, 2003; Lundegaard, C., et al., Nucleic Acids Res., 1, W509-512, 2008) makes high-accuracy predictions of major histocompatibility complex (MHC): peptide binding to a number of different HLA alleles. The predictions are based on artificial neural networks trained on different datasets (human and non-human) from several MHC alleles and position-specific scoring matrices (PSSMs).

[0144] In terms of additional filtering of variants from DNA/RNA data that would pass to analysis for identifying peptides, the following filters were used on coverage for tumor and normal, below which a variant is discarded from further consideration:

[0145] >=5× Normal coverage

[0146] >=10× Tumor coverage

[0147] <=2% Normal VAF

[0148] >=30% Tumor VAF

[0149] FPKM>1 (this is the only RNA-based filter).

[0150] In silico work flow.

[0151] The present inventors have developed an in silico automated pipeline for neoantigen prediction (pVAC-Seq) that can utilize several types of data input from next-generation sequencing assays. First a list of nonsynonymous mutations is identified by a somatic variant-calling pipeline using exomic sequencing and transcript sequencing of both normal and tumor tissue. This variant list can then be annotated with amino acid changes and transcript sequence. The HLA-haplotypes of the patient, can be derived through clinical genotyping assays or in silico approaches. These data can be input into the pVAC-Seq workflow which implements three steps: performing, epitope prediction, integrating sequencing-based information and lastly, filtering neoantigen candidates. The following paragraphs describe the analysis methodology from preparation of inputs to the selection of neoantigen vaccine candidates via pVAC-Seq.

[0152] Prepare Input Data: HLA-Typing, Alignment, Variant Detection and Annotation

[0153] As described above, pVAC-Seq utilizes input data generated from the analysis of next-generation sequence data that includes annotated nonsynonymous somatic variants that have been translated into mutant amino acid changes, as well as patient-specific HLA haplotypes. While these data could be obtained from any appropriate variant calling, annotation and HLA typing pipeline, the inventors' approach as disclosed herein utilized the following analysis methods for preparing these input data. In brief, BWA (version 0.5.9) (Li, H. and Durbin, R., Bioinformatics, 25, 1754-1760, 2009) was used as the aligner of choice with

default parameters except the number of threads was set to 4 (−t 4) for faster processing, and the quality threshold for read trimming to 5 (−q 5). The resulting alignments were de-duplicated via Picard MarkDuplicates (version 1.46; Broad Institute, Cambridge, Mass.).

[0154] In cases where clinically genotyped HLA haplotyping calls were not available, the inventors used in silico HLA typing by HLAminer (Version1)(Warren, R. L., et al., Genome Med., 4, 95, 2012) to provide HLA haplotypes from either whole genome sequence data or RNA-seq data, or by Athlates (Liu, C., et al., Nucleic Acids Res, 41, e142, 2013) when exome data were available. Typing was performed on samples of the patient's normal cells, rather than cells from the tumor sample. The two software tools were >85% concordant in the inventors' test data; both algorithms were used in order to break ties reported by HLAminer (see below).

[0155] 1. HLAminer for in silico HLA-typing using WGS data: When predicting HLA class I alleles tram WGS data, the inventors used HLAminer in de novo sequence alignment mode using TASR (Warren, R. L. and Holt, R. A., PLoS One., 6, e19816, 2011) (params: −i 1 −m 20) by running the script HPTASRwgs_classI.sh, provided in the download. (The download includes detailed instructions for customizing this script, and the scripts on which it depends, for the user's computing environment.) For each of the three HLA loci, HLAminer reports predictions ranked in decreasing order by score, where "Prediction #1" and "Prediction #2" are the most likely alleles for a given locus. When ties were present for Prediction 1 or Prediction 2, the inventors used all tied predictions downstream neo-epitope prediction. However, it should be noted that most epitope prediction algorithms, including NetMHC (Lundegaard, C., et al., Nucleic Acids Res., 36, 509-512, 2008; Nielsen, M., et al., Protein Sci., 12, 1007-1017, 2003), only work with an algorithm-specific subset of HLA alleles, so we are constrained to the set of NetMHC-compatible alleles. The current version NetMHC v3.4 supports 78 human alleles.

[0156] II. Athlates for in silico HLA-typing using exome sequence data: The inventors diverged from the recommended procedure to run Athlates at two points in the procedure: 1) they performed the alignment step to align exome sequence data (corresponding to the normal tissue sample) against the HLA allele sequences present in the IMGT/HLA database (Robinson, J., et. al., Nucleic Acids Res., 41, D1222-D1227, 2013), using BWA with zero mismatches (params: bwa aln −e 0 −o 0 −n 0) instead of NovoAlign (Hercus. C., Novocraft short read alignment package, 2009) with one mismatch, and 2) in the subsequent step, sequence reads that matched, for example, any HLA-A sequence from the database were extracted from the alignment using bedtools (Quinlan, A. R. and Hall, I. M., Bioinformatics 26, 841-842, 2010) instead of Picard. This procedure is resource-intensive, and may require careful resource management. Athlates reports alleles that have a Hamming distance of at most 2 and meet several coverage requirements. Additionally, it reports "inferred allelic pairs," which are identified by comparing each possible allelic pair to a longer list of candidate alleles using a Hamming distance-based score. The inventors typically used the inferred allelic pair as input to subsequent steps in the neo-epitope prediction pipeline.

[0157] After alignments (and optional HLA typing) were completed, somatic mutation detection was performed using the following series of steps. (1) Samtools (Li, H., et al., Bioinformatics, 25, 2078-2079, 2009; Li, H. Bioinformatics, 27, 2987-2993, 2011) mpileup v0.1.16 was run with parameters '−A −B' with default setting for the other parameters. These calls were filtered based on GMS 'snp-filter v1' and were retained if they met all of the following rules: (a) Site is greater than 10 bp from a predicted indel of quality 50 or greater, (b) The maximum mapping quality at the site is ≥40, (c) Fewer than 3 SNV calls are present in a 10 bp window around the site, (d) The site is covered by at least 3 reads and less than 1×109 reads, and (e) Consensus and SNP quality is ≥20. The filtered Samtools variant calls were intersected with those from Somatic Sniper version 1.0.2 (Larson, D. E., et al., Bioinformatics, 28, 311-317, 2012) (params: −F vcf q 1 −Q 15), and were further processed through the GMS 'false-positive filter v1' (params: -bam-readcount-version 0.4-bamreadcount-min-base-quality 15-min-mapping-quality 40-min-somatic-score 40). This filter used the following criteria for retaining variants: (a) ≥1% of variant allele support comes from reads sequenced on each strand, (b) variants have ≥5% Variant Allele Fraction (VAF) (c) more than 4 reads support the variant, (d) the average relative distance of the variant from the start/end of reads is greater than 0.1, (e) the difference in mismatch quality sum between variant and reference reads is less than 50, (f) the difference in mapping quality between variant and reference reads is less than 30, (g) the difference in average supporting read length between variant and reference reads is less than 25, (h) the average relative distance to the effective 3' end of variant supporting reads is at least 0.2, and (i) the variant is not adjacent to 5 or more bases of the same nucleotide identity (e.g. a homopolymer run of the same base), (2) VarScan Somatic version 2.2.6 (Koboldt, D. C., et al., Bioinformatics, 25, 2283-2285, 2009; Koboldt, D. C., et al., Genome Res., 22, 568-576, 2012) was run with default parameters and the variant calls were filtered by GMS filter 'varscan-high-confidence filter version v1'. The 'varscan-high-confidence v1' filter employed the following rules to filter out variants (a) p-value (reported by Varscan) is greater than 0.07, (5) Normal VAF is greater than 5%, (c) Tumor VAF is less than 10% or (d) less than 2 reads support the variant. The remaining variant calls were then processed through false-positive filter v1 (params: -bam-readcount-version 0.4-bamreadcount-min-base-quality 15) as described above. (3) Strelka version 1.0.10 (Saunders, C. T., et al., Bioinformatics, 28, 1811-1817, 2012) (params: isSkipDepthFilters=1).

[0158] The consolidated list of somatic mutations identified from these different variant-callers was then annotated using our internal annotator as part of the GMS pipeline. This annotator leverages the functionality of the Ensembl database (Flicek, P, et al., Nucleic Acids Res., 41, D48-55, 2013) and Variant Effect Predictor (VEP)(McLaren, W., et al., Bioinformatics, 26, 2069-2070, 2010).

[0159] From the annotated variants, there are two components that are needed for pVAC-Seq: amino acid change and transcript sequence. Even a single amino acid change in the transcript arising from missense mutations can alter the binding affinity of the resulting peptide with the MHC Class I molecule. Larger insertions and deletions, such as, for example, those arising from frameshift and truncating mutations, splicing aberrations or gene fusions can also result in

potential neoantigens. However, for the present iterations of pVAC-Seq, the inventors chose to focus their analysis on only missense mutations.

[0160] One feature of the inventor's pipeline is the ability to compare the differences between tumor neo-antigens and normal peptides in terms of the peptide binding affinity. Additionally, it leverages RNA-Seq data to incorporate isoform-level expression information and to quickly cull variants that are not expressed in the tumor. To integrate RNA-Seq data, both transcript ID as well as the entire wild-type transcript amino acid sequence can be used as part of the annotated variant file.

Perform Epitope Prediction

[0161] One component of pVAC-Seq is predicting epitopes that result from mutations by calculating their binding affinity against the Class I MHC molecule. This process involves the following steps for effectively preparing the input data as well as parsing the output.

Generate FASTA File of Peptide Sequences:

[0162] Peptide sequences are an input to the MHC binding prediction tool, and the existing process to compare the germline normal with the tumor can be very onerous. To streamline the comparison, the inventors first build a FASTA file that consists of two amino acid sequences per variant site—wild-type (normal) and mutant (tumor). The FASTA sequence can be built using approximately 8-10 flanking amino acids on each side of the mutated amino acid. However, if the mutation is towards the end or beginning of the transcript, then the preceding or succeeding 16-20 amino acids can be taken respectively, as needed, to build the FASTA sequence. Subsequently, a key file can be created with the header (name and type of variant) and order of each FASTA sequence in the file. This can be done to correlate the output with the name of the variant protein, as subsequent epitope prediction software strips off each name.

Run Epitope Prediction Software:

[0163] To predict high affinity peptides that bind to the HLA class I molecule, the standalone version of NetMHC 3.4 is used. The input to this software is the HLA type of the patient, determined via genotyping or using in silico methods, as well as the FASTA file generated in the previous step comprised of mutated and wild-type 17-21-mer sequences. Typically, antigenic epitopes presented by MHC class I molecules can vary in length from 8 to 13 or 8 to 11 amino acids. Therefore, specifying the same range when running epitope prediction software is recommended.

Parse and Filter the Output:

[0164] Starting with the output list of all possible epitopes from the epitope prediction software, the inventors apply specific filters to choose the best mutant peptide incorporating candidates. First, further consideration is restricted to strong to intermediate binding peptides by focusing on candidates with a mutant (MT) binding score of less than 500 nM or less than 250 nM. Second, epitope binding calls are evaluated only for those peptides that contain the mutant amino acid (localized peptides). This filter eliminates any wild-type (WT) peptides that may overlap between the two FASTA sequences. The pVAC-seq workflow enables screening across multiple lengths and multiple alleles very efficiently. If predictions are run to assess multiple epitope lengths (e.g., 9-mer, 10-mer, etc.), and/or to evaluate all different patient HLA allele types, the inventors review all localized peptides and choose the single best binding value representative across lengths (9aa, 10aa, etc.) based on lowest binding score for MT sequence. Furthermore, they choose the 'best candidate' (lowest MT binding score) per mutation between all independent HLA allele types that were used as input.

Integrate Expression and Coverage Information

[0165] Subsequently several filters are applied to ensure that the predicted neoantigens are expressed as RNA variants, and are predicted correctly based on coverage depth in the normal and tumor tissue data sets. Specifically, gene expression levels from RNA-Seq data measured as Fragments per kilobase of exon per million reads mapped (FPKM) provide a method to filter only the expressed transcripts. We used the tuxedo suite—Tophat (Trapnell, C. et al., Bioinformatics, 25, 1105-1111, 2009; Kim, D., et al., Genome Biol., 14, R36, 2013) and Cufflinks (Trapnell, C., et al., Nat. Protoc., 7, 562-578, 2012) as part of the GMS to align RNA-Seq data and subsequently infer gene expression for our in-house sequencing data. Depending on the type of RNA prep kit, OVATION® RNA-Seq System V2 (NuGEN Technologies, Inc. San Carlos, Calif.) or TRUSEQ® Stranded Total RNA Sample Prep kit (ILLUMINA®, Inc. San Diego, Calif.), used, Tophat was run with the following parameters: Tophat v2.0.8 '-bowtie-version-2.1.0' for OVATION®, and '-library-type fr-firststrand-bowtie-version=2.1.0' for TRUSEQ®. For OVATION® data, prior to alignment, paired 2×100 bp sequence reads were trimmed with Flexbar version 2.21 (Dodt, M., et al. Biology (Basel), 1, 895-905, 2012.) (params: -adapter CTTTGTGTTTGA (SEQ. ID NO: 474)-adapter-trim-end LEFT-nono-length-dist-threads 4-adapter-min-overlap 7-maxuncalled 150-min-readlength 25) to remove single primer isothermal amplification adapter sequences. Expression levels (FPKM) were calculated with Cufflinks v2.0.2 (params-max-bundle-length=10000000-num-threads 4).

[0166] For selecting unique vaccine candidates, targeting the best 'quality' of mutations is an important factor for prioritizing peptides. Sequencing depth as well as the fraction of reads containing the variant allele (VAF) are used as criteria to filter or prioritize mutations. This information was added in our pipeline via bam-readcount (Larson, D., The Gnome Institute at Washington University). Both tumor (from DNA as well as RNA) and normal coverage are calculated along with the VAF from corresponding DNA and RNA-Seq alignments.

Filter Neoepitope Candidates

[0167] Since manufacturing antigenic peptides can be one of the most expensive steps in vaccine development and efficacy depends on selection of the best neoantigens, the inventors filter the list of predicted high binding peptides to the most highly confident set, primarily with expression and coverage based filters.

The Filters can be Employed as Follows:

[0168] Depth based filters: any variants with normal coverage <=5× and normal VAF of >=2% can be filtered out. The normal coverage cutoff can be increased up to 20× to

eliminate occasional misclassification of germline variants as somatic. Similarly, the normal VAF cutoff can be increased based on suspected level of contamination by tumor cells in the normal sample. For tumor coverage from DNA and/or RNA, a cutoff can be placed at >=10× with a VAF of >=10% or 30%. This can ensure that neoantigens from the major clones in the tumor are included, but the tumor VAF can be lowered to capture more variants, which may or may not be present in all tumor cells. Alternatively, if the patients are selected based on a pre-existing disease-associated mutation such as BRAF V600E in the case of melanoma, the VAF of the specific presumed driver mutation can be used as a guide for assessing clonality of other mutations.

[0169] Expression based filters: as a standard, genes with FPKM values of greater than zero are considered to be expressed. The inventors slightly increase this threshold to 1, to eliminate noise. Alternatively, the FPKM distribution (and the corresponding standard deviation) can be analyzed over the entire sample, to determine the sample-specific cutoffs for gene expression. Spike-in controls can also be added to the RNA-Seq experiment to assess quality of the sequencing library and to normalize gene expression data. This filtered list of mutations can be manually reviewed via visual inspection of aligned reads in a genome viewer like IGV (Robinson, J. T., et al., Nat Biotechnol., 29, 24-26, 2011; Thorvaldsdottir, H., et al. Brief Bioinform., 14, 178-192, 2013) to reduce the retention of obvious false positive mutations.

Analysis of T Cell Responses

[0170] For functional characterization, neoantigen-specific T cell lines were generated using autologous mDC and antigen loaded artificial antigen presenting cells at a ratio of 1:1 as previously described (Carreno, B. M., et al., J. Immunol., 188, 5839-5849, 2012). To determine the peptide avidity (effective concentration at 50% maximal lysis, EC50) of neoantigen-specific T cells, T2 cells were pulsed with titrated peptide concentrations for 1 h, followed by ^{51}Cr (25μCi) labeling for 1 h, washed twice and tested in a standard 4 h ^{51}Cr release assay using neoantigen-specific cells as effectors. For production of cytokines, neoantigen-specific T cells were restimulated using artificial antigen presenting cells in the presence or absence of peptide, supernatants collected at 24 h and cytokine produced determined using MILLIPLEX® MAP Human Cytokine Panel I (EMD Millipore).

Overview of the Present Teachings

[0171] FIG. **4** illustrates a scheme showing neo-antigen identification and its incorporation into a personalized dendritic cells vaccine. The upper diagram depicts a pipeline for neoantigen identification. Tumor cells and matched peripheral blood mononuclear cells (PBMC) are subjected to whole exome sequencing to identify somatic missense mutations. Missense mutations are evaluated as peptides (8-13 aa long) through MHC class I binding and algorithms to identify potential candidate neoantigens and the expression of transcripts encoding mutated protein is confirmed by transcriptome sequencing. Synthetic peptides encoding candidate neoantigens can be tested experimentally for MHC class I binding and vaccine candidates can be selected using characteristics described infra. The lower diagram represents a vaccination process whereby dendritic cells (DC) can be generated from monocytes using GM-CSF and IL-4, and matured using CD40L/IFN-g/poly IC and R848. Mature DC can be pulsed with candidate neoantigen peptides and infused in order to generate mutation (missense)-specific T cells.

EXAMPLES

[0172] The present teachings it descriptions that are not intended to limit the scope of any aspect or claim. Unless specifically presented in the past tense, an example can be a prophetic or an actual example. The examples and methods are provided to further illustrate the present teachings. Those of skill in the art, in light of the present disclosure, will appreciate that many changes can be made in the specific embodiments that are disclosed and still obtain a like or similar result without departing from the spirit and scope of the present teachings.

Example 1

[0173] This example illustrates the clinical use of common cancer antigen peptides and the difficulties of using matured dendritic cells in cancer vaccines.

[0174] Vaccination was performed with HLA-A*0201-restricted gp100 melanoma antigen-derived peptides (G209-2M, and G280-9V) (Carreno, B. M., et al., J. Clin. Investigation, 123, 3383-3394, 2013; Kawakami, Y., et al., J. Immunol., 154, 3961-3968, 1995; Skipper, J. C., et al., Int. J. Cancer, 82, 669-677, 1999) using autologous peptide-pulsed, CD40L/IFN-γ-activated mature DCs (mDCs). The top of FIG. **17** illustrates the comparison of gp100 (G209-2M and G280-9V)-specific T cell frequencies observed pre- and post-vaccine. Statistical assessment was performed using paired two-tail t-test; p values are indicated in figure. The table on FIG. **17** bottom left summarizes the characteristics of patients enrolled in the trial and details their clinical outcomes: CR, complete response; PR, partial response: PD, progressive disease.

[0175] The bottom left of FIG. **17** illustrates radiologic studies (FDG-PET/CT imaging) that were obtained on Patient 1 before vaccination, 11 months and 21 months after treatment. Coronal whole body PET images show complete regression of left supra-clavicular and hilar lymph nodes as well as multiple subcutaneous lesions on the right leg. P1 remains in remission as of December 2012.

[0176] FIG. **18** illustrates that ex-vivo dendritic cell (DC) IL-12 production and Tc1 profile correlates with clinical outcome (TTP, time to progression) (Carreno, B. M., et al., J. Clin. Invest., 123, 3383-3394, 2013). A Cox regression analysis followed by likelihood-ratio test revealed a positive correlation between IL-12 production and TTP (FIG. **18**, top; p=0.0198, log rank). Filled (dark) circles indicate patients that had a confirmed clinical response (P1, CR; P5 and P6, PR; FIG. **17**, bottom left) with disease progression observed at or after 11.5 months of treatment initiation. The open (white) circles represent patients with rapid disease progression. The analysis was performed on Aug. 5, 2012, P1 remains in complete remission 4 years after initiation of treatment. No correlation was observed between IL-12 production and immune response or immune response and clinical outcome. Cytokine ratios differed among clinical responders (Clin Resp) and non-responder (Clin non-Resp) patients and demonstrate a Tc1 profile (FIG. **18**, bottom;

high IFN-g, low IL-5 or IL-13) among responders. p values are indicated in figure, unpaired two-tailed t-test.

[0177] FIG. **19** illustrates that weak p35 transcription accounts for the IL-12p70 defect in clinical non-responder patients (Carreno, B. M., et al., J. Clin. Invest. 123, 3383-3394, 2013). FIG. **19** top, left DC from age and gender matched healthy (H) donors and melanoma (M) patients were activated with CD40L/IFN-γ for 24 h, supernatants harvested and assayed for IL-12 production by ELISA. Horizontal lines and whiskers indicated median and interquartile range. p=0.0420, Wilcoxon matched-pairs test. Healthy individuals;produced on average ~10× more IL12p70 than melanoma patients. Patient DC were activated with CD40L/IFN-γ for 24 h, supernatants were collected and IL-12p40 (circles) and IL-12p70 (squares) production measured by ELISA (FIG. **19**, top right). Results are shown for 10 melanoma patients. Horizontal lines and whiskers indicated median and interquartile range. Results demonstrate a defect on IL-12p70 (p40/p35) but not in IL-12p40 suggesting defect lies in induction of IL-12p35. To examine IL-12p35 gene activation, DC were activated with CD40L/IFN-γ for 6 h, cells harvested, washed and total RNA prepared. Total RNA was also prepared from immature DC. Using p35 and CD11c (DC lineage marker) specific primers, qRT-PCR was performed and analyzed using the relative standard method. Values shown in FIG. **19** (bottom) were normalized to expression CD11c and p35 fold induction in mature DC calculated relative to immature DC. Results decreased IL-12p35 induction in clinical non-responding patients (P2, P3, P7).

Example 2

[0178] This example illustrates techniques of maturing DC that overcome the limitations discussed in Example 1.

[0179] Based on the results obtained in Example 1, different DC maturation techniques were required to increase clinical response to cancer antigens. The inventors therefore tested maturation signals for dendritic cells. Immature DC were stimulated with a combination of CD40L/IFN-γ plus poly I:C (30 ug/mL, TLR3 agonist) and R848 (5 μg/mL, TLR8 agonist) (P8-P10) for 24 h and supernatants assayed for IL-12. As a control, data from immature dendritic cells stimulated with CD40L/IFN-γ(patients P1-P7; Carreno, B. M., et al., J. Clin. Invest. 123, 3383-3394, 2013) were plotted on the same graph. The results depicted in FIG. **20** demonstrate that a combination of all 4 signals enhances IL-12p70 production to levels similar to those observed m healthy individuals (see FIG. **19** top left for the baseline).

[0180] A combination of innate and adaptive signals for DC maturation enhances the kinetics of the immune responses to gp100 (g209-2M and G280-9V) antigens. FIG. **21**, left demonstrates that gp100-specific T cell responses can be detected in patients vaccinated with CD40L/IFN-γ/TLR3/8 agonist-matured DC as early as one week after vaccination (bottom left). In contrast, two vaccinations with CD41/IFN-g matured DCs are required for detection of gp100-specific cell responses (FIG. **21**, top left). Time is recorded in weeks. Antigen-specific numbers were calculated based on dextramer percentage and total live cell yields. The dot plots (FIG. **21**, right) depict frequencies of gp100-specific T cells in ex-vivo expanded peripheral blood mononuclear cells obtained pre- and post-vaccination. FIG. **22** illustrates that a combination of innate and adaptive signals for DC maturation promotes Tc1-polarized immunity. Purified CD8+ T cells were stimulated twice in vitro and antigen-specific frequencies determined by peptide/HLA-A*0201 tetramers. T cells were adjusted to 10^6 cell/mL, stimulated with antigen and supernatants harvested at 20 h. Cytokine production was determined using MILLIPLEX® MAP Human Cytokine Panel I (FIG. **22**, top). To compare production of Tc1 (IFN-γ) and Tc2 (IL-5, IL-13) cytokines among patients, a cytokine ratio was derived by dividing pg/mL IFN-γ by pg/mL IL-5 or IL-13. Ratios>1 indicate a Tc1 phenotype (FIG. **21**, bottom).

Example 3

[0181] This example illustrates in silico analysis of missense mutations found in melanoma tumors.

[0182] FIG. **23** illustrates that cutaneous melanoma harbors a significant mutation burden and hence continues a cancer model to study tumor somatic mutations as neoantigens. Mutation pattern, spectrum and clinical features in 15 metastases from 13 WGS melanoma cases are illustrated. Numbers and frequencies of Tier 1 transitions and transversions events identified in all 15 tumors are shown. Hence, melanoma patients were chosen for further study of personalized vaccines.

[0183] The diagram in FIG. **2** illustrates an example derived from analysis of a tumor/PBMC matched pair derived from a melanoma patient. As depicted multiple candidate patient-specific tumor-derived epitopes can be identified per HLA-class 1 molecule; in this particular case, those presented by HLA-A*0201 are shown. The analysis depicted here can be performed for each of the HLA class I alleles (n=3-6) expressed by the patient.

[0184] In various embodiments, the present teachings include analysis of missense mutations by prediction algorithms for binding to HLA-A*0201. Table 1 shows the chromosomal (CHR) location, genomic alignment position and nucleotide change encoding missense mutation in metastases (breast, abdominal wall) derived from a patient. Exomic variant allele fraction (under exome column) for each mutation as well as gene encoding mutation and amino acid change are shown. One mutation in OR5K2 is unique to breast metastasis, while mutations in CCDC57 and IL17Ra are unique to abdominal wall metastasis. Proteins encoding missense mutations were analyzed using the NetMHC and NetMHCstab algorithms in order to predict mutation-containing peptides (9-11 amino acid in length) that may bind to any of patient's HLA-class I molecules. Candidate peptides to consider for a vaccine are selected based on variant frequencies (exome, transcriptome>10), expression (FPKM>1) and HLA class I affinity (<250 nM0 and stability (>2 h). In Table 1, mutated peptides fulfilling these criteria are highlighted in bold. NR=not recorded.

Example 4

[0185] This example illustrates the in vitro binding of neoantigen peptides to HLA class I molecules.

[0186] In some embodiments, the present teachings disclose HLA class I binding capacity of peptides containing tumor-specific missense mutations. The binding capacity of missense mutation-containing peptides is experimentally evaluated using a flow cytometric assay. Peptide binding to cell surface HLA class I can lead to stable peptide/HLA class I complexes that can be detected using a HLA-class I allele specific antibody. Four control peptides can be included in

the assay, two known HLA-A*0201 binding peptides (FluM1,G280-9V) and 2 negative controls (G17, NP265). In the graph shown in FIG. **3**, binding of mutation-containing peptides to HLA-A*0201 expressed on the surface of T2 cells is examined. Nine of the 15 mutation-containing peptides tested bound to HLA-A*0201 and all these peptides show affinities<250 nM.

Example 5

[0187] This example illustrates the translation of tumor missense imitations into patient-specific vaccines. FIG. **24** (top) illustrates the distribution of somatic missense mutations identified in a melanoma patient (MEL38) tumor. HLA-A*02:01-binding candidate peptides were in silico identified among amino acid substituted peptides and expression of gene encoding mutated protein determined from cDNA capture data. FIG. **24** (bottom) illustrates the immune-monitoring of neoantigen-specific CD8+ cell responses. Results are derived from PBMC isolated before DC vaccination (Pre-vaccine) and at peak (Post-Vaccine). PBMCs were cultured in vitro in the presence of peptide and IL-2 for 10 days followed by HLA-A*02:01/neoantigen-peptide dextramer assay. This immune monitoring strategy allows the reliable detection, as well as, the assessment of replicative potential of vaccine-induced T cell responses. Numbers within dot plots represent percent neoantigen-specific T cells in lymph+/CD8+ gated cells. A pre-existing response to one neoantigen (SEC24A) was observed; vaccination enhance this response and reveal two additional ones (AKAP13 and OR8B3). Demonstrating that tumor somatic mutations can be immunogenic and that vaccination can expand the antigenic diversity of such response.

Example 6

[0188] This example illustrates CD8+ T cell response to mutation containing peptides.

[0189] In some embodiments, the present teachings include vaccination with tumor-specific missense mutations to elicit CD8+ T cell immunity. As shown in FIG. **5**, a dextramer assay (Carreno, B. M., et al., J. Clin. Invest., 123, 3383-3394, 2013) was used to monitor development of CD8+ T cell immunity to mutation-containing peptides. Dot plots show frequencies of CD8+ T cells specific for the mutation-containing peptides prior to vaccination (pre-vacc) and after 2-3 vaccinations (post-vacc). In all 3 patients, responses to 3 of the 7 peptides are observed as demonstrated by an increase in the frequency of dextramer+ T cells.

[0190] In some embodiments, predicted affinities (FIG. **6** top) and stabilities (FIG. **6** bottom) of mutated peptides and their wild-type counterparts can be compared. In FIG. **6**, mutated peptides (two-antigens) that elicited CD+ T cell immunity are indicated by rectangles. All immunogenic peptides display HLA-A*0201 affinities of <50 nM and stabilities>3 h. These characteristics can be important as determinants of immunogenicity. These characteristics can be taken into consideration when choosing mutation-containing peptides to incorporate in a vaccine.

[0191] In some embodiments, the present teachings include vaccine-induced CD8+ T cells directed at tumor missense mutations display high replicative potential. As shown in FIG. **7** and FIG. **8**, after 3 DC vaccinations, leukapheresis was performed in patients in order to obtain PBMC. CD8+ T cells purified from PBMC were stimulated with neo-antigen-peptide pulsed autologous DC and cultured in the presence of IL-2 for 10 days. These primary cultures were re-stimulated with peptide-pulsed K562-expressing HLA-class I single-chain dimer (SCD) as described (Carreno, B. M., et al., J. Immunol., 188, 5839-5849, 2012). Cultures were maintained for an additional 10 day period in the presence of IL-2. FIG. **7** depicts results from the dextramer assay, the frequencies (%) neo-antigen specific T cells found in the CD8+ T cell population at initiation of cultures (Blood, day 0) and after DC/SCD stimulation (Expanded, day 20) were determined. FIG. **8** illustrates that based on viable cell counts and antigen-specific T cell frequencies, at initiation and termination of cultures, antigen-specific T cell yields and expansion folds were calculated. Antigen-specific yields were calculated as the % of HLA/Ag dextramer+ CD8+ T cells×total CD8+ T cell numbers at day 20. Antigen-specific cell folds represented (% of HLA/Ag dextramer+ CD8+ T cells×total CD8+ T cell numbers at day 20)/(% of HLA/Ag dextramer+ CD8+ T cells× total CD8+ T cell numbers at day 0). Results demonstrated that this method allows the expansion of vaccine-induced T cells over 10^4 fold (FIG. **8**, right panel). A 10^4 fold expansion yields 10^8 antigen-specific T cells from a starting population with $<10^4$ antigen-specific T cells.

Example 7

[0192] This example illustrates the specificity of neoantigen peptide recognition by CD8+ T cells.

[0193] In various embodiments, the present teachings include disclosure of discrimination between mutated and wild-type sequences by vaccine-induced CD8+ T cells.

[0194] As illustrated in FIG. **9** and FIG. **10**, to determine whether vaccine-induced T cells could recognize naturally processed antigen, the melanoma tumor cell line DM6 was transduced with a multi-mini-gene construct encoding mutated (MUT) or wild-type (WT) sequences of peptides incorporated into a vaccine. FIG. **9** illustrates that each minigene consists of 21 aa encoding either the MUT or WT sequences. A scheme depicting minigene construct characteristics and a representative MUT 21-mer aa sequence encoded in construct is shown. Vaccine-induced T cells, specific for AKAP13 containing the Q285K mutation, were incubated with MUT or WT expressing DM6 cells, supernatants collected after 24 h of incubation, and IFN-γ produced by T cells was measured in supernatants by ELISA (FIG. **10**). Results indicate that the AKAP13 (Q285K) neo-antigen is processed, presented and recognized by vaccine-induced T cells. The results indicate that a vaccine comprising mutation-containing peptides plus autologous DC can induce cells that will recognize processed and presented antigens on the tumor cell surface.

[0195] For therapeutic use of vaccine-induced T cells, it can be important to determine whether responses elicited by MUT peptides can cross-react with WT sequences. T cell responses that cannot discriminate between MUT and WT sequences may have adverse effects if given to patients as part of adoptive cell therapy.

[0196] To examine cross-reactivity, T2 cells were pulsed with MUT or WT peptide at the indicated concentrations, labeled with ^{51}CR-chromium and used as target in a cytotoxic assay. Vaccine-induced T cells were incubated with peptide-pulsed T2 cells and ^{51}Cr-Chromium release measured at 4 h. Results obtained with T cell lines specific for 3 mutated peptides are shown in FIG. **11-12**. The results

indicate that T cells can display exquisite antigen specificity and can discriminate between peptide sequence containing single an changes, as shown for AKAP13 and Sec24A (FIG. **11**). Only peptides containing the mutated aa can induce lysis of targets. On the other hand, other T cell lines cannot discriminate between MUT and WT sequences as shown for responses directed at OR8B3 (FIG. **12**). Thus, screening for cross reactivity can be important in the selection of mutation-specific vaccine-induced T cells to be incorporated in adoptive T cell therapies, only those free of reactivity to WT sequences should be considered.

Example 8

[0197] This example illustrates that vaccine-induced mutation-specific T cells discriminate between mutated (MUT) and wild type (WT) sequences and recognized processed and presented antigens. Neoantigen-specific T cells recognition of mutated (closed circles) and wild type (open circles) peptides was determined in a standard 4 h ^{51}Cr-release assay using peptide titrations on T2 (HLA-A*02:01) cells. Percent specific lysis of triplicates (mean±standard deviation) is shown in FIG. **25** (left) for each peptide concentration; spontaneous lysis was <5%. Results are shown at 10:1 E:T ratio. T cells generated against mutated sequences do not recognize wild-type sequences. Thus, T cells induced by vaccine demonstrate an exquisite specificity for mutated antigen. Neoantigen-specific T cells were co-cultured with DM6 expressing mutated—(closed rectangles) or wild type—(closed circles) tandem mini-gene constructs in a 4 h ^{51}Cr-release assay. Media represent lysis obtained with parental DM6 cells. Percent specific lysis of triplicates (mean±standard deviation) is shown in FIG. **25** (right) for each E:T ratio; spontaneous lysis was <5%. Therefore, immunization with autologous mature IL-12p70 producing DC elicits shared self-antigen specific T cell responses in humans with cancer. Collectively, these data show that clinical benefit correlates with IL-12p70 which dictates lineage commitment to type-I T cell immunity.

Example 9

[0198] This example illustrates cytokine production in response to neoantigen peptides.

[0199] In various embodiments, a vaccine of the present teachings can induce CD8+ T cells to display a Tc1 profile.

[0200] Substantial evidence supports the hypothesis that Th2/Tc2 immune polarization correlates with worse disease outcome in patients with cancer (Fridman, W. H., et al., Nat. Rev. Cancer, 12, 298-306, 2012). In our previous study (Carreno, B. M., et al., J. Clin. Invest., 123, 3383-3394, 2013) the inventors demonstrated that patients presenting vaccine-induced T cells displaying a Tc1 (high IFN-γ, low IL-4, -5, -13 production) benefited from vaccine as determined by an increased time to progression. Thus, we determined production of cytokines upon antigen stimulation as described above. In these studies, neo-antigen-specific AKAP13 (Q285K) T cells were incubated with peptide-pulsed SCD-expressing cells and supernatants collected 24 h after stimulation. Cytokine production was determined using a multi-plex bead assay. Results illustrated in FIG. **13** indicate that vaccine-induced T cells produced large amounts of IFN-γ relative to IL-4, -5 and -13 and hence display a Tc1 phenotype.

Example 10

[0201] This example illustrates successful treatment of melanoma in mice using a vaccine of the present teachings.

[0202] In some embodiments, the present teachings disclose that adoptive transfer of human antigen-specific T cells can lead to melanoma rejection. In investigations by the inventors, humanized mice were inoculated i.v. with luciferase-expressing melanoma. Ten days later (indicated by vertical arrows FIG. **14-15**) mice received a single dose of melanoma-specific human T cells (n=5 mice/treatment). FIG. **14** depicts tumor regression monitored by luciferase (photon flux). As shown in FIG. **14** and FIG. **15**, in untreated mice luciferase signal increases with time as a result of tumor growth. Conversely in mice treated with T cells, a decrease in luciferase signal was observed. This signal decrease is proportional to the number on cells transferred. These data demonstrate the T cell transfer can result in tumor regression. Importantly, tumor regression can lead to increased survival (FIG. **16**). In some configurations, concentration of $>10^7$ T cells/mouse can lead to significant changes in survival rates in this model. Adoptive transfer of mutation-specific T cells can lead to tumor regression in this animal model. Furthermore, these pre-clinical results can translate into therapeutic benefit for cancer patients.

Example 11

[0203] This example illustrates selection of neoantigens for further study.

[0204] Tumor missense mutations (MM), translated into amino acid substitutions (AAS), may provide a form of antigens that the immune system perceives as foreign, which elicits tumor-specific T cell immunity (Wölfel, T., et al., Science, 269, 1281-1284, 1995; Coulie, P. G., et al., Proc. Nat'l. Acad. Sci. USA 92, 7976-7980, 1995; van Rooij, N. et al., J. Clin. Oncol., 31, e439-e442, 2013; Robbins, P. F., et al., Nat. Med., 19, 747-752, 2013). In these experiments, three patients (MEL21, MEL38 and MEL218) with stage III resected cutaneous melanoma were consented for genomic analysis of their surgically excised tumors and subsequently enrolled in a phase 1 clinical trial with autologous, functionally mature, interleukin (IL)-12p70-producing dendritic cell (DC) vaccine (FIG. **26**A-B) (Carreno, B. M., et al., J. Clin. Invest., 123, 3381-3394, 2013). FIG. **26**A illustrates that dendritic cells (DC) were matured with CD40L, IFN-γ plus TLR3 (poly I:C) and TLR8 (R848) agonists in order to optimize the production of IL-12p70. Results shown are the ex-vivo IL-12p70 levels produced by patient-derived mature DC used for manufacturing vaccines doses D1-D3 (each symbol represents a vaccine dose). DC supernatants were harvested 24 h after activation and IL-12p70 production levels determined by ELISA. Results represent mean±SEM. FIG. **26**B illustrates that study timelines depicting cyclophosphamide treatment (300 mg/m^2 i.v), DC vaccinations (D1-D3), PBMC sampling for immune monitoring and leukapheresis collections. The vaccine dosing schedule was altered from every 3 weeks to every 6 weeks based on the kinetics of the T cell response previously reported (Carreno, B. M., et al., J. Clin. Invest., 123, 3383-3394, 2013).

[0205] All tumor samples were flash frozen except one from MEL 21 (skin, Jun. 6, 2013), which was formalin-fixed paraffin embedded. Peripheral blood mononuclear cells (PBMC) were cryopreserved as cell pellets. DNA samples were prepared using QIAAMP® DNA Mini Kit (Qiagen)

and RNA using High Pure RNA Paraffin kit (Roche), DNA and RNA quality was determined by NANODROP® 2000 and quantitated by the QUBIT® Fluorometer (Life Technologies). For each patient, tumor/PBMC (normal) matched genomic DNA samples were processed for exome sequencing with one normal and two tumor libraries, each using 500 ng DNA input (Service, S. K. et al., P.L.o.S. Genet., 10, e1004147, 2014). Exome sequencing was performed to identify somatic mutations in tumor samples.

[0206] Tumor M M, translated as AAS-encoding nonamer peptides, were filtered through in silico analysis to assess HLA-A*02:01 peptide binding affinity (Nielsen, M. et al., Protein Sci., 12, 1007-1017, 2003). Alignment of exome reads was performed using the inventors' Genome Modeling System (GMS) processing-profile. This pipeline uses BWA (version 0.5.9) for alignment with default parameters except for the following: '–t 4 –q 5'. All alignments were against GRCh37-lite-build37 of the human reference genome and were merged and subsequently de-duplicated with Picard (version 1.46). Detection of somatic mutations was performed using the union of three variant callers: 1) SAMtools version r963 (params: –A –B) filtered by snp-filter v1 and further intersected with Somatic Sniper version 1.0.2 (params: –F vcf q 1 –Q 15) and processed through false-positive filter v1 (params: -bam-readcount-version 0.4-bam-readcount-min-base-quality 15 min-mapping-quality 40-min-somatic-score 40) 2) VarScan Somatic version 2.2.6 filtered by varscan-high-confidence filter version v1 and processed through false-positive filter v1 (params, -bam-readcount-version 0.4bamreadcount-min-base-quality 15), and 3) Strelka version 1.0.10 (params: isSkipDepthFilters=1). Amino acid substitutions (AAS) corresponding to each of the coding missense mutations (MM) were translated into a 21-mer amino acid FASTA sequence, with ideally 10 amino acids flanking the substituted amino acid on each side.

[0207] Each 21-mer amino acid sequence was then evaluated through the HLA class I peptide binding algorithm NetMHC 3.4 to predict high affinity HLA-A*02:01 nonamer peptides for the AAS—as well as the WT sequence to calculate differences in binding affinities (8, 32). Any peptides with binding affinity IC_{50} value<500 nM were considered for further analysis.

[0208] Experimental expression of genes encoding predicted HLA-A*02:01 peptide candidates was determined by cDNA capture. All RNA samples were DNase-treated with TURBO DNA-FREE™ kit (Invitrogen) according to the manufacturer's instructions; RNA integrity and concentration were assessed using Agilent Eukaryotic Total RNA 6000 assay (Agilent Technologies) and QUANT-IT™ RNA assay kit on a QUBIT™ Fluorometer (Life Technologies Corporation).

[0209] Given the dynamic nature of genomic technologies, multiple overlapping methods were tested. However, results for tumors within a patient (Tables 2-4) are consistent with one methodology: NuGen OVATION® V2 for MEL38 and MED218, Illumina TRUSEQ® Stranded for MEL21. The MicroPoly(A)PURIST™ Kit (Ambion) was used to enrich for poly(A) RNA from MEL218 and MEL38 DNAse-treated total RNA; MEL21 RNA was ribo-depleted using the RIBO-ZERO™ Magnetic Gold Kit (EpiCeture, Madison Wis.) following the manufacturer protocol. The inventors used either the OVATION® RNA-Seq System V2 (NuGen, 20 ng of either total or polyA RNA), or the OVATION® RNA-Seq FFPE System (NuGen, 150 ng of DNase-treated total RNA) or the TRUSEQ® Stranded Total RNA Sample Prep kit (Illumina, 20 ng ribosomal RNA-depleted total RNA) for cDNA synthesis. All NuGen cDNA sequencing libraries were generated using NEBNEXT® ULTRA™ DNA Library Prep Kit for ILLUMINA® with minor modifications.

[0210] All NuGEN generated cDNA was processed as described previously (Cabanski, C. R., et al., J. Mol. Diagn., 16, 440-451, 2014). Briefly, 500 ng of cDNA was fragmented, end-repaired, and adapter-ligated using IDT synthesized "dual same index" adapters. The TRUSEQ® stranded cDNA was also end-repaired and adapter-ligated using IDT synthesized "dual same index" adapters. These indexed adapters, similar to Illumina TRUESEQ® HT adapters, contain the same 8 bp index on both strands of the adapter. Binning reads requires 100% identity from the forward and reverse indexes to minimize sample crosstalk in pooling strategies. Each library ligation reaction was PCR-optimized using the Eppendorf Epigradient SqPCR instrument, and PCR-amplified for limited cycle numbers based on the Ct value in the optimization step.

[0211] Libraries were assessed for concentration using the QUANT-IT™ dsDNA HS Assay (Life Technologies) and for size using the BioAnalyzer 2100 and the Agilent DNA 1000 Assay (Agilent Technologies). The ILLUMINA®-ready libraries were enriched using the Nimblegen SeqCap EZ Human. Exome Library v3.0 reagent. The targeted genomic regions in this kit cover 63.5 Mb or 2.1% of the human reference genome, including 98.8% of coding regions, 23.1% of untranslated regions (UTRs), and 55.5% of miRNA bases (as annotated by Ensembl version 73 (Flicek. P., et al., Nucleic Acids Res., 41, D48-55, 2013)). Each hybridization reaction was incubated at 47° C. for 72 hours, and single-stranded capture libraries were recovered and PCR-amplified per the manufacturer's protocol. Post-capture library pools were sized and mixed at a 1:0.6 sample: Ampure XP magnetic head ratio to remove residual primer-dimers and to enrich for a library fragment distribution between 300 and 500 bp. The pooled capture libraries were diluted to 2 nM for Illumina sequencing.

[0212] For cDNA-capture data were aligned with Tophat v2.0.8 (params: version=2.1.0 for OVATION®; -library-type fr-firststrand-bowtie-version=2.1.0 for TRUSEQ®). For OVATION® data, prior to alignment, paired 2×100 bp sequence reads were trimmed with flexbar v 2.21 (params: -adapter CTTTGTGTTTGA (SEQ ID NO: 474-adapter-trim-end LEFT-nono-length-dist-threads 4-adapter-min-overlap 7-maxuncalled 150-min-readlength 25) to remove single primer isothermal amplification adapter sequences. In seqcap, the relative expression of a transcript is proportional to the number of cDNA fragments that originate from it. Therefore, expression levels expressed as fragments per kilobase of exon per million fragments mapped (FPKM) were calculated with Cufflinks v2.0.2 (Trapnell et al. 2010, Nature Biotechnology 28, 511; params-max-bundle-length=10000000-num-threads 4). A visual review step of cDNA capture data was performed to evaluate for expression of MM identified by exome data. Both cDNA-capture and FPKM values were considered for candidate prioritization.

[0213] FIG. **27** illustrates distribution of somatic (exomic and missense) mutations identified in patients MEL21 and MEL38 metachronous tumors (anatomical location and date

of collection indicated) and patient MEL218 tumor are shown. HLA-A*02:01-binding candidate peptides were identified among AAS and expression of gene encoding mutated protein determined from cDNA capture data (Tables 2-4) as discussed supra. Venn diagrams show expression, among metachronous tumors, of mutated genes encoding vaccine neoantigens. The identities of the three immunogenic neoantigens identified in each patient are depicted in diagrams; type style identifies naturally occurring (italics) and vaccine-induced (bold) neoantigens.

[0214] Peptide candidates for experimental validation were selected according to the strategy described in FIG. **28**: Tumor-specific missense mutations (MM) in melanoma samples were detected using exome sequencing and identified using the union of three variant calling algorithms. BRAF allelic frequency (Tables 2-4) was considered the upper limit variant allelic fraction fix each tumor and used as a comparator to assess the clonality of other MM-encoding genes. Amino acid substitutions (AAS) corresponding to each of the coding MM were translated into a 21-mer amino acid FASTA sequence and evaluated through the HLA class I peptide binding algorithm NetMHC 3.4 to predict HLA-A*02:01 nonamer AAS-encoding peptides with EC_{50}<500 nM. Transcriptional status of genes encoding AAS candidates was determined by cDNA-capture and their expression levels determined using Cufflinks. Filters were applied to deprioritize those with low cDNA-capture (Alt_reads<5) and prioritized those with high numbers of Atl_reads and/or FPKM>1. For MEL21 and MEL38 patients, candidates were prioritized if expressed by more than one metachronous tumor. For experimental validation, candidates were further prioritized on the basis of predicted HLA-A*02:01 binding affinity and/or HLA-A*02:01 affinity differential between AAS- and WT-peptide (Tables 2-4). Only those peptides with confirmed HLA-A*02:01 binding as determined by T2 assay (FIG. **29**) and fluorescence polarization assay [log(IC_{50} nM)<4.7, Table 5]were prioritized for vaccine formulation.

[0215] HLA-A*02:01 binding was evaluated using the T2 assay (See Analysis of T cell responses) (FIG. **29**) (Elvin, J., et al., J. Immunol. Methods, 158, 161-171, 1993) and confirmed in the fluorescence polarization-based competitive peptide binding assay (Buchli, R., et al., Biochemistry, 44, 12491-12507, 2005). FIG. **29** illustrates AAS-encoding peptide binding to HLA-A*02:01. T2 cells were incubated with 100 uM of the indicated peptide for 16 h, washed and stained with PE-conjugated anti-HLA-A*02:01 (clone BB7.2) monoclonal antibody. Melanoma G280-9V and Influenza NP265 peptides represent positive and negative controls, respectively. Binding fold are calculated as MFI experimental peptide/MFI NP265 peptide. Data are representative of 3 independent experiments. Peptides selected for incorporation in the vaccine formulation are indicated with an asterisk. Per patient, 7 AAS peptide candidates were selected among validated HLA-A*02:01 binders (Table 5) for incorporation into a personalized vaccine formulation along with the melanoma gp100-derived peptides G209-2M and G280-9V (as positive controls for vaccination) (Carreno, B. M., et al., J. Clin. Invest., 123, 3383-3394, 2013). The expression pattern of mutated genes encoding vaccine candidates is shown in Venn diagrams in FIG. **27**.

Example 12

[0216] This example illustrates the effectiveness of personalized dendritic vaccines.

[0217] To examine the kinetics and magnitude of T cell immunity to AAS peptides upon vaccination, peripheral blood mononuclear cells (PBMC) were collected prior to vaccination and weekly thereafter. The CD8+ T cell response to each peptide was analyzed using a HLA-A*02:01/AAS-peptide dextramer assay after a single round of in vitro stimulation. FIG. **30**A illustrates kinetics of immune responses to neoantigens. Time is recorded in weeks (0 indicates pre-vaccination). Culture conditions and staining details are described infra. Antigen-specific numbers were calculated based on dextramer percentage and total live cell yields. Immunologic analysis to evaluate the kinetic and magnitude of T cell response to AAS-encoding and gp100-derived peptides was performed using PBMC collected weekly, starting before DC vaccination (Pre-vaccine in the figures) as described (Carreno, B. M., et al., J. Clin. Invest., 123, 3383-3394, 2013). Briefly, fresh PBMC obtained by Ficoll-Paque PLUS gradient centrifugation were cultured with 40 ug/mL peptide and IL-2 (50 U/mL). On day 10 (peak of response, unpublished data, labeled "Post-Vaccine" in the figures), neoantigen specific T cell frequencies were determined by staining with HLA-A*02:01/peptide dextramers (Immudex), followed by addition of FITC-CD4, -CD14, -CD19 (Invitrogen) and ALEXA® 488-CD56 (BD Pharmigen), APC-CD8 (Invitrogen). Cells were washed, resuspended in FACS buffer containing 7AAD. Twenty five thousand events in the CD8+ gate were collected using a hierarchical gating strategy that included FSC/SSC and excluded 7AAD-positive (dead cells) and CD4/14/19/56-positive cells. PBMC/CD8+ T cells derived from an unrelated HLA-A*02:01 patient were used as negative controls for assessing specificity of HLA-A*02:01/AAS-peptide dextramers (data not shown). Data were acquired and analyzed using Flow-Jo software. Immune monitoring demonstrated that in each patient, T cell immunity to one AAS peptide could be detected in pre-vaccine PBMC samples after in vitro stimulation (FIG. **31**, MEL21:TMEM48 F169L; MEL38; SEC24A P469L and MEL218: EXOC8 Q656P, type style identifies naturally occurring (italics) and vaccine-induced (bold) neoantigens) although not directly from the blood. FIG. **30**B illustrates the frequency of neoantigen specific T cells in CD8+ populations isolated directly from PBMC samples and after ex-vivo expansion using autologous DC and artificial antigen presenting cells. For dominant neoantigens TMEM48 F169L, SEC24A P469L and EXOC8 Q656, results are shown for samples obtained before vaccination (Pre-vaccine) and after 3 vaccine doses (Post-vaccine). For remaining neoantigens, results obtained with post-vaccine PBMC samples are shown. Percentage of neoantigen-specific CD8+ T cells is indicated in the right upper quadrant of the plot. A representative experiment of two performed is shown. Pre-existing immunity to these three neoantigens was confirmed in ex-vivo expanded pre-vaccine purified CD8+ T cells using dextramer assay (FIG. **30**B) and interferon (IFN)-γ production. FIG. **30**C illustrates ex-vivo expanded pre-vaccine neoantigen-specific T cells (dextramer % shown in FIG. **30**B) were stimulated with artificial antigen presenting cells in the presence (closed bar) or absence (open bar) of AAS-peptide and supernatants were harvested at 24 h. IFN-γ production was determined using ELISA assay. Mean values+/−standard deviation (SD) of duplicates are shown. Cytokine production by T cells in the absence of any stimuli was <100 pg/mL.

[0218] Vaccination augmented the cell response to these neoantigens with observed frequencies of 23% TMEM48 F169L+ CD8+ T cells, 64% SEC24A P469L+ CD8+T cells and 89% EXOC8 Q656P+ CD8 T cells detected, upon culture, at the peak of response (FIG. **31**). Immune monitoring also revealed vaccine-induced T cell immunity to two additional neoantigens per patient: TKT R438W and CDKN2A E153K (55% and 12%, respectively) in patient MEL21; AKAP13 Q285K and OR8B3 T190I (47% and 42%, respectively) in patient MEL38, and MRPS5 P59L and

PABC1 R520Q (58% and 84%, respectively) in patient MEL218 (FIG. **31**). Two (MEL21 and MEL218) of the three patients had pre-existing immunity to G209-2M and G280-9V peptides, as determined by the presence of gp100-specific T cells in pre-vaccine PBMC samples and their ex-vivo expansion upon antigen stimulation. FIG. **32** illustrates the frequency of G209-2M- and G280-9V-specific T cells in CD8+ populations isolated directly from PBMC samples and after ex-vivo expansion using autologous DC and artificial antigen presenting cells. Results are shown for samples obtained before vaccination (Pre-vaccine) and at peak post vaccination (Post-vaccine). Percentage of antigen-specific CD8+ T cells is indicated in the right upper quadrant of the plot. A representative experiment of three performed is shown. Upon vaccination, these T cell responses were enhanced in patients MEL21 and MEL218 and revealed in patient MEL38. FIG. **33** illustrates the kinetics of immune responses to G209-2M and G280-9V peptides. Time is recorded in weeks (0 indicates prevaccination). Culture conditions and staining details are described supra. Antigen specific numbers were calculated based on dextramer percentage and total live cell yields. No T cell immunity was detected to the remaining 12 AAS peptides. Overall, robust neoantigen T cell immunity was detectable as early as week 2 and peaked at week 8-9 after the initial vaccine dose (FIG. **30**A). Neoantigen-specific CD8+ T cells are readily identified by dextramer assay directly in post-vaccine PBMC samples (FIG. **30**B) and memory T cells are detected up to 4 months after the final vaccine dose.

[0219] Analysis of T cell reactivity among the three patients indicated no preferential skewing towards AAS at specific positions in the peptide sequence—that is towards TCR, contact residues or primary anchor residues (Kim, Y., et al., J. Immunol. Methods, 374, 62-69, 2011). Rather, in each patient, T cell immunity appeared to focus on the 3 AAS candidates exhibiting the highest HLAA*02:01 binding affinity while the remaining medium-high affinity peptides were nonimmunogenic (Table 5) (Nielsen M., et al., Protein Sci., 12, 1007-1017, 2003; Buchli, R., et al., Biochemistry, 44, 12491-12507, 2005). Immunogenic AAS peptides (FIG. **27**) were not preferentially derived from genes with high allelic frequency or expression levels (Tables 2-4).

[0220] To characterize the function of vaccine-induced neoantigen-specific T cells, short-term expanded CD8+ T cell lines were established and antigen specificity confirmed by dextramer assay (FIG. **30**B) (Carreno B. M., et al., J. Clin. Invest., 123, 3383-3394, 2013; Carreno, B. M. et al., J. Immunol, 188, 5839-5849, 2012). Neoantigen-specific T cell lines were generated using autologous mDC and antigen loaded artificial antigen presenting cells at a ratio of 1:1 as previously described (Carreno, B. M. et al., J. Immunol. 188, 5839-5849, 2012); antigen-specific frequencies in cell lines are shown in FIG. **30**B. To determine the peptide avidity (effective concentration at 50% maximal lysis, EC_{50}) of neoantigen-specific T cells, T2 cells were pulsed with titrated peptide concentrations for 1 h, followed by ^{51}Cr (25μCi) labeling for 1 h, washed twice and tested in a standard 4 h ^{51}Cr release assay using neoantigen-specific T cells as effectors. For production of cytokines, neoantigen-specific T cells were restimulated using artificial antigen presenting cells in the presence or absence of peptide, supernatants collected at 24 h and cytokine produced determined using MILLIPLEX® MAP Human Cytokine Panel I (EMD Millipore).

[0221] FIG. **34** illustrates that neoantigen-specific T cells recognition of AAS (closed circles) and WT (open circles) peptides was determined in a standard 4 h ^{51}Cr-release assay using peptide titrations on T2 (HLAA*02:01) cells. Percent specific lysis of triplicates (mean+standard deviation) is shown for each peptide concentration; spontaneous lysis was <5%. Results are shown at 10:1 E:T ratios for all cell lines except TMEM48 F169L and CDKN2A E153K cells which are shown at 60:1 E:T ratio. A representative experiment of two independent evaluations is shown. Neoantigen-specific T cells displayed significant levels of cytotoxic activity at AAS peptide concentrations of 1 to 10 nM, a finding that is consistent with high avidity cell recognition of antigen (FIG. **34**). OR8B3 T190I-specific T cells could not discriminate between AAS and wild-type (WT) peptide when presented on T2 cells, while all of the remaining cell lines showed clear specificity for AAS peptide sequences (FIG. **34**).

[0222] The cytokine production profile of these cells was characterized as previously described (Carreno, B. M., et al., J. Clin. Invest., 123, 3383-3394, 2013; Fridman, W. H., et al., Nat. Rev. Cancer, 12, 298-306, 2012). This characterization is illustrated in FIG. **35**: Neoantigen-specific T cells were stimulated with artificial antigen presenting cells in the presence (open bar) or absence (close bar) of AAS-peptide and supernatants were harvested at 24 h. Cytokine production was determined using MILLIPLEX® MAP Human Cytokine Panel I. Mean values+/−SD of duplicates are shown. Cytokine production by T cells in the absence of any stimuli was <100 pg/mL. A representative experiment of 2 performed is shown. FIG. **36** illustrates a comparison of production of Type 1 (IFN-γ) and Type 2 (IL-4, IL-5, IL-13) cytokines among neoantigen-specific T cells, a cytokine index was derived by dividing pg/mL IFN-γ by pg/mL IL-13, IL-5 or IL-4. IFN-γ/IL-13, IFN-γ/IL-5 and IFN-γ/IL-4 ratios above 1 are indicative of Type 1 phenotype. Results are representative of two experiments. Upon antigen stimulation, most vaccine-induced neoantigen-specific T cells produced high amounts of IFN-γ relative to IL-4, IL-5 and IL-13, a pattern that is indicative of a type 1 phenotype (FIG. **35-36**). However, SEC24A P469L specific cells exhibited a type 2-skewed phenotype (high IL-4, IL-5 and IL-13 levels relative, to IFN-γ), and TMEM48 F169L specific T cells showed a mixed phenotype with only higher IL-13 (hut not IL-4 or IL-5) levels relative to IFN-γ (FIG. **35-36**).

Example 13

[0223] This example illustrates the in vitro detection of neoantigens that are presented to immune cells in vivo.

[0224] Tandem mini-gene constructs (TMC) were used for evaluating processing and presentation of neoantigens. The structure of a representative TMC (MEL21 AAS sequences) is shown in FIG. **37**A. All constructs were 19-21-mers encoding AAS- or WT-sequences for peptides included in vaccine. No spacers are present between sequences. A ubiquitination signal and two mini-gene controls (encoding G280 and WNV SVG9 peptides) were included to monitor processing and presentation. The amino acid sequence of a 21-mer encoding TMEM48 F169L is shown with mutated amino acid residue underlined. TMC also encoded the West Nile Virus (WNV) SVG9 (McMurtrey, C. P., et al., P.N.A.S., 105, 2981-2986, 2008) and melanoma G280 (Cox, A. L., et al., Science, 264, 716-719, 1994) antigenic determinants as controls (Table 6).

[0225] TMC were cloned into pMX (GFP+), expressed as retrovirus and used to transfect the HLA-A*02:01+ melanoma lines DM6 (Darrow, T. L., et al., J. Immunol., 142, 3329-3335, 1989) or A375 (obtained from ATCC and mycoplasma free). TMC expressing cells were selected by sorting for GFP+ cells expressing cell surface HLA-A*02:01/SVG9 peptide complexes as detected by a T cell receptor mimic (TCRm) monoclonal antibody (Kim S., et al., J. Immunol., 184, 4423-4430, 2010). AAS- and WT-TMC reactivity with the HLA-A*02:01/SVG9 peptide complex specific TCRm monoclonal antibody validated expression of the mini-gene

constructs. FIG. **37**B demonstrates that expression of AAS- and WT-TMC constructs was determined using a TCR-mimic monoclonal antibody that detects HLAA*02:01/SVG9 (SVGGVFTSV SEQ ID NO: 31) complexes Kim S., et al., J. Immunol., 184, 4423-4430, 2010). Results are shown for parental DM6 (shaded histogram) and DM6 cells expressing AAS—(dashed line) and WT (solid line) TMC constructs. A representative experiment of four performed is shown.

[0226] DM6 cells expressing TMC were labeled with 25μCi ^{51}Cr for 1 h, washed and tested as targets in a standard 4 h assay using neoantigen-specific T cells as effectors (Carreno B. M. et al. 2012 J Immunol 188, 5839). DM6 cells expressing AAS—(closed rectangles) or WT—(closed circles) TMC were co-cultured with neoantigen-specific T cells at a 1:1 ratio, supernatants harvest at 16 h and IFN-γ production evaluated by ELISA as described (Carreno, B. M., et al., J Immunol., 188, 58395849, 2014; plots in FIG. **38**). Open triangles represent lysis obtained with parental DM6 cells. Percent specific lysis of triplicates (mean+standard deviation) is shown for each E:T ratio; spontaneous lysis was <5%. A representative experiment of two independent evaluations is shown.

[0227] FIG. **39** illustrates that neoantigen-specific CD8 T cells were co-cultured with DM6 expressing AAS- or WT-encoding TMC for 20 h and IFN-γ production determined by ELISA. T cells cultured with parental DM6 cells are indicated as media. Mean values+/−SD of duplicates are shown. Results are representative of 2 experiments performed. Seven (TMEM48 F169L, TKT R438W, CDKN2A E153K, SEC24A P469L, AKAP13 Q285K, EXOC8 Q656P and PABPC1 R520Q) of the nine immunogenic neoantigens are processed and presented as evidenced by cytotoxic activity (FIG. **38**) and IFN-γ production (FIG. **39**) by corresponding neoantigen-specific T cells upon co-culture with DM6 expressing AAS-encoding TMC. In contrast, neither cytotoxic activity (FIG. **38**) nor IFN-γ production (FIG. **39**) was observed upon co-culture of OR8B3 T190I- and MRPS5 P59L-specific T cells with DM6 expressing AAS-encoding TMC showing that these neoantigens are not processed and presented from endogenously expressed protein. None of the neoantigen-specific T cells recognized WT-encoding TMC (FIGS. **38** and **39**). Based on these findings and the immune monitoring results (FIG. **31**), the nine neoantigens identified in this study fall into three distinct antigenic determinant categories (Sercarz, E. E., et al., Annu. Rev. Imunol., 11, 729-766, 1993; Assarsson, E., et al., J. Immunol., 178, 7890-7901, 2007). TMEM48 F169L, SEC24A P469L, and EXOC8 Q656P represent dominant antigens as T cell immunity was detected prior to vaccination (naturally occurring) (FIG. **31** and these neoantigens are processed and presented from endogenously expressed protein (FIG. **38**). TKT R438W, CDKN2A E153K, AKAP13 Q285K and PABPC1 R520Q are characterized as subdominant antigens as T cell immunity required peptide vaccination (FIG. **31**) and these neoantigens are processed and presented from endogenously expressed protein (FIG. **38**). And finally, OR8B3 T190I and MRPS5 P59L constitute cryptic antigens since peptide vaccination elicited T cell immunity but these neoantigens are not processed from endogenously expressed protein.

Example 14

[0228] This example illustrates the use of proteomic techniques to determine which neoantigens are presented to cells in vivo.

[0229] To validate neoantigen processing and presentation, proteomic analysis was performed on peptides eluted from soluble HLA-A*02:01 molecules isolated from melanoma cells expressing a TMC encoding AAS candidates from patient MEL218 tumor (Sercarz, E. E., et al., Annu. Rev. Imunol., 11, 729-766, 1993; Assarsson, E., et al., J. Immunol., 178, 7890-7901, 2007). TMC expressing A375 melanoma cells were transfected with soluble HLA-A*02:01(sHLA-A*02:01) and single cell sorted for a high (>1000 ng/ml in static culture) sHLAA*02:01 producing clone. The sHLA-A*02:01 construct includes a C-terminal VLDLr epitope purification tag (SVVSTDDDLA SEQ ID NO. 32) that is recognized by the anti-VLDLr mAb (ATCC CRL-2197). This antibody was also used for quantification of sHLA production as the capture antibody in a sandwich ELISA, with an antibody directed against β2-microglobulin (Dako Cytomation) as the detector antibody. Cells were grown in roller bottles and sHLA/peptide complexes were purified from supernatants by affinity chromatography with the anti-VLDLr antibody (Kaabinejadian, S., et al., P.L.o.S. One, 8, e66298, 2013). Eluate fractions containing sHLA/peptide complexes were brought to a final acetic acid concentration of 10%, pooled, and heated to 78° C. in a water bath. Peptides were purified through a 3 kDa molecular weight cutoff cellulose membrane (EMD Millipore) and lyophilized.

[0230] Synthetic peptides corresponding to the mutant sequences were resuspended in 10% acetic acid in water at 1 μM, and fractionated by RP-HPLC with an acetonitrile gradient in 10 mM ammonium formate at pH 10. Peptide-containing fractions were dried and resuspended in 25 ul of 10% acetic acid and subjected to nanoscale RP-HPLC at pH 2.5 utilizing an Eksigent nanoLC coupled to a TripleTOF 5600 (AB Sciex) quadrupole time-of-flight mass spectrometer (LC/MS). Information dependent acquisition (IDA) was used to obtain MS and MS/MS fragment spectra for peptide ions. The sequence of each peptide was determined by observed mass and fragment ions, and the 1st dimension fraction number and LC/MS retention times were recorded.

[0231] Next, peptides purified from TMC expressing A375 melanoma cells were resuspended in 10% acetic acid and HPLC fractionated under the same conditions and gradient method. Reverse phase HPLC was used to reduce the complexity and determine the elution profile of the pool of soluble HLA-A*02:01 restricted peptides presented by melanoma cells, as well as, the synthetic AAS peptide mixture. FIGS. **40**A and **40**E illustrate RP-HPLC fractionation of HLA-A*02:01 peptides eluted from the AAS-TMC expressing melanoma cell line (solid trace) and the synthetic peptide mixture containing MEL218 neoantigen candidates (dashed trace), with fraction **50** (FIG. **40**A) and fraction **44** (FIG. **40**E) indicated. The HPLC fractions corresponding to those containing the synthetic peptides were then subjected to the same LC/MS conditions. Resulting spectra were found positive for the presence of the mutant peptides if the following criteria were met: 1. The observed fragment ions were in the same RP-HPLC fraction as the synthetic, 2. LC/MS elution time was within 2 minutes of the synthetic, and 3. Fragment ion masses matched those of the synthetic with an accuracy of ±25 ppm. PEAKVIEW® Software version: 1.2,0,3 was used for exploring and interpreting of the LC/MS data.

[0232] Separation and sequencing of peptides were carried out by two-dimensional liquid chromatography, followed by information dependent acquisition (IDA) generated tandem MS (MS/MS). For the first dimension, the peptide sample was loaded on a reverse-phase C^{18} column (pore size, 110 Å; particle size, 5 μm; 2 mm i.d. by 150 mm long Gemini column; Phenomenex) with a Michrom BioResources Paradigm MG4 high performance liquid chromatograph (HPLC) with UV detection at 215 nm wavelength. Elution was at pH 10 using 10 mM ammonium formate in 2% acetonitrile/98% water as solvent A and 10 mM ammonium formate in 95% acetonitrile/5% water for solvent B. The 1st dimension

HPLC column was preequilibrated at 2% solvent B, then the peptide sample, dissolved in 10% acetic acid/water, was loaded at a flow rate of ~120 μl/min over an 18 minute period. Then a two segment gradient was performed at 160 μl/min; the 1st segment was a 40 minute linear gradient from 4% B to 40% B, followed by an eight minute linear gradient from 40% B to 80% B. Forty peptide-rich fractions were collected and dried by vacuum centrifugation.

[0233] For the second dimension chromatography, each dried fraction was resuspended in 10% acetic acid and subjected to nano-scale RP-HPLC (Eksigent nanoLC415, AB Sciex). The second dimension nano-HPLC setup included a C^{18} trap column (350 μm i.d. by 0.5 mm long; ChromXP (Eksigent) with 3 μm particles and 120 Å pores and a ChromXP, C^{18} separation column with dimensions of 75 μm i.d. by 15 cm long packed with the same medium. A two-solvent system was utilized, where solvent A is 0.1% formic acid in water and solvent B contains 0.1% formic acid in 95% acetonitrile/5% water. Samples were loaded at 5 μL/min flow rate on the trap column and at 300 nL/min flow rate on the separation column that was equilibrated in 2% solvent B. The separation was performed by a program with two linear gradients: 10% to 40% solvent B for 70 min and then 40% to 80% solvent B for 7 min. The column effluent was connected to the nanospray III ion source of an AB Sciex TripleTOF 5600 quadrupole-time of flight mass spectrometer with the source voltage set to 2400 v.

[0234] Extracted ion chromatograms revealed the presence of an eluted peptide with a retention time within 2 minutes of synthetic EXOC8 Q656P peptide in fraction 50. FIG. **40**B illustrates an extracted ion chromatogram of the parent ion with the theoretical m/z of 480.8156 (+2) in HPLC fraction 50 from the HLA-A*02:01 eluted peptides (solid line) overlaid with the EXOC8 Q656P synthetic peptide (dashed line). MS/MS fragmentation pattern comparison of the eluted and the synthetic peptides ensured EXOC8 Q656P sequence identity and confirmed HLA-A*02:01 presentation of this dominant neoantigen. The eluted EXOC8 Q656P peptide MS/MS fragmentation pattern is illustrated in FIG. **40**C and that of the corresponding synthetic peptide is illustrated in FIG. **40**D. A similar analysis of fraction **44** demonstrated the HLA-A*02:01 presentation of subdominant neoantigen PABPC1 R520Q. FIG. **40**F illustrates the extracted ion chromatogram of the parent ion (depicted in FIG. **40**E, supra) with the theoretical m/z 524.2808 (+2) in HPLC fraction **44** from the HLA-A*02:01 elated peptides (solid line) overlaid with the PABPC1 R520Q synthetic peptide (dashed line). The MS/MS fragmentation pattern of the eluted peptide is shown in FIG. **40**G and that of the corresponding synthetic peptide is shown in **3**H. Altogether, these results show that two of the 7 neoantigens included inpatient MEL218 vaccine, along with antigen controls WNV SVG9 and G280, are processed and presented in the context of HLA-A*02:01 molecules. MS/MS fragmentation pattern of the peptide elated from HLA-A*02:01 identified as YLEPGPVTA (SEQ ID No. 165) (FIG. **41**A), and the corresponding G280 synthetic peptide. MS/MS fragmentation pattern (FIG. **41**C) of the peptide elated from HLA-A*02:01 identified as SVG-GVFTSV (SEQ ID No. 33) (FIG. **41**B), and the corresponding WNV SVG9 synthetic peptide (FIG. **41**D).

Example 15

[0235] This example illustrates characterization of the composition and diversity of neoantigen-specific T cells and the effect vaccination can have on these repertoires.

[0236] Short-term ex-vivo expanded neoantigen-specific T cells were purified to 97-99% purity by cell sorting in a Sony SY3200 BSC (Sony Biotechnology) fitted with a 100 um nozzle, at 30 psi, using 561 nm (585/40) and 642 nm (665/30) lasers and cell pellets were prepared. DNA isolation and TCRβ sequencing was performed by Adaptive Biotechnologies and The Genome Institute at Washington University. Sequencing was performed at either survey (for neoantigen-specific TCRβ reference libraries) or deep (for pre- and post-vaccine CD8+ T cell populations) level (Robins, H., et al., J. Immunol. Methods, 375, 14-19, 2012; Carlson, C. S., et al., Nat. Commun., 4, 2680, 2013). TCRβ V-, D-, J-genes of each CDR3 regions were defined using IMGT (ImMunoGeneTics)/Junctional algorithms and data uploaded into the ImmunoSeq Analyzer (Adaptive Biotechnologies) for analysis. Complete amino acid identity between the reference library and pre- and post-vaccine CD8 samples was required for assigning a TCRβ match. In the reference library, TCRβ clonotypes with frequencies above 0.1% (>100-fold sequencing depth) were set as a threshold for identification of neoantigen-specific TCRβ CDR3 sequences within pre- and post-vaccine CD8+ T cell populations.

[0237] Reference T cell receptor-β (TCRβ) complementarity-determining region 3 (CDR3) sequence libraries (shown schematically in FIG. **42**, Tables 7-11) were generated from short-term expanded sorted neoantigen-specific T cells (97-99% dextramer-positive), in Tables 7-11, TCRBV, TCRBD and TCRBJ are shown according to consensus nomenclature and CDR3 sequence for each clonotype indicated. Read counts indicates the number of times a given CDR3 sequence was found in the short term ex-vivo expanded neoantigen population. TCRβ clonotypes with frequencies above 0.1% (>100-fold sequencing depth), in reference library, were set as a threshold for identification of neoantigenspecific TCRβ CDR3 sequences within CD8+ T cell populations isolated from PBMC obtained pre- and post-vaccination. FIG. **43**A illustrates profiles purified neoantigen-specific CD8+ T cells used for the generation of TCRβ CDR3 reference libraries. In FIG. **43**A, purified CD8+ T cells isolated from PBMC obtained after vaccination were stimulated in an antigen-specific manner as described supra. Cells were stained using HLA-A*02:01/AAS-peptide dextramers and anti-CD8 monoclonal antibody; neoantigen-specific CD8+ cells were sorted in a Sony SY3200 BSC Cell Sorter. Purity of post-sort populations is shown in dot plots (upper right quadrants, 97-99% purity). FIG. **43**B illustrates the comparison of clonotype distribution in sorted/expanded dominant and subdominant neoantigen-specific CD8 T cells obtained from each of the indicated patients. These clonotypes represent the TCRβ CDR3 reference libraries used for probing pre- and post-vaccine CD8+ T cell populations. Frequencies are shown as percent of total reads. Reference library comprised clonotypes with frequencies of 0.1 or above (Lossius, A., et al., Eur. J. Immunol., 44, 3439-3452, 2014). The total number of clonotypes in each antigen population is indicated in the x- and y-axis and CDR3 sequences arc listed in Tables 7-11. The one clonotype that overlapped between EXOC8 Q656P and PABPC1 R520Q (indicated by circle) was excluded from analysis. These sequence libraries were used to characterize neoantigen TCRβ clonotypes in purified CD8+ T cells isolated from pre- and post-vaccine PBMC samples (Robins, et al., J. Immunol Methods, 375, 14-19, 2012; Lossius, A., et al., Eur. J. Immunol., 44, 3439-3452, 2014; Robins, H. S., et al., Sci. Transl. Med., 5, 214ra169, 2013). In pre-vaccination CD8+ T cell populations, as few as one and as many as 10 unique TCRβ clonotypes per neoantigen were identified. FIG. **44**A summarizes the TCRβ clonotypes identified, using neoantigen-specific TCRβ CDR3 reference libraries (see Tables 7-11), in CD8+ T cell populations isolated from

PBMC obtained before and after vaccination. Each symbol represents a unique TCRβ sequence and its frequency (%) in pre- and post-vaccine samples. Wilcoxon-signed rank test was performed and p values indicated in figure. Thus, vaccination increased the frequency of most existing pre-vaccine TCRβ clonotypes and revealed new clonotypes for all 6 neoantigens (FIG. **44**A). For both dominant and sub-dominant neoantigens, the TCRβ repertoire was increased significantly after vaccination. FIG. **44**B illustrates TCRβ CDR3 sequence of clonotypes (Tables 7-11) identified in pre—(black bars) and post—(white bars) vaccine CD8+ T cell populations for neoantigens TKT R438W (pre=5, post=84 clonotypes); SEC24A P469L (pre=9, post=61) and EXOC8 Q656P (pre=2, post=12). Frequency of each unique clonotype is reported as percentage of total read counts. 84 clonotypes representing TCRβ families are detected for TKT R438W, 61 clonotypes representing 12 TCRβ families are detected for SEC:24A P469L and 12 clonotypes representing 8 TCRβ families are detected for EXOC8 Q656P (FIG. **44**B). Thus, peptide vaccination with functionally mature DC can promote the expansion of a highly diverse neoantigen TCR repertoire.

Example 16

[0238] This example illustrates vaccination of patients using multiple HLA cell types.

[0239] Distribution of somatic (exomic and missense) mutations was identified in metachronous tumors of patients MEL66 is illustrated in FIG. **45** (anatomical location and date of collection indicated). HLA-A*02:01- and HLA-B*08:01-binding candidate peptides were identified in silico according to the methods of the present teachings among amino acid substitutions present in the patient's tumor; expression of genes encoding mutated proteins was determined from cDNA capture data. Venn diagrams show expression, among metachronous tumors, of mutated genes encoding vaccine neoantigens. The identities of the 6 immunogenic neoantigens identified among the 10 included in vaccine are indicated; type style identifies naturally occurring (italics) and vaccine-induced (bold) neoantigens.

[0240] Distribution of somatic (exomic and missense) mutations identified in metachronous tumors of patients MEL69 is illustrated in FIG. **46** (anatomical location and date of collection indicated). HLA-A*02:01- and HLA-A*11:01-binding candidate peptides were identified in among amino acid substitutions in the patient's tumor according to a method of the present teachings; expression of genes encoding mutated proteins was determined from cDNA capture data (Table 12). Venn diagrams show expression, among metachronous tumors, of mutated genes encoding vaccine neoantigens. The identities of the 5 immunogenic neoantigens identified among the 10 included in vaccine are indicated; type style identifies naturally occurring (italics) and vaccine-induced (bold) neoantigens.

[0241] The vaccine for patient MEL66 included neoantigens that bound to HLA-A*02:01 and HLA-B*08:01 molecules. The vaccine for MEL69 included neoantigens that bound to HLA-A*03:01 and HLA-A*11:01 molecules. Both vaccines were prepared by contacting the neoantigens with the patient's own dendritic cells and maturing them prior to administration in accordance with the present teachings. Representative results (dextramer assay) to neoantigens restricted to these alleles are shown (FIG. **47**) before DC vaccination (pre-vaccine) and at peak of immune response (post-vaccine). Numbers within dot plots represent percentage neoantigen-specific T cells within the lymph+/CD8+ gated cells. A naturally occurring response to HLA-A*11:01-restricted neoantigen ERCC6L V476I was observed in patient MEL69.

[0242] All cited publications are hereby incorporated by reference, each in its entirety.

TABLE 1

Analysis of missense mutations by prediction algorithms for binding to HLA-A*0201

		Protein	MUTATED				WILD-TYPE			
CHR	Gene	AA Change	AA seq	Sequence Listing	Binding Affinity (nM)	Affinity (h)	AA seq	Sequence Listing	Binding (nM)	Affinity (h)
15	AKAP13	Q285K	KLMNIQQKL	SEQ ID NO: 1	19	5.02	KLMNIQQQL	SEQ ID NO: 16	17	4.72
8	ARFGEF1	R782C	FVSALCMFL	SEQ ID NO: 2	19	3.09	FVSALRMFL	SEQ ID NO: 17	88	0.88
17	CCDC57	R353C	QLCEDASTV	SEQ ID NO: 3	352	2.77	QLREDASTV	SEQ ID NO: 18	2265	1.02
8	CPNE3	P448L	LMSIIIVGV	SEQ ID NO: 4	16	6.98	PMSIIIVGV	SEQ ID NO: 19	817	1.77
14	DICER1	Y153C	LIMTCCVAL	SEQ ID NO: 5	46	4.99	LIMTCYVAL	SEQ ID NO: 20	43	1.88
16	GLYR1	P386L	ALVSGNQQL	SEQ ID NO: 6	273	1.05	APVSGNQQL	SEQ ID NO: 21	25384	0.3
1	HSD17B7	H108Y	YISKCWDYA	SEQ ID NO: 7	233	0.94	YISKCWDHA	SEQ ID NO: 22	971	0.78
22	IL17RA	T362M	FIMGISILL	SEQ ID NO: 8	4	7.46	FITGISILL	SEQ ID NO: 23	24	3.58
1	KIF14	G842W	IQLSWVLIA	SEQ ID NO: 9	144	0.7	IQLSGVLIA	SEQ ID NO: 24	658	0.59
12	MED13L	G2045W	ILMTWNLHS	SEQ ID NO: 10	259	0.97	ILMTGNLHS	SEQ ID NO: 25	1243	0.78
1	OR5K2	G64E	YIFLENLAL	SEQ ID NO: 11	55	1.15	YIFLGNLAL	SEQ ID NO: 26	38	1.02
11	OR8B3	T190I	QLSCISTYV	SEQ ID NO: 12	18	6.54	QLSCTSTYV	SEQ ID NO: 27	35	5.06
5	SEC24A	P469L	FLYNLLTRV	SEQ ID NO: 13	4	19.62	FLYNPLTRV	SEQ ID NO: 28	6	13.57

TABLE 1-continued

Analysis of missense mutations by prediction algorithms for binding to HLA-A*0201										
17	TAOK1	A196V	WMAPEVILV	SEQ ID NO: 14	7	4.32	WMAPEVILA	SEQ ID NO: 29	40	1.32
6	UTRN	Q1058K	QLDKCSAFV	SEQ ID NO: 15	12	6.63	QLDQCSAFV	SEQ ID NO: 30	22	7.65

			breast (Feb. 14, 2013)					abdominal wall (Apr. 16, 2013)		
CHR	Gene	Protein AA Change	Exome Var Freq	Transcriptome Var Freq	FPKM	CHR	Gene	Protein AA Change	Exome Var Freq	Transcriptome Var Freq	FPKM
15	AKAP13	Q285K	13.97	23.49	NR	15	AKAP13	Q285K	25.13	26	NR
8	ARFGEF1	R782c	19.17	15.07	23.73	8	ARFGEF1	R782C	11.65	10.79	17.51
17	CCDC57	R353C	23.97	30.23	0.79	17	CCDC57	R353C			
8	CPNE3	P448L	15.49	17.46	0.29	8	CPNE3	P448L	16.11	16.87	2.27
14	DICER1	Y153C	39.34	49.55	7.21	14	DICER1	Y153C	31.03	31.48	8.05
16	GLYR1	P386L	48.64	42.81	35.963	16	GLYR1	P386L	43.18	38.21	32.52
1	HSD17B7	H108Y	17.89	19.97	0.11	1	HSD17B7	H108Y	18.41	17.86	0.2
22	IL17RA	T362M	30.97	26.83	0.22	22	IL17RA	T362M			
1	KIF14	G842W	20.97	22.92	3.63	1	KIF14	G842W	16.27	22.22	2.1
12	MED13L	G2045W	44.44	43.58	13.64	12	MED13L	G2045W	30.43	28.1	14.97
1	OR5K2	G64E	29.67	63.64	0.47	1	OR5K2	G64E			
11	OR8B3	T190I	60.52	NR	NR	11	048B3	T190I	20.23	NR	NR
5	SEC24A	P469L	37.5	42.48	1.34	5	SEC24A	P469L	24.05	20.12	0.39
17	TAOK1	A196V	30.8	35.31	11.32	17	TAOK1	A196V	31.57	29	8.28
6	UTRN	Q1058K	58.33	81.5	15.94	6	UTRN	Q1058K	38.98	57.43	12.56

TABLE 2

MEL21								
						Predicted Affinity(nM)[a]		
CHR	Hugo Symbol	AAS- peptide	AAS-SEQID	wild-type peptide	WT SEQ ID	mutated	wild-tpe	Amino Acid Substitution (AAS)
1	AGMAT	NLSGNTALL	SEQ ID. 35	DLSGNTALL	SEQ ID. 36	247	8129	D326N
8	**ARFGEF1**	**QTIDNIVFL**	**SEQ ID. 37**	**QTIDNIVFF**	**SEQ ID. 38**	**387**	**10867**	**F1637L**
9	**CDKN2A**	**KMIGNHLWV**	**SEQ ID. 39**	**EMIGNHLWV**	**SEQ ID. 40**	**14**	**1044**	**E153K**
19	CYP2S1	FTMLALQDL	SEQ ID. 41	FTMLALRDL	SEQ ID. 42	287	1164	R136Q
7	FBXL13	SLWNAIDFF	SEQ ID. 43	SLWNAIDFS	SEQ ID. 44	414	348	S201F
4	FHDC1	ELQDEVYTL	SEQ ID. 45	ELQDEAYTL	SEQ ID. 46	111	518	A426V
5	**GPX8**	**LLSIVPCTV**	**SEQ ID. 47**	**LLSIVLCTV**	**SEQ ID. 48**	**52**	**33**	**L27P**
6	**KDM1B**	**IIGAGPAEL**	**SEQ ID. 49**	**IIGAGPAGL**	**SEQ ID. 50**	**469**	**928**	**G394E**
13	LCP1	NLFNRYLAL	SEQ ID. 51	NLFNRYPAL	SEQ ID. 52	57	30	P375L
2	LRP1B	WLTRNFYFV	SEQ ID. 53	WLTRNLYFV	SEQ ID. 54	9	7	L297F
18	NPC1	MLSSVACSL	SEQ ID. 55	VLSSVACSL	SEQ ID. 56	21	55	V664M
12	OASL	ILNPADPTL	SEQ ID. 57	ILDPADPTL	SEQ ID. 58	71	40	D305N
5	PCDHB3	FLFLVLLFV	SEQ ID. 59	FLFSVLLFV	SEQ ID. 60	6	3	S704L
5	PCDHB11	MLLEISENS	SEQ ID. 61	MLLEIPENS	SEQ ID. 62	252	210	P143S
X	**PHKA2**	**LLSIIFFPA**	**SEQ ID. 63**	**LLSIISFPA**	**SEQ ID. 64**	**23**	**25**	**S264F**
6	PTPRK	PLANSIWNV	SEQ ID. 65	PLANPIWNV	SEQ ID. 66	34	106	P137S
5	SH3RF2	HIVEISTPV	SEQ ID. 67	HMVEISTPV	SEQ ID. 68	27	6	M320I
3	**TKT**	**AMFWSVPTV**	**SEQ ID. 69**	**AMFRSVPTS**	**SEQ ID. 70**	**4**	**1525**	**R438W**
1	**TMEM48**	**CLNEYHLFL**	**SEQ ID. 71**	**CLNEYHLFF**	**SEQ ID. 72**	**23**	**3442**	**F169L**
7	BRAF[d]							V600E

		Lymph Node (Jan. 30, 2011)						
		EXOME			cDNA-capture			
CHR	Hugo Symbol	Alt re	Ref re	VAF[b]	Alt re	Ref re	VAF	FPKM[c]
1	AGMAT	16	49	24.62	1	22	4.35	0.38
8	**ARFGEF1**	**21**	**129**	**14.00**	**64**	**240**	**20.98**	**31.37**
9	**CDKN2A**	**13**	**49**	**20.97**	**162**	**38**	**81.00**	**0.18**
19	CYP2S1	3	68	4.23	0	12	0.00	0.12
7	FBXL13	12	44	21.43	2	6	25.00	0.00
4	FHDC1	22	93	18.97	0	3	0.00	0.39
5	**GPX8**	**7**	**63**	**10.00**	**20**	**62**	**24.39**	**15.02**
6	**KDM1B**	**15**	**55**	**21.43**	**23**	**24**	**48.94**	**7.33**

TABLE 2-continued

				MEL21			
13 LCP1	12	82	12.77	36	766	4.47	49.11
2 LRP1B	11	38	22.45	0	5	0.00	0.00
18 NPC1	4	24	14.29	54	36	60.00	36.55
12 OASL	3	35	7.89	0	23	0.00	1.62
5 PCDHB3	46	225	16.97	24	2	92.31	7.05
5 PCDHB11	0	40	15.69	1	7	12.50	5.25
X PHKA2	**13**	**25**	**34.21**	**13**	**21**	**38.24**	**4.60**
6 PTPRK	14	89	13.59	118	297	28.43	0.00
5 SH3RF2	14	61	18.67	49	207	18.99	10.19
3 TKT	**10**	**45**	**18.18**	**124**	**190**	**39.49**	**0.64**
1 TMEM48	**7**	**40**	**14.89**	**292**	**382**	**43.13**	**0.17**
7 BRAF[d]	10	55	15.38				
				Skin (May 10, 2012)			
Hugo		EXOME			cDNA-capture		
CHRSymbol	Alt re	Ref re	VAF	Alt re	Ref re	VAF	FPKM
1 AGMAT	51	50	50.50	5	2	71.43	0.14
8 ARFGEF1	**109**	**154**	**41.44**	**140**	**177**	**44.03**	**34.67**
9 CDKN2A	**30**	**17**	**63.83**	**168**	**26**	**86.60**	**0.05**
19 CYP2S1	41	50	45.05	0	1	0.00	0.05
7 FBXL13	15	50	22.39	0	1	0.00	1.61
4 FHDC1	53	52	50.48	0	0	0.00	0.40
5 GPX8	**35**	**27**	**56.45**	**30**	**12**	**71.43**	**6.92**
6 KDM1B	**35**	**51**	**40.70**	**34**	**28**	**54.84**	**12.67**
13 LCP1	30	88	25.42	2	189	1.05	16.73
2 LRP1B	39	50	43.82	34	122	21.79	9.23
18 NPC1	0	51	0.00	0	255	0.00	0.103
12 OASL	26	19	57.78	6	16	27.27	2.96
5 PCDHB3	155	124	55.36	50	1	98.04	10.89
5 PCDHB11	17	40	29.82	4	16	20.00	5.64
X PHKA2	**31**	**5**	**86.11**	**47**	**11**	**81.03**	**6.98**
6 PTPRK	61	75	44.85	172	144	54.43	0.02
5 SH3RF2	43	35	55.13	101	71	58.72	6.82
3 TKT	**36**	**25**	**59.02**	**129**	**122**	**51.19**	**128.54**
1 TMEM48	**20**	**24**	**45.45**	**430**	**263**	**61.52**	**0.24**
7 BRAF[d]	49	48	50.52				
				Skin (Jun. 6, 2013)			
Hugo		EXOME			cDNA-capture		
CHRSymbol	Alt re	Ref re	VAF	Altre	Ref re	VAF	FPKM
1 AGMAT	42	62	40.38	1	7	12.50	0.3
8 ARFGEF1	**31**	**103**	**23.13**	**69**	**195**	**25.84**	**34.23**
9 CDKN2A	**19**	**18**	**51.35**	**30**	**27**	**52.63**	**0.83**
19 CYP2S1	31	54	36.47	0	14	0.00	0.11
7 FBXL13	6	33	15.38	0	6	0.00	0.00
4 FHDC1	33	52	38.82	3	14	17.65	7.24
5 GPX8	**18**	**45**	**28.57**	**17**	**47**	**26.56**	**0.16**
6 KDM1B	**17**	**37**	**31.48**	**10**	**37**	**21.28**	**12.01**
13 LCP1	8	75	9.64	8	284	2.73	23.56
2 LRP1B	16	49	24.62	22	47	31.88	4.57
18 NPC1	0	53	0.00	0	203	0.00	44.81
12 OASL	12	27	30.77	0	16	0.00	0.89
5 PCDHB3	59	94	38.06	39	7	84.78	5.65
5 PCDHB11	4	27	12.90	2	10	16.67	4.10
X PHKA2	**11**	**12**	**45.83**	**41**	**26**	**61.19**	**7.46**
6 PTPRK	26	69	27.37	58	149	38.02	0.23
5 SH3RF2	28	49	36.36	47	76	38.21	7.63
3 TKT	**21**	**21**	**50.00**	**173**	**338**	**33.86**	**0.93**
1 TMEM48	**12**	**15**	**44.44**	**40**	**72**	**34.19**	**0.43**
7 BRAFd	23	49	31.94				

[a]Predicted affinity as determined using NetMHC3.4 algorithm.

[b]VAF = Variant Allelic Fraction as determined from exome sequencing. BRAF VAF are reported as these were used as comparator to assess clonality of other mutations. Candidates formulated in vaccine are shown bolded.

[c]FPKM = Fragment Per Kilobase of transcript per Million per transcriptome as determined from cDNA-capture data

[d]BRAF VAF values are reported and were used as comparator to interpret frequencies of remaining MM-genes.

TABLE 3

Patient Mel38								
					Predicted Affinity (nM)[a]			
Hugo CHR Symbol	AAS-peptide	SEQ ID	wild-type peptide	SEQ ID	mutated	wild-type	Amino Acid Substitution	
15 AKAP13	**KLMNIQQKL**	**SEQ ID NO: 1**	**KLMNIQQQL**	**SEQ ID NO: 16**	**19**	**17**	**Q285K**	
8 ARPGEF1	**FVSALCMFL**	**SEQ ID NO: 2**	**FVSALRMFL**	**SEQ ID NO: 17**	**19**	**88**	**R792C**	
17 CCDC57	QLCHDASTV	SEQ ID NO: 3	QLRSDASTV	SEQ ID NO: 18	352	2265	R353C	
8 CPNE3	LMSIIIVGV	SEQ ID NO: 4	PMSIIIVGV	SEQ ID NO: 19	18	817	F448L	
14 DICER1	LIMTCCVAL	SEQ ID NO: 5	LIMTCYVAL	SEQ ID NO: 20	45	43	Y153C	
16 GLYR1	ALVSGNQQL	SEQ ID NO: 6	APVSGNQQL	SEQ ID NO: 21	273	25384	P386L	
1 HSD17B7	**YISKCWDYA**	**SEQ ID NO: 7**	**YISKCWDHA**	**SEQ ID NO: 22**	**233**	**971**	**N108Y**	
22 IL17RA	FIMGISILL	SEQ ID NO: 8	FITGISILL	SEQ ID NO: 23	4	24	T326M	
1 KIP14	IQLSWVLIA	SEQ ID NO: 9	IQLSGVLIA	SEQ ID NO: 24	144	658	G842W	
12 MED13L	ILMTWNLRS	SEQ ID NO: 10	ILMTGNLHS	SEQ ID NO: 25	259	1243	G2045W	
3 OR5K2	YIFLENLAL	SEQ ID NO: 11	YIFLGNLAL	SEQ ID NO: 26	55	38	G64E	
11 OR8B3	**QLSCISTYV**	**SEQ ID NO: 12**	**QLSCTSTYV**	**SEQ ID NO: 27**	**18**	**35**	**T190I**	
11 PSKCDBP	**CLPPQTLAA**	**SEQ ID NO: 73**	**CLSPQTLAA**	**SEQ ID NO: 74**	**81**	**694**	**S153F**	
5 SEC24A	**FLYNLLTRV**	**SEQ ID NO: 13**	**FLYNPLTRV**	**SEQ ID NO: 28**	**4**	**6**	**P469L**	
17 TAOK1	MMAPEVILV	SEQ ID NO: 14	MMAPEVILA	SEQ ID NO: 29	7	40	A196V	
6 UTRN	**QLDKCSAFV**	**SEQ ID NO: 15**	**QLDQCSAFV**	**SEQ ID NO: 30**	**21**	**22**	**Q1058K**	
2 WDR35	FLNCNSSRL	SEQ ID NO: 75	SLNCNSSRL	SEQ ID NO: 76	38	616	S550F	
7 ZYX	SLKGTSFIV	SEQ ID NO: 77	PLEGTSFIV	SEQ ID NO: 78	64	5774	P329S	
7 BRAF[d]							V600E	

Acilla (Apr. 19, 2012)							
	EXOME			cDNA-capture			
Hugo CHR Symbol	Alt_ reads	Ref_ reads	VAF[b]	Alt_reads	Ref re	VAF	FPKM[c]
15 AKAP13	**20**	**50**	**28.57**	**4**	**13**	**23.53**	**54.3**
8 ARPGEF1	**23**	**81**	**22.12**	**60**	**161**	**27.15**	**7.1**
17 CCDC57	35	41	26.78	53	351	13.12	9.5
8 CPNE3	31	127	19.62	113	536	17.41	14.3
14 DICER1	10	21	32.26	2	4	33.33	4.1
16 GLYR1	21	25	45.65	124	150	45.26	155.5
1 HSD17B7	**52**	**183**	**22.13**	**68**	**228**	**22.97**	**29.7**
22 IL17RA	12	28	30	4	26	13.33	1.9
1 KIP14	23	68	25.27	5	25	16.67	2.2
12 MED13L	12	8	60	71	81	46.71	8.8
3 OR5K2	57	64	47.11	3	0	100	0.1
11 OR8B3	**15**	**0**	**100**	**13**	**1**	**92.88**	**0.6**
11 PSKCDBP	**13**	**0**	**100**	**24**	**0**	**100.00**	**0.0**
5 SEC24A	**22**	**25**	**46.81**	**50**	**56**	**46.73**	**2.6**
17 TAOK1	23	33	41.07	23	29	44.23	3.0
6 UTRN	**22**	**0**	**100**	**44**	**1**	**97.78**	**6.9**
2 WDR35	34	15	69.39	90	41	58.7	15.2
7 ZYX	18	48	27.27	26	67	27.96	6.7
7 BRAF[d]	58	14	80				

Breast (Feb. 14, 2013)							
	EXOME			cDNA-capture			
Hugo CHR Symbol	Alt_ reads	Ref_ reads	VAF	Alt_ reads	Ref_ reads	VAF	FPKM
15 AKAP13	**19**	**117**	**14.0**	**31**	**101**	**23.5**	**1.47**
8 ARPGEF1	**46**	**194**	**19.2**	**206**	**1161**	**15.1**	**23.73**
17 CCDC57	29	92	24.0	91	210	30.2	0.79
8 CPNE3	42	229	15.5	608	2833	17.5	0.29
14 DICER1	24	37	39.3	65	56	49.6	7.21
16 GLYR1	54	57	48.7	384	513	42.8	35.63
1 HSD17B7	**102**	**467**	**17.9**	**411**	**1644**	**20.0**	**0.11**
22 IL17RA	35	77	31.3	33	90	26.8	0.22
1 KIP14	35	132	22.0	22	74	20.9	3.63
12 MED13L	20	25	44.4	156	202	43.6	13.64
3 OR5K2	125	227	35.5	0	20	0.0	0.00
11 OR8B3	**40**	**21**	**65.8**	**3**	**0**	**100.0**	**0.35**
11 PSKCDBP	**21**	**6**	**77.8**	**161**	**11**	**93.6**	**0.64**
5 SEC24A	**33**	**55**	**37.5**	**127**	**172**	**42.5**	**1.34**

TABLE 3-continued

Patient Mel38							
17 TAOK1	37	83	30.8	185	339	35.3	11.32
6 UTRN	**35**	**25**	**58.3**	**207**	**46**	**81.5**	**15.94**
2 WDR35	56	50	52.8	389	247	61.8	0.04
7 ZYX	27	104	20.6	115	405	22.1	14.64
7 BRAF[d]	103	45	69.38				

	Abd. wall(Apr. 16, 2013)						
	EXOME			cDNA-capture			
Hugo CHRSymbol	Alt_ reads	Ref_ reads	VAF	Alt_ reads	Ref_ reads	VAF	FPKM
15 AKAP13	**39**	**116**	**25.16**	**13**	**37**	**26.00**	**0.14**
8 ARPGEF1	**29**	**219**	**11.65**	**56**	**460**	**10.79**	**17.51**
17 CCDC57	32	85	27.35	45	170	20.93	2.23
8 CPNE3	38	203	16.12	342	1684	16.86	2.27
14 DICER1	18	40	31.03	17	27	31.48	8.05
16 GLYR1	38	50	43.18	214	246	38.21	32.52
1 HSD17B7	**100**	**443**	**18.42**	**195**	**896**	**17.86**	**0.20**
22 IL17RA	22	69	24.18	7	83	7.78	0.27
1 KIP14	28	143	16.28	6	21	22.22	2.10
12 MED13L	14	32	30.43	77	197	26.10	14.97
3 OR5K2	105	246	29.83	14	8	63.64	0.47
11 OR8B3	**17**	**52**	**24.64**	**1**	**2**	**33.33**	**0.25**
11 PSKCDBP	**17**	**9**	**65.38**	**112**	**13**	**88.89**	**1.94**
5 SEC24A	**19**	**60**	**24.05**	**34**	**134**	**20.12**	**0.39**
17 TAOK1	30	65	31.58	78	191	29.00	8.28
6 UTRN	**23**	**36**	**38.98**	**58**	**42**	**57.43**	**12.56**
2 WDR35	59	62	48.76	239	365	59.16	0.02
7 ZYX	22	81	19.47	44	477	8.43	20.16
7 BRAF[d]	69	56	55.20				

[a]Predicted affinity as determined using NetMHC3.4 algorithm.

[b]VAF = variant Allelic Fraction as determined from exome sequencing. BRAF VAF are reported as tehse were used as comparator to assess clonality of other mutations.

[c]FPKM = Fragment Per Kilobase of transcript per Million per transcriptome as determined from cDNA-capture data.

[d]BRAF VAF values are reported and were used as comparator to interpret frequencies of remaining MM-genes

TABLE 4

MEL 218								
						Predicted Affinity (nM)		
Hugo CHRSymbol	AAS-peptide	SEQ ID	wild-type peptide	SEQ ID		mutated	wild-type	Amino Acid Substitution (AAS)
X ABCD1	GMHLLITGL	SEQ ID NO: 79	GMHLLITGP	SEQ ID NO: 80		202	18419	P508L
2 ALMS1	VLAVSVLAA	SEQ ID NO: 81	VSAVSVLAA	SEQ ID NO: 82		170	13703	S934L
15 BTBD1	FMLLTQARI	SEQ ID NO: 83	FMLLTQARL	SEQ ID NO: 84		52	36	L189T
9 CDC14B	IQYFRNHNV	SEQ ID NO: 85	IQYFKNHNV	SEQ ID NO: 86		93	93	K253R
15 DMXL2	SVMIMAFSV	SEQ ID NO: 87	SDMIMAFSV	SEQ ID NO: 88		19	6986	D2662V
1 EIF2B3	SISKPLLPV	SEQ ID NO: 89	STPKPLLPV	SEQ ID NO: 90		105	166	P24S
1 EXOC8	**IILVAVPHV**	**SEQ ID NO: 91**	**IILVAVQHV**	**SEQ ID NO: 92**		**25**	**143**	**Q656P**
22 FBXO7	LMLESGYIL	SEQ ID NO: 93	LMLESGYIP	SEQ ID NO: 94		10	5952	P100L
7 GET4	AVDDGKLTV	SEQ ID NO: 95	AVDGGKLTV	SEQ ID NO: 96		357	1067	G196D
15 HERC1	SLLLLSVSV	SEQ ID NO: 97	SLLLLPVSV	SEQ ID NO: 98		20	24	P1074S
6 HLA-DRB5	YMAELTVTL	SEQ ID NO: 99	YMAKLTVTL	SEQ ID NO: 100		4	7	K14E
8 KAT6A	KLSREIKPV	SEQ ID NO: 101	KLSREIMPV	SEQ ID NO: 102		62	6	M1180K
4 LARP7	**AVIDAYTEI**	**SEQ ID NO: 103**	**AVINAYTEI**	**SEQ ID NO: 104**		**213**	**775**	**N515D**
7 MRPS17	**VLLRALPVL**	**SEQ ID NO: 105**	**VLLRALPVP**	**SEQ ID NO: 106**		**24**	**11696**	**P167L**
2 MRPS5	**HLYASLSRA**	**SEQ ID NO: 107**	**HPYASLSRA**	**SEQ ID NO: 108**		**116**	**23536**	**P59L**
12 OSBPL8	FCFKLSHPL	SEQ ID NO: 109	FCFKLFHPL	SEQ ID NO: 110		174	126	P213S
8 PABPC1	**MLGEQLFPL**	**SEQ ID NO: 111**	**MLGERLFPL**	**SEQ ID NO: 112**		**3**	**3**	**R520Q**
3 PLA1A	**FIWGDAPPT**	**SEQ ID NO: 113**	**SIWGDAPPT**	**SEQ ID NO: 114**		**41**	**744**	**S6F**
17 RNASEK	RLLCPPARA	SEQ ID NO: 115	RPLCPPARA	SEQ ID NO: 116		432	22016	P10L
20 SMOX	**KLANPLPYT**	**SEQ ID NO: 117**	**KLAKPLPYT**	**SEQ ID NO: 118**		**38**	**63**	**K499N**
1 SRP9	**IMAHCILDL**	**SEQ ID NO: 119**	**IIAHCILDL**	**SEQ ID NO: 120**		**22**	**250**	**I64M**
13 TPP2	SLAETFLET	SEQ ID NO: 121	SLAETFWET	SEQ ID NO: 122		82	17	W1168L

TABLE 4-continued

MEL 218							
1 VANGL1	FVFCALLLV SEQ ID NO: 123	FVFRALLLV	SEQ ID NO: 124	6	10	R186C	
16 ZFP90	FTQEKWYHV SEQ ID NO: 125	FTQEEWYHV	SEQ ID NO: 126	22	20	E27K	
7 BRAF[d]						V600E	

	Lymph Node (Apr. 4, 2005)						
Hugo	EXOME			cDNA-capture			
CHR Symbol	Alt re	Ref re	VAF[b]	Alt_reads	Ref reads	VAF	FPKM[c]
X ABCD1	23	38	37.7	156	12	92.86	10.65
2 ALMS1	5	11	31.25	20	20	50	5.74
15 BTBD1	6	17	26.09	170	358	32.14	18.84
9 CDC14B	6	67	8.11	27	136	16.56	10.73
15 DMXL2	10	46	17.86	102	704	12.64	50.71
1 EIF2B3	5	24	17.24	55	111	32.93	13.83
1 EXOC8	**7**	**26**	**21.21**	**145**	**300**	**32.37**	**4.83**
22 FBXO7	12	45	21.05	900	1597	36.04	87.45
7 GET4	20	27	42.55	57	51	52.78	5.2
15 HERC1	12	55	17.91	68	162	29.57	71.99
6 HLA-DRB5	81	85	48.8	573	1645	25.8	247.95
8 KAT6A	25	116	17.73	261	463	36	27.21
4 LARP7	**6**	**36**	**14.29**	**30**	**50**	**37.5**	**10.15**
7 MRPS17	**5**	**71**	**6.58**	**29**	**75**	**27.88**	**1.48**
2 MRPS5	**10**	**58**	**14.49**	**60**	**125**	**32.43**	**14.55**
12 OSBPL8	6	35	14.63	341	614	35.63	105.47
8 PABPC1	**16**	**44**	**26.67**	**4073**	**11235**	**26.6**	**1180.59**
3 PLA1A	18	79	18.56	4	10	28.57	4.07
17 RNASEK	9	58	13.43	9	18	33.33	109.67
20 SMOX	**131**	**0**	**100**	**11**	**50**	**18.03**	**3.01**
1 SRP9	**0**	**58**	**0***	**43**	**41**	**51.19**	**2.31**
13 TPP2	10	98	9.26	98	265	26.92	25.93
1 VANGL1	22	159	12.15	289	714	28.76	26.52
16 ZFP90	11	70	13.58	22	53	29.33	4.29
7 BRAF[d]	13	47	21.67				

[a]Predicted affinity as determined using NetMHC3.4 algorithm.

[d]BRAF VAF values are reported and were used as comparator to interpret frequencies of remaining MM-genes.

(*) Expression of mutated gene was validated by cDNA-capture and Sanger sequencing.

Candidates formulated in vaccine are shown in bold.

TABLE 5

Analysis of HLA-A*02: 01 restricted AAS-directed CD8+ T cell responses

Patient	Hugo symbol	Amino Acid Substitution (AAS)	Mutated Peptide[a]	SEQ ID	Predicted affinity (nM)	Experimental Affinity log(IC50, nM)[b]	Spontaneous Immunity[c]	Immunogenicity	Recognition of processed antigen	Antigenic Determinant[d]
MEL21	ARFGEF1	F1637L	QTIDNIVFL	SEQ ID 37	67	3.19	No	No		
	CDKN2A	K153K	**KMIGNHLWV**	SEQ ID 39	14	3.18	No	Yes	Yes	SUBDOMINANT
	GPY8	L27P	LLSIVPCTV	SEQ ID 47	52	3.09	No	No		
	KDM1B	G394E	IIGAGPAEV*	SEQ ID 166	111	3.82	No	No		
	PHKA2	S264F	LLSIIFFPA	SEQ ID 63	23	3.90	No	No		
	TKT	R438W	**AMFWSVPTV***	SEQ ID 69	4	2.35	No	Yes	Yes	SUBDOMINANT
	TMEM48	P169L	*CLNEYHLFL*	SEQ ID 71	23	3.09	Yes	Yes	Yes	DOMINANT
MKL38	AKAP13	Q285K	**KLMNIQQKL**	SEQ ID 1	19	3.07	No	Yes	Yes	SUBDOMINANT
	ARFGEF1	R782C	FVSALQMFL	SEQ ID 2	19	3.18	No	No		
	HSD1787	H108Y	YISKCWDYA	SEQ ID 7	233	4.28	No	No		
	OR8B3	T190I	**QLSCISTYV**	SEQ ID 12	18	3.10	No	Yes	No	CRYPTIC
	PRKCDEP	S153F	CLFPQTLAA	SEQ ID 73	81	3.53	No	No		
	SKC24A	P469L	*FLYNLLTRV*	SEQ ID 13	4	2.68	Yes	Yes	Yes	DOMINANT
	UTRN	Q1058K	QLDKCSAFV	SEQ ID 15	21	3.36	No	No		
MEL218	EXOC8	Q656P	*IILVAVPKV*	SEQ ID 91	25	3.06	Yes	Yes	Yes	DOMINANT
	LARP7	N518D	AVIDAYTEI	SEQ ID 103	213	4.41	No	No		
	MRPS5	P59L	**HLYASLSRV***	SEQ ID 167	19	3.28	No	Yes	No	CRYPTIC
	MRPS17	P167L	VLLRALPVL	SEQ ID 105	24	3.05	No	No		

TABLE 5-continued

Analysis of HLA-A*02: 01 restricted AAS-directed CD8+ T cell responses

Patient	Hugo symbol	Amino Acid Substitution (AAS)	Mutated Peptide[a]	SEQ ID	Predicted affinity (nM)	Experimental Affinity log(IC50, nM)[b]	Spontaneous Immunity[c]	Immunogenicity	Recognition of processed antigen	Antigenic Determinant[d]
	PABPC1	R520Q	**MLGEQLFPL**	SEQ ID 111	3	2.35	No	Yes	Yes	SUBDOMINANT
	SMOX	K499N	KLANPLPYT	SEQ ID 117	134	3.73	No	No		
	SRP8	I64M	IMAHCILDL	SEQ ID 119	37	4.02	No	No		

[a]Mutated residues are underlined and peptides that elicited immune responses are itacized (naturally-occurring) and bold (vaccine-induced).
*Indicates anchor-modified peptides at P9 (Tables 2-4).

[b]Affinity experimentally determined using fluorescence polarization-based competitive peptide-binding assay, high affinity binding peptides in this assay are log(IC50; nM) <3.7 (11).

[c]As determined by immune monitoring assay (FIG. 31, FIG. 30B),

[d]Antigenic determinant classification according to Sercarz et al. Annu. Rev. Immunol. 11, 729-766 (1993).

TABLE 6

Composition of TMC constructs

Tumor	Gene	Mut AA Position	Nucleotide sequence*	Seq ID No.
MEL21	ARFGEF1	1637	CAGCTGGAGCTGATCCAGACGATAGACAACATCGTGTTCGTGCCTGCAACTAGTAAG	SEQ ID NO: 168
	GPX8	27	AAAGTTTTCGCTGTCTTGCTCTCCATTGTGCCGTGCACAGTGACACTTTTTCTGCTT	SEQ ID NO: 169
	KDM1B	384	AACAAGAGCGTGATAATTATAGGAGCTGGCCCAGCAGAAGTGGCAGCAGCTAGACAA	SEQ ID NO: 170
	PHKA2	264	GAGATCGATGCTGGACTGCTTAGCATAATCTTTTTTCCTGCTTTTGCGGTAGAGGAT	SEQ ID NO: 171
	TKT	438	GCGCTGGAAGACCTGGCTATGTTTTGGTCAGTGCCCACAGTGACAGTCTTCTACCCTTCTGAT	SEQ ID NO: 172
	TMEM48	168	CCTGCAGCTCAGACCTGTCTCAACGAGTATCACCTGTTCCTGCTTCTCACAGGTGCC	SEQ ID NO: 173
	CDKN2A	153	GCTGAGGGACCCTCCAAAATGATAGGTAACCATCTGTGGGTATGTCGGAGTCGCCAT	SEQ ID NO: 174
MEL38	AKAP13	285	ACTGGCCCTATTTTTAAGCTCATGAATATCCAGCAAAAGCTTATGAAAACAAATCTGAAG	SEQ ID NO: 175
	ARFGEF1	782	TTTAGCGGAAAAGATTTTGTGAGCGCACTCTGCATGTTTCTCGAGGGATTCAGGCTGCCA	SEQ ID NO: 176
	PRKCDEP	153	GTGCCCAGTCATGCGTGTCTTTTCCCCCAAACTCTGGCCGCTGAGGAGGAGGGCGAGGTG	SEQ ID NO: 177
	SKC24A	469	GATGTGCCAGAGGAGTTTCTCTATAATCTGCTTACACGCGTCTACGGAGAGGCACACCGG	SEQ ID NO: 178
	UTRN	1058	GCTGGATTGCAGCGGCAGCTGGACAAATGCAGCGCATTCGTAAATGAGATCGAAACCATA	SEQ ID NO: 179
	OR8B3	190	ATCCTGCCACTGCTGCAACTGTCTTGCATTCTACCTACGTGAATGAAGTCGTGGTGCTC	SEQ ID NO: 180
	HSD1787	108	TCCGAGATCAGACCATACATTAGCAAGTGCTGGGACTATGCC	SEQ ID NO: 181
MEL218	MRPS17	167	ACAGTGGGGGACATTGTGCTGCTCCGAGCACTGCCCGTACTTCGAGCAAAACACGTGAAG	SEQ ID NO: 182
	MRPS5	59	GGCACACGGGACACACATCTGTATGCCAGCTTGAGCCGCGCACTCCAAACACAGTGCTGC	SEQ ID NO: 183
	SRP8	64	CAATGCTCCGGTATGATCATGGCCCACTGTATCCTCGACTTGTTGGCAGCAGCGGGCCC	SEQ ID NO: 184
	LARP7	528	CCAGAGGACGCACAGGCAGTGATCGACGCCTACACCGAGATAAACAAGAAACATTGCTGG	SEQ ID NO: 185
	EXOC8	654	GAATCCCTGGTCGAGATCATCCTGGTAGCTGTTCCACATGTCGATTACAGCCTTAGGTGT	SEQ ID NO: 186
	SMOX	499	GGTGCCGATGTCGAAAAGCTCGCCAACCCTCTCCCTTATACGGAATCAAGCAAAACCGCG	SEQ ID NO: 187
	PABPC1	538	CCACAGGAGCAAAAAATGTTGGGCGAACAATTGTTCCCGCTGATTCAGGCGATGCACCCG	SEQ ID NO: 188

Contol Ag	Gene	Mut AA Position	Nucleotide sequence	Seq ID No.
G380	GP100	N/A	GTGGTGACACACACCTATCTCGAGCCGGGCCCCGTGACAGCCCAGGTAGTTCTGCAGGCC	SEQ ID NO: 189
SVG8	KNV	N/A	GCTTGGGATTTCGGGAGCGTGGGTGGCGTCTTCACATCTGTTGGCAAGGCAGTGCATCAG	SEQ ID NO: 190

*nucleotide sequences encoding 19-21-mer amino acid sequence containing missense mutation targeted by peptides included in vaccine.

TABLE 7

Reference TCR CDR3 library from dominant TMEM4 F169L expanded CD8+ T cells (MEI

CDR3 amino acid sequence	SEQ ID	TCRBV	TCRBD	TCRBJ	Frequency	Read Counts
CASSQDLSGGVYYGYTF	EQ ID NO: 19	TCRBV04-01		TCRBJ01-02	18.24	494191
CSTLLAGGGDEQYV	EQ ID NO: 19	TCRBV29-01	TCRBD02	TCRBJ02-07	3.96	107162
CASSPTGLGETQYF	EQ ID NO: 19	TCRBV10-02	TCRBD01	TCRBJ02-05	2.97	80581
CSAPPGPLAHTQYF	EQ ID NO: 19	TCRBV20	TCRBD02	TCRBJ02-03	2.14	58087
CASSFKGTGPNQPQHF	EQ ID NO: 19	TCRBV27-01	TCRBD01	TCRBJ01-05	0.98	26493
CASSFGGPPNTGELFF	EQ ID NO: 19	TCRBV06	TCRBD02	TCRBJ02-02	0.88	23788

TABLE 7-continued

Reference TCR CDR3 library from dominant TMEM4 F169L expanded CD8+ T cells (MEI						
CDR3 amino acid sequence	SEQ ID	TCRBV	TCRBD	TCRBJ	Frequency	Read Counts
CASSIGPVNTEAFF	EQ ID NO: 19	TCRBV19-01	TCRBD01	TCRBJ01-01	0.21	5787
CASSVAASPSGNTIYF	EQ ID NO: 19	TCRBV09-01		TCRBJ01-03	0.19	5051
CASSPYRAGYEQYF	EQ ID NO: 19	TCRBV03	TCRBD01	TCRBJ02-07	0.11	3056
CASSRTGITDTQYF	EQ ID NO: 20	TCRBV03	TCRBD01	TCRBJ02-03	0.06	1619

TABLE 8

Reference TCRB CDR3 library from subdominant TXT R438W expanded CD8+ T cells (MEL21)						
CDR3 amino acid sequence	Seq ID No.	TCRBV	TCRBD	TCRBJ	Frequency	Read Counts
CASSIASGIYEQYF	SEQ ID NO: 201	TCRBV19-01	TCRBD02	TCRBJ02-07	4.97	112412
CASSISSSEKLFF	SEQ ID NO: 202	TCRBV19-01	TCRBD02	TCRBJ01-04	4.79	108219
CASSLVVGLALEQYF	SEQ ID NO: 203	TCRBV12	TCRBD02	TCRBJ02-07	2.96	66048
CASSFWGLSTEAFF	SEQ ID NO: 204	TCRBV12	TCRBD02	TCRBJ01-01	2.75	62085
CASSSDLYEQYF	SEQ ID NO: 205	TCRBV05-04		TCRBJ02-03	2.38	53716
CASSQEVGSGNTIYF	SEQ ID NO: 206	TCRBV04-03		TCRBJ01-03	2.00	45241
CASSSAGGGGNTIYF	SEQ ID NO: 207	TCRBV07-08	TCRBD01	TCRBJ01-07	1.97	44623
CASSIAGGYEQYV	SEQ ID NO: 208	TCRBV19-01	TCRBD01	TCRBJ02-01	1.86	42081
CSVVGGLLEAFF	SEQ ID NO: 209	TCRBV19-01	TCRBD02	TCRBJ01-01	1.84	41524
CASSSDWGLMNTEAFF	SEQ ID NO: 210	TCRBV05-06	TCRBD01	TCRBJ01-01	1.78	40297
CASSAVDRVTSYNEQFF	SEQ ID NO: 211	TCRBV27-01	TCRBD01	TCRBJ02-03	1.67	37852
CASSLIAGNSDTQYF	SEQ ID NO: 212	TCRBV27-01	TCRBD02	TCRBJ02-05	1.64	37136
CASRLTAGEYQETQYF	SEQ ID NO: 213	TCRBV12-02	TCRBD02	TCRBJ02-02	1.64	36999
CASSLWDYGYTF	SEQ ID NO: 214	TCRBV05-06		TCRBJ01-01	1.59	35919
CASSLWGVGTEAFF	SEQ ID NO: 215	TCRBV12	TCRBD02	TCRBJ01-06	1.54	34759
CASSYFGVNSPLHF	SEQ ID NO: 216	TCRBV06	TCRBD02	TCRBJ01-01	1.48	33424
CATSALAGQGRDEQFF	SEQ ID NO: 217	TCRBV24	TCRBD01	TCRBJ02-03	1.42	32032
CASSRLAGTDTQYF	SEQ ID NO: 218	TCRBV12	TCRBD02	TCRBJ02-01	1.36	30644
CASSFPGYGLNTEAFF	SEQ ID NO: 219	TCRBV06	TCRBD02	TCRBJ01-01	1.59	36045
CASSVLAGGLDTQYF	SEQ ID NO: 220	TCRBV10-02	TCRBD02	TCRBJ02-03	1.15	26035
CASSYMLQTFNTEAFF	SEQ ID NO: 221	TCRBV06		TCRBJ01-01	1.00	22716
CASSPGLLAGGSSWETQYF	SEQ ID NO: 222	TCRBV07-02	TCRBD02	TCRBJ02-05	0.99	22276
CASTSTPGQVGQPQHF	SEQ ID NO: 223	TCRBV27-01	TCRBD01	TCRBJ01-05	0.95	21583
CASKGLAGAYTDTQYF	SEQ ID NO: 224	TCRBV12	TCRBD02	TCRBJ02-03	0.87	19584
CASSLGGNEQYF	SEQ ID NO: 225	TCRBV07-08		TCRBJ02-07	0.86	19499
CASSFTAGLNTEAFF	SEQ ID NO: 226	TCRBV12	TCRBD01	TCRBJ01-01	0.83	18659
CASSLVWGLGTEAFF	SEQ ID NO: 227	TCRBV28-01		TCRBJ01-01	0.80	18100
CASSLGLSGESF	SEQ ID NO: 228	TCRBV07-08	TCRBD02	unresolved	0.78	17740

TABLE 8-continued

Reference TCRB CDR3 library from subdominant TXT R438W expanded CD8+ T cells (MEL21)

CDR3 amino acid sequence	Seq ID No.	TCRBV	TCRBD	TCRBJ	Frequency	Read Counts
CASSKLAGGLDTQYF	SEQ ID NO: 229	TCRBV10-02	TCRBD02	TCRBJ02-03	0.78	17662
CASTHRTGLNTEAFF	SEQ ID NO: 230	TCRBV12	TCRBD01	TCRBJ01-01	0.77	17470
CASSIGGQEETQYF	SEQ ID NO: 231	TCRBV03	TCRBD01	TCRBJ02-05	0.76	17163
CASSLEIVGETEAFF	SEQ ID NO: 232	TCRBV05-06		TCRBJ01-01	0.68	15460
CASSISGGYEQYV	SEQ ID NO: 233	TCRBV19-01	TCRBD01	TCRBJ02-07	0.68	15403
CSARTLAGFTDTQYF	SEQ ID NO: 234	TCRBV20	TCRBD02	TCRBJ02-03	0.65	14669
CASSDLLTGELFF	SEQ ID NO: 235	TCRBV06-01	TCRBD03	TCRBJ02-02	0.58	13155
CASSSGLAGYLM	SEQ ID NO: 236	TCRBV07-08	TCRBD02	TCRBJ02-03	0.55	12339
CASSHRTTDEETQYF	SEQ ID NO: 237	TCRBV23-01	TCRBD01	TCRBJ02-05	0.54	12253
CASSYPGYGLNTEAFF	SEQ ID NO: 238	TCRBV06		TCRBJ01-01	0.49	11037
CASSLDLYEQYF	SEQ ID NO: 239	TCRBV05-04		TCRBJ02-07	0.44	9958
CASSWTGFGLNTEAFF	SEQ ID NO: 240	TCRBV06	TCRBD01	TCRBJ01-01	0.44	9860
CASSLITGLSYEQYF	SEQ ID NO: 241	TCRBV12	TCRBD01	TCRBJ02-07	0.42	9469
CASSTWTGMNTEAFF	SEQ ID NO: 242	TCRBV28-01	TCRBD01	TCRBJ01-01	0.40	9127
CASSELWGAGDNEQFF	SEQ ID NO: 243	TCRBV10-02	TCRBD02	TCRBJ02-01	0.39	8722
CASSFITTSLNVEQYF	SEQ ID NO: 244	TCRBV28-01	TCRBD02	TCRBJ02-07	0.38	8666
CSAQQGIQPQHF	SEQ ID NO: 245	TCRBV20	TCRBD01	TCRBJ01-05	0.38	8478
CASSLVGGLAETQYF	SEQ ID NO: 246	TCRBV27-01		TCRBJ02-05	0.35	7817
CASSFSGGLTHEQYV	SEQ ID NO: 247	TCRBV06	TCRBD02	TCRBJ02-07	0.35	7808
CASSLGAGEQYF	SEQ ID NO: 248	TCRBV07-08		TCRBJ02-07	0.33	7414
CASSPIFGLTNEQYF	SEQ ID NO: 249	TCRBV02-01	TCRBD02	TCRBJ02-07	0.31	6910
CASSYFGGEQFF	SEQ ID NO: 250	TCRBV06	TCRBD02	TCRBJ02-01	0.30	6856
CASSQDWGLNYEQYF	SEQ ID NO: 251	TCRBV04-01		TCRBJ02-07	0.30	6776
CASSTSGGYEQYF	SEQ ID NO: 252	TCRBV19-01	TCRBD02	TCRBJ02-07	0.28	6396
CASSRLAGGLDTQYF	SEQ ID NO: 253	TCRBV10-02	TCRBD02	TCRBJ02-03	0.28	6392
CASSGLITDTQYF	SEQ ID NO: 254	TCRBV19-01	TCRBD02	TCRBJ02-03	0.26	5848
CSARELAGFQETQYF	SEQ ID NO: 255	TCRBV20	TCRBD02	TCRBJ02-05	0.25	5732
CSPIRGIEQYV	SEQ ID NO: 256	TCRBV20-01	TCRBD02	TCRBJ02-07	0.24	5486
CAIGPQGGFYEQYF	SEQ ID NO: 257	TCRBV10-02	TCRBD01	TCRBJ02-07	0.24	5364
CATSSAILAGVKETQYF	SEQ ID NO: 258	TCRBV15-01	TCRBD02	TCRBJ02-05	0.24	5313
CASSEGVGLAFEQFF	SEQ ID NO: 259	TCRBV02-01	TCRBD02	TCRBJ02-01	0.23	5254
CAIGLAGAYEQYF	SEQ ID NO: 260	TCRBV10-03	TCRBD02	TCRBJ02-07	0.23	5123
CASSSWTGLSLSFYGYTF	SEQ ID NO: 261	TCRBV28-01	TCRBD01	TCRBJ01-02	0.22	5077
CASSEPGTVEAFF	SEQ ID NO: 262	TCRBV02-01	TCRBD02	TCRBJ01-01	0.21	4771
CSVEEGIDEQYF	SEQ ID NO: 263	TCRBV29-01		TCRBJ02-07	0.20	4627
CASSLGAGEQFF	SEQ ID NO: 264	TCRBV07-08	TCRBD02	TCRBJ02-01	0.20	4549

TABLE 8-continued

Reference TCRB CDR3 library from subdominant TXT R438W expanded CD8+ T cells (MEL21)

CDR3 amino acid sequence	Seq ID No.	TCRBV	TCRBD	TCRBJ	Frequency	Read Counts
CASSFQGGTGNTIYF	SEQ ID NO: 265	TCRBV07-08	TCRBD02	TCRBJ01-03	0.20	4505
CASSLALPYEQYF	SEQ ID NO: 266	TCRBV12	TCRBD02	TCRBJ02-07	0.18	4029
CASSPTQGLAITGELFF	SEQ ID NO: 267	TCRBV19-01	TCRBD02	TCRBJ02-02	0.18	3969
CASSQTHPPGELFF	SEQ ID NO: 268	TCRBV04-03		TCRBJ02-02	0.17	3928
CASSISAGYEQYV	SEQ ID NO: 269	TCRBV19-01	TCRBD02	TCRBJ02-07	0.16	3684
CASSVDGAYNEQFF	SEQ ID NO: 270	TCRBV09-01	TCRBD02	TCRBJ02-01	0.16	3650
CAFGVNWDLPHSGNTIYF	SEQ ID NO: 271	TCRBV30-01		TCRBJ01-03	0.15	3435
CASSFTWGLNTEAFF	SEQ ID NO: 272	TCRBV12		TCRBJ01-01	0.14	3276
CASSYFSYEQYF	SEQ ID NO: 273	TCRBV06		TCRBJ02-04	0.14	3150
CASSSDRGLPSGNTIYF	SEQ ID NO: 274	TCRBV28-01	TCRBD01	TCRBJ01-03	0.13	2973
CSAHEGLEQYF	SEQ ID NO: 275	TCRBV20-01		TCRBJ02-07	0.13	2906
CASSASWTDYYGYTF	SEQ ID NO: 276	TCRBV27-01	TCRBD01	TCRBJ01-02	0.13	2902
CASSTGTGSYEQYF	SEQ ID NO: 277	TCRBV06		TCRBJ02-07	0.12	2718
CASSLWYNQPQHF	SEQ ID NO: 278	TCRBV27-01		TCRBJ01-05	0.12	2715
CASSPLAAPGSFETQYF	SEQ ID NO: 279	TCRBV06	TCRBD02	TCRBJ02-05	0.11	2420
CASSVDGDYNEQFF	SEQ ID NO: 280	TCRBV09-01	TCRBD02	TCRBJ02-01	0.11	2406
CASSPTPSGLWWELFF	SEQ ID NO: 281	TCRBV12	TCRBD02	TCRBJ02-02	0.11	2400
CASSTGTGLNTEAFF	SEQ ID NO: 282	TCRBV02-01	TCRBD01	TCRBJ01-01	0.10	2348
CATSALPGQETTDTQYF	SEQ ID NO: 283	TCRBV24	TCRBD01	TCRBJ02-03	0.10	2267
CASSLVGGLSNQPQHF	SEQ ID NO: 284	TCRBV27-01	TCRBD02	TCRBJ01-05	0.10	2265

TABLE 9

Reference TCRB CDR3 library from dominant SEC24A P469L expanded CD8+ T cells (MEL38)

CDR3 amino acid sequence	Seq ID No.	TCRBV	TCRBD	TCRBJ	Frequency	Read Counts
CASSQQAGGITYNEQFF	SEQ ID NO: 285	TCRBV03	TCRBD01	TCRBJ02-01	13.04	142392
CASSYSTAGQPQHF	SEQ ID NO: 286	TCRBV06-05	TCRBD01	TCRBJ01-05	6.25	68241
CASSPTGAGYEQYF	SEQ ID NO: 287	TCRBV06-05	TCRBD01	TCRBJ02-07	3.96	43243
CASSLLSGSTEAFF	SEQ ID NO: 288	TCRBV28-01	TCRBD02	TCRBJ01-01	3.83	41830
CASSYGTSTNEQFF	SEQ ID NO: 289	TCRBV06-05	TCRBD02	TCRBJ02-01	3.26	35641
CASSQGDSGTDTQYF	SEQ ID NO: 290	TCRBV03	TCRBD01	TCRBJ02-03	1.57	17192
CASSFSNQPQHF	SEQ ID NO: 291	TCRBV28-01		TCRBJ01-05	1.57	17171
CASSGGQGTQPQHF	SEQ ID NO: 292	TCRBV28-01		TCRBJ01-05	1.49	16310
CASSYSGAGQPQHF	SEQ ID NO: 293	TCRBV06-05	TCRBD01	TCRBJ01-05	1.42	15495
CASSLLQGAESPLHF	SEQ ID NO: 294	TCRBV13-01	TCRBD01	TCRBJ01-06	1.39	15226
CASSPQDRGPNYGYTF	SEQ ID NO: 295	TCRBV28-01	TCRBD01	TCRBJ01-02	1.21	13219
CASSFDYSYEQYF	SEQ ID NO: 296	TCRBV05-04	TCRBD02	TCRBJ02-07	0.88	9558

TABLE 9-continued

Reference TCRB CDR3 library from dominant SEC24A P469L expanded CD8+ T cells (MEL38)

CDR3 amino acid sequence	SEQ ID No.	TCRBV	TCRBD	TCRBJ	Frequency	Read Counts
CAAGGVNQPQHF	SEQ ID NO: 297	TCRBV28-01		TCRBJ01-05	0.84	9144
CASSLLAGELFF	SEQ ID NO: 298	TCRBV06-05	TCRBD02	TCRBJ02-02	0.76	8282
CASSPSSPYEQYF	SEQ ID NO: 299	TCRBV12	TCRBD02	TCRBJ02-07	0.72	7894
CASSEGTDTQYF	SEQ ID NO: 300	TCRBV10-02		TCRBJ02-03	0.67	7299
CASGISNQPQHF	SEQ ID NO: 301	TCRBV28-01		TCRBJ01-05	0.66	7225
CASSLDPPFDRQNYGYTF	SEQ ID NO: 302	TCRBV28-01	TCRBD01	TCRBJ01-02	0.59	6456
CASSYGDMAYNEQFF	SEQ ID NO: 303	TCRBV06-05		TCRBJ02-01	0.59	6440
CATMGTGGSLYYGYTF	SEQ ID NO: 304	TCRBV28-01	TCRBD01	TCRBJ01-02	0.59	6433
CASSVSNQPQHF	SEQ ID NO: 305	TCRBV28-01		TCRBJ01-05	0.58	6305
CASSFTSGGYNEQFF	SEQ ID NO: 306	TCRBV28-01	TCRBD02	TCRBJ02-01	0.55	6055
CASSLYRANTGELFF	SEQ ID NO: 307	TCRBV28-01	TCRBD01	TCRBJ02-02	0.53	5747
CASSLTSLTDTQYF	SEQ ID NO: 308	TCRBV06-05	TCRBD02	TCRBJ02-03	0.51	5617
CASSKSKGSPLHF	SEQ ID NO: 309	TCRBV21-01		TCRBJ01-06	0.42	4580
CASSLAGQGPNSPLHF	SEQ ID NO: 310	TCRBV05-06	TCRBD01	TCRBJ01-06	0.41	4470
CASSPTGAGQPQHF	SEQ ID NO: 311	TCRBV06-05	TCRBD01	TCRBJ01-05	0.40	4417
CASSSGTSGSDTQYF	SEQ ID NO: 312	TCRBV28-01	TCRBD02	TCRBJ02-03	0.35	3791
CASSFSGPRSPQHF	SEQ ID NO: 313	TCRBV12		TCRBJ01-05	0.33	3592
CASNLQGLDYEQYF	SEQ ID NO: 314	TCRBV12	TCRBD01	TCRBJ02-07	0.32	3519
CASSLGQGNQPQHF	SEQ ID NO: 315	TCRBV28-01	TCRBD01	TCRBJ01-05	0.32	3486
CASSFWGANEKLFF	SEQ ID NO: 316	TCRBV28-01	TCRBD02	TCRBJ01-04	0.32	3474
CASSYSVGVNTEAFF	SEQ ID NO: 317	TCRBV06-05	TCRBD02	TCRBJ01-01	0.31	3419
CASRYRAAPNQPQHF	SEQ ID NO: 318	TCRBV28-01	TCRBD01	TCRBJ01-05	0.30	3235
CASSQDAGGVFGNTIYF	SEQ ID NO: 319	TCRBV03	TCRBD02	TCRBJ01-03	0.27	2894
CASSLYSNQPQHF	SEQ ID NO: 320	TCRBV28-01		TCRBJ01-05	0.25	2744
CATAPINSPLHF	SEQ ID NO: 321	TCRBV28-01	TCRBD02	TCRBJ01-06	0.24	2636
CASSPPNQPQHF	SEQ ID NO: 322	TCRBV28-01		TCRBJ01-05	0.21	2262
CASSFNNQPQHF	SEQ ID NO: 323	TCRBV28-01	TCRBD02	TCRBJ01-05	0.21	2255
CASGVSNQPQHF	SEQ ID NO: 324	TCRBV28-01	TCRBD01	TCRBJ01-05	0.20	2180
CASSYESNYGYTF	SEQ ID NO: 325	TCRBV06	TCRBD02	TCRBJ01-02	0.19	2093
CASSLDVATNEKLFF	SEQ ID NO: 326	TCRBV06-05		TCRBJ01-04	0.18	2018
CSDSSTGGAGFTF	SEQ ID NO: 327	TCRBV29-01	TCRBD01	TCRBJ01-02	0.17	1868
CASSESGGGYRWTEAFF	SEQ ID NO: 328	TCRBV10-01	TCRBD02	TCRBJ01-01	0.17	1839
CASSEGPSGYTF	SEQ ID NO: 329	TCRBV09-01		TCRBJ01-02	0.17	1838
CASSPGLGEQYF	SEQ ID NO: 330	TCRBV28-01	TCRBD02	TCRBJ02-07	0.16	1777
CASSLEGVYGYTF	SEQ ID NO: 331	TCRBV06		TCRBJ01-02	0.16	1758
CASTIGPGITDTQYF	SEQ ID NO: 332	TCRBV05-06		TCRBJ02-03	0.16	1715

TABLE 9-continued

Reference TCRB CDR3 library from dominant SEC24A P469L expanded CD8+ T cells (MEL38)

CDR3 amino acid sequence	SEQ ID No.	TCRBV	TCRBD	TCRBJ	Frequency	Read Counts
CASSPRDRGPRSPQHF	SEQ ID NO: 333	TCRBV28-01	TCRBD01	TCRBJ01-05	0.16	1714
CASSRTGAGEKLFF	SEQ ID NO: 334	TCRBV06-05	TCRBD01	TCRBJ01-04	0.16	1705
CASSLGIAGPYNEQFF	SEQ ID NO: 335	TCRBV07-06	TCRBD02	TCRBJ02-01	0.15	1634
CAGGLLNQPQHF	SEQ ID NO: 336	TCRBV28-01	TCRBD02	TCRBJ01-05	0.14	1520
CASSLGQGAQPQHF	SEQ ID NO: 337	TCRBV28-01	TCRBD01	TCRBJ01-05	0.14	1497
CASSPMNTEAFF	SEQ ID NO: 338	TCRBV28-01	TCRBD02	TCRBJ01-01	0.14	1493
CASSLSSHGYTF	SEQ ID NO: 339	TCRBV28-01	TCRBD02	TCRBJ01-02	0.13	1397
CASSFATVGEKLFF	SEQ ID NO: 340	TCRBV06-05	TCRBD01	TCRBJ01-04	0.12	1364
CASTLYTGDNEQFF	SEQ ID NO: 341	TCRBV06-05	TCRBD02	TCRBJ02-01	0.12	1358
CASSYSAGGYYGYTF	SEQ ID NO: 342	TCRBV06-05	TCRBD01	TCRBJ01-02	0.12	1310
CASSYQQGSQPQHF	SEQ ID NO: 343	TCRBV28-01	TCRBD01	TCRBJ01-05	0.11	1212
CASSPLNTEAFF	SEQ ID NO: 344	TCRBV19-01		TCRBJ01-01	0.11	1198
CASSWSNQPQHF	SEQ ID NO: 345	TCRBV28-01		TCRBJ01-05	0.10	1072

TABLE 10

Reference TCRB CDR3 library from subdominant AKAP13 Q285K expanded CD8+ T cells (MEL38)

CDR3 amino acid sequence	SEQ ID No.	TCRBV	TCRBD	TCRBJ	Frequency	Read Counts
CASSPVTGGDNSPLHF	SEQ ID NO: 346	TCRBV13-01	TCRBD01	TCRBJ01-06	8.80	69934
CASSSGNYEQYF	SEQ ID NO: 347	TCRBV13-01		TCRBJ02-07	8.52	67687
CASSLGLSGAYNEQFF	SEQ ID NO: 348	TCRBV13-01	TCRBD01	TCRBJ02-01	7.87	62566
CAWSVASGNEQFF	SEQ ID NO: 349	TCRBV30-01	TCRBD02	TCRBJ02-01	6.44	51166
CASSWGQGGYEQYF	SEQ ID NO: 350	TCRBV13-01	TCRBD01	TCRBJ02-07	4.66	37068
CAWSVGVSNQPQHF	SEQ ID NO: 351	TCRBV30-01		TCRBJ01-05	4.36	34646
CASSLGQGGELFF	SEQ ID NO: 352	TCRBV13-01	TCRBD01	TCRBJ02-02	4.30	34205
CASSLGNYEQYF	SEQ ID NO: 353	TCRBV13-01	TCRBD01	TCRBJ02-07	2.10	16658
CAWSAGTGGNEKLFF	SEQ ID NO: 354	TCRBV30-01	TCRBD01	TCRBJ01-04	1.82	14434
CAWSVAGGHEQYF	SEQ ID NO: 355	TCRBV30-01	TCRBD01	TCRBJ02-07	1.49	11869
CASSLGQGYEQYF	SEQ ID NO: 356	TCRBV13-01	TCRBD01	TCRBJ02-07	0.98	7807
CASSFGQRETEAFF	SEQ ID NO: 357	TCRBV05-06		TCRBJ01-01	0.86	6805
CASSQGTGVTEAFF	SEQ ID NO: 358	TCRBV13-01	TCRBD01	TCRBJ01-01	0.85	6761
CASSFGTGYEQYF	SEQ ID NO: 359	TCRBV06-05	TCRBD01	TCRBJ02-07	0.81	6446
CASSLNPDTQYF	SEQ ID NO: 360	TCRBV05-06		TCRBJ02-03	0.33	2657
CAWSPGQGGTNEKLFF	SEQ ID NO: 361	TCRBV30-01	TCRBD01	TCRBJ01-04	0.29	2319

TABLE 10-continued

Reference TCRB CDR3 library from subdominant AKAP13 Q285K expanded CD8+ T cells (MEL38)

CDR3 amino acid sequence	SEQ ID No.	TCRBV	TCRBD	TCRBJ	Frequency	Read Counts
CAWSAYGGELFF	SEQ ID NO: 362	TCRBV30-01	TCRBD01	TCRBJ02-02	0.23	1846
CAWSVGAGVGEQYF	SEQ ID NO: 363	TCRBV30-01	TCRBD02	TCRBJ02-07	0.20	1625
CAWSGDRPLAFF	SEQ ID NO: 364	TCRBV30-01		TCRBJ01-01	0.18	1470

TABLE 11

Reference TCRB CDR3 library from domiant EXOC8 Q656P and subdominant PABPC1 R520Q expanded CD8+ T cells (MEL 218)

CDR3 amino acid sequence	SEQ ID No.	TCRBV	TCRBD	TCRBJ	Frequency	Read Counts
EXOC8 Q656P						
CASSVGLSETTALYNEQFF	SEQ ID NO: 365	TCRBV25	TCRBD02	TCRBJ02-01	4.85	15597
CASSLEVVQETQYF	SEQ ID NO: 366	TCRBV11-02		TCRBJ02-05	3.64	11717
CSARDPASWGEKLFF	SEQ ID NO: 367	TCRBV20		TCRBJ01-04	2.75	8846
CASSVAGLQGAEQYF	SEQ ID NO: 368	TCRBV09-01		TCRBJ02-07	2.5	8039
CASSYEQGSYEQYF	SEQ ID NO: 369	TCRBV06-05	TCRBD01	TCRBJ02-07	1.87	6014
CASSFGPLGMNWAEAFF	SEQ ID NO: 370	TCRBV06		TCRBJ01-01	1.53	4914
CASSYLSVQETQYF	SEQ ID NO: 371	TCRBV11-02	TCRBD02	TCRBJ02-05	0.33	1061
CASSLETGYGEQYF	SEQ ID NO: 372	TCRBV05-05	TCRBD01	TCRBJ02-07	0.33	1062
CASSVFGLAGAEQYF	SEQ ID NO: 373	TCRBV09-01	TCRBD02	TCRBJ02-07	0.32	1033
CASSEFGGGSPDTQYF	SEQ ID NO: 374	TCRBV09-01	TCRBD02	TCRBJ02-03	0.21	661
CASSVYGGAEAFF	SEQ ID NO: 375	TCRBV09-01	TCRBD02	TCRBJ01-01	0.12	370
CASSTYGLAGETQYF	SEQ ID NO: 376	TCRBV09-01	TCRBD02	TCRBJ02-05	0.1	322
PABPC1 R520Q						
CSVENRVIYGYTF	SEQ ID NO: 377	TCRBV29-01	TCRBD01	TCRBJ01-02	16.65	28165
CSVEDPTFYGYTF	SEQ ID NO: 378	TCRBV29-01		TCRBJ01-02	15.13	25599
CASSLGSSGNTIYF	SEQ ID NO: 379	TCRBV09-01		TCRBJ01-03	9.83	16628
CSVEGQIAGKYGYTF	SEQ ID NO: 380	TCRBV29-01		TCRBJ01-02	8.42	14240
CASSYGTSGTEQFF	SEQ ID NO: 381	TCRBV07-06	TCRBD02	TCRBJ02-01	3.20	5412
CSVEDGAAKQIYGYTF	SEQ ID NO: 382	TCRBV29-01		TCRBJ01-02	0.47	797
CASSVEYSNQPQHF	SEQ ID NO: 383	TCRBV02-01	TCRBD02	TCRBJ01-05	.27	457
CSVEDRVNYGYTF	SEQ ID NO: 384	TCRBV29-01	TCRBD01	TCRBJ01-02	0.16	275
CASSQWSSTNEKLFF	SEQ ID NO: 385	TCRBV14-01		TCRBJ01-04	0.12	199
CARNHDRDRLYEQYF	SEQ ID NO: 386	TCRBV02-01	TCRBD01	TCRBJ02-07	0.11	185
CASSSWGTSDEQYF	SEQ ID NO: 387	TCRBV07-09	TCRBD02	TCRBJ02-07	0.10	172

TABLE 12

MEL69 HLA A2

CHR	Hugo Symbol	AAS-peptide	AAS-SEQID	wild-type peptide	WT SEQ ID	Predicted Affinity (nM) mutated	wild-type	Amino Acid Substitution (AAS)
2	**MPV17**	**VLDGFIPGT**	**SEQ ID NO: 127**	**VLDRFIPGT**	**SEQ ID NO: 128**	**51**	**233**	**R75G**
5	**RUFY1**	**KLADYLNVL**	**SEQ ID NO: 129**	**KLADYLKVL**	**SEQ ID NO: 130**	**5**	**15**	**K225N**
7	LANCL2	YSFLFLYRL	SEQ ID NO: 131	YSFLSLYRL	SEQ ID NO: 132	71	213	S370F
12	UBE3B	HLGFLSPRV	SEQ ID NO: 133	HLGSLSPRV	SEQ ID NO: 134	60	42	S321F
16	AARS	RVVFIGVPV	SEQ ID NO: 136	RVVSAGVPV	SEQ ID NO: 136	488	237	S698F
17	CASC3	SMSPGQPPL	SEQ ID NO: 137	SMSPGQPPP	SEQ ID NO: 138	17	8696	P513L
X	ZMYM3	VVDFTESIPV	SEQ ID NO: 139	VVDSTESIPV	SEQ ID NO: 140	444	360	S258F
2	**GPC1**	**RLFGEAPREIL**	**SEQ ID NO: 141**	**RPFGEAPREL**	**SEQ ID NO: 142**	**83**	**21700**	**P201L**
1	SRSF11	ALAALGLSGA	SEQ ID NO: 143	ALAALGLPGA	SEQ ID NO: 144	176	73	P137S
12	OASL	TIPSEIQIFV	SEQ ID NO: 145	TIPSEIQVFV	SEQ ID NO: 146	274	470	V438I
19	**SIPA1L3**	**ILGIFNEFV**	**SEQ ID NO: 147**	**ILGISNEFV**	**SEQ ID NO: 148**	**45**	**118**	**S893F**

TABLE 12-continued

MEL69 HLA A2

18	NPC1	FVGALSFSI	SEQ ID NO: 149	FVGVLSFSI	SEQ ID NO: 150	23	88	V845A
10	MARCH5	YYLDLANRL	SEQ ID NO: 151	YVLDLADRL	SEQ ID NO: 152	37	54	D90N
11	**SCYL1**	**FLFELIPEP**	**SEQ ID NO: 153**	**FPFELIPEP**	**SEQ ID NO: 154**	**21**	**12401**	**P13L**
5	**PRRC1**	**QMIYSAARV**	**SEQ ID NO: 155**	**QMIYSAARA**	**SEQ ID NO: 156**	**79**	**1783**	**A431V**
13	LMO7	SLVEEQSPA	SEQ ID NO: 157	SPVEEQSPA	SEQ ID NO: 158	79	21881	P583L
19	HSD11B1L	MAFPEAPESV	SEQ ID NO: 159	MASPEAPESV	SEQ ID NO: 160	156	1145	S90F
19	PPAN	SLVRDVFSSL	SEQ ID NO: 161	SLVRDVVSSL	SEQ ID NO: 162	106	135	V69F
7	**BRAF**	**LATEKSRWS**	**SEQ ID NO: 163**	**LATVKSRWS**	**SEQ ID NO: 164**	**24853**	**27478**	**V600E**

CHR	Hugo Symbol	MEL69A.2 (Limb) Exome VAF	MEL69A.2 (Limb) RNA VAF	MEL69A.2 (Limb) FPKM	MEL69B.2 (Scalp) Exome Tumor VAF	MEL69B.2 Scalp) RNA Tumor VAF	MEL69B.2 (Scalp) FPKM
2	**MPV17**	**34.78**	**31.51**	**44.1711**	**36.59**	**37.87**	**44.5254**
5	**RUFY1**	**32.5**	**17.95**	**10.8626**	**23.81**	**42.05**	**12.321**
7	LANCL2	16.07	31.86	15.3511	31.58	42.57	15.187
12	UBE3B	28.57	41.94	13.1866	37.68	42.11	18.9171
16	AARS	13.51	43.51	21.7187	39.02	48.85	44.5936
17	CASC3	21.05	26.79	6.77417	33.33	28.81	8.93879
X	ZMYM3	35.29	51.81	9.72465	80.95	75.44	14.715
2	**GPC1**	**28.12**	**30**	**7.40362**	**33.33**	**38.89**	**9.89646**
1	SRSF11	11.76	26.4	63.5826	46.15	44.17	62.4002
12	OASL	16.36	14.79	10.8827	40.43	27.56	9.78642
19	**SIPA1L3**	**8.33**	**29.41**	**1.41955**	**30**	**64.71**	**3.27408**
18	NPC1	30.77	32	32.9957	46.67	48.27	48.3298
10	MARCH5	0	0	9.44984	30.43	37.8	11.4002
11	**SCYL1**	**15.38**	**27.54**	**29.3756**	**46.15**	**37.41**	**48.8269**
5	**P44C1**	**11.11**	**26.14**	**26.921**	**30.56**	**36.17**	**31.9828**
13	LMO7	23.68	0	12.5597	30.25	13.04	8.01764
19	HSD11B1L	18.52	0	0.551889	33.33	100	0.367626
19	PPAN	0	0	7.52204	34.29	43.53	11.0531
7	**BRAF**	**30**	**67.67**	**13.3533**	**56.25**	**56.1**	**14.5002**

CHR	Hugo Symbol	AAS-peptide	AAS-SEQID	wild-type peptide	WT SEQ ID	Predicted Affinity (nM) mutated	Predicted Affinity (nM) wild-type	Amino Acid Substitution (AAS)
5	ZSWIM6	LSALTRCEK	SEQ ID NO: 388	LSALTLCEK	SEQ ID NO: 389	295	215	L1002R
12	KIAA0528	LSACNSPSK	SEQ ID NO: 390	LPACNSPSK	SEQ ID NO: 391	91	14975	P256S
12	**SMARCC2**	**KVFEHVGSR**	SEQ ID NO: 392	**KVSEHVGSR**	SEQ ID NO: 393	**69**	**390**	**S624F**
19	**PIP5K1C**	**FISNTVFRK**	SEQ ID NO: 394	**FMSNTVFRK**	SEQ ID NO: 395	**21**	**25**	**M439I**
20	PPP1R16B	HQCCIDNFK	SEQ ID NO: 396	HQCCIDNFE	SEQ ID NO: 397	162	21019	E114K
22	RHBDD3	SSAAGSFGY	SEQ ID NO: 398	SSAAGSCGY	SEQ ID NO: 399	51	668	C119F
X	**ERCC6L**	**KIYRRQIFK**	SEQ ID NO: 400	**KIYRRQVFK**	SEQ ID NO: 401	**12**	**13**	**V476I**
7	**BRAF**	**LATEKSRWS**	SEQ ID NO: 163	**LATVKSRWS**	SEQ ID NO: 164	**24853**	**27478**	**V600E**

CHR	Hugo Symbol	MEL69A.2 (Limb) Exome VAF	MEL69A.2 (Limb) RNA VAF	MEL69A.2 (Limb) FPKM	MEL69B.2 (Scalp) Exome Tumor VAF	MEL69B.2 (Scalp) RNA Tumor VAF	MEL69B.2 (Scalp) FPKM
5	ZSWIM6	25.49	43.75	9.3725	33.33	51.16	11.045
12	KIAA0528	28.57	11.96	24.255	50	25	20.069
12	**SMARCC2**	**27.66**	**17.78**	**14.734**	**26.83**	**41.77**	**20.227**
19	**PIP5K1C**	**22.5**	**23.81**	**6.1374**	**24**	**38.57**	**11.467**
20	PPP1R16B	18.92	15.79	2.8959	25.81	45.16	2.8599
22	RHBDD3	30	57.14	11.48	66.67	83.33	8.2471
X	**ERCC6L**	**55.56**	**69.23**	**2.4877**	**43.24**	**63.64**	**2.4041**
7	**BRAF**	**30**	**67.67**	**13.353**	**56.25**	**56.1**	**14.6**

Predicted affinity (MT and WT score) as determined using NetMCH3.4 algorithm.

VAF = Variant Allelic Fraction as determined from exome sequencing. BRAF VAF are reported as these were used as comparator to assess clonality of other mutations

FPKM = Fragment Per Kilobase of transcript per Million per transcriptome as determined from cDNA-capture data.

BRAF VAF values are reported and were used as comparator to interpret frequencies of remaining missense mutation encoding-genes.

Candidates formulated in vaccine are shown bolded.

TABLE 13

MEL 66 HLA A2

Hugo CHR	Symbol	AAS-peptide	AAS-SEQID	wild-type peptide	WT SEQ ID	Predicted Affinity (nM) mutated	wild-type	Amino Acid Substitution (AAS)
7	LMBR1	LLLLLCTSV	SEQ ID NO: 402	LLLLLCTPV	SEQ ID NO: 403	19	10	P210S
2	SH3BP4	RLIQGFVLL	SEQ ID NO: 404	RLIQDFVLL	SEQ ID NO: 405	41	51	D843G
1	ATP2B4	QLIVIFIFV	SEQ ID NO: 406	QLIVIFILV	SEQ ID NO: 407	34	60	L934F
2	MGAT4A	ALAFITFFL	SEQ ID NO: 408	ALAFITSFL	SEQ ID NO: 409	7	26	S17F
X	PORCN	LLHGFSFYL	SEQ ID NO: 410	LLHGFSFHL	SEQ ID NO: 411	5	11	H346Y
7	PHKG1	TLFENTPKA	SEQ ID NO: 412	ALFENTPKA	SEQ ID NO: 413	18	14	A401T
14	ATG2B	KLNLVCCEL	SEQ ID NO: 414	KLMPVCCEL	SEQ ID NO: 415	95	23	P679L
12	CAMKK2	YLGMESFIV	SEQ ID NO: 416	HLGMESFIV	SEQ ID NO: 417	9	111	H46Y
2	ZDBF2	YILKYSVFL	SEQ ID NO: 418	YISKYSVFL	SEQ ID NO: 419	5	11	S2228L
11	EXT2	VLQEATICV	SEQ ID NO: 420	VLQEATFCV	SEQ ID NO: 421	13	7	F350I
9	ZNF658	GLYDKAICI	SEQ ID NO: 422	GLYDKTICI	SEQ ID NO: 423	25	13	T228A
14	PLEKHH1	YLLKIGSQV	SEQ ID NO: 424	YLLKMGSQV	SEQ ID NO: 425	15	18	M588I
17	GAS7	FLGEAWAQV	SEQ ID NO: 426	SLGEAWAQV	SEQ ID NO: 427	11	32	S270F
20	SLC2A10	FLSSMACCI	SEQ ID NO: 428	SLSSMACCI	SEQ ID NO: 429	27	232	S113F
3	LMLN	SLVVTLWPL	SEQ ID NO: 430	SLVVTLWLL	SEQ ID NO: 431	12	36	L637P
2	CERS6	SMWRFTFYL	SEQ ID NO: 432	SMWRFSFYL	SEQ ID NO: 433	3	3	S140T
6	CUL9	CLLQLCPRL	SEQ ID NO: 434	RLLQLCPRL	SEQ ID NO: 435	64	25	R1335C
12	GCN1L1	SLLRSLENV	SEQ ID NO: 436	SLLRSPENV	SEQ ID NO: 437	21	59	P274L
20	SLC13A3	FLISILYSA	SEQ ID NO: 438	FLISIPYSA	SEQ ID NO: 439	3	4	P239L
8	ARHGEF10	YLLRWSVPL	SEQ ID NO: 440	YLLKWSVPL	SEQ ID NO: 441	3	3	K697R
22	SF3A1	MLTTAIPKV	SEQ ID NO: 442	MPTTAIPKV	SEQ ID NO: 443	5	12945	P6L
1	WDR63	HILEILWTL	SEQ ID NO: 444	HILEIPWTL	SEQ ID NO: 445	7	11	P793L
14	SLC24A4	NMFDILVGL	SEQ ID NO: 446	NVFDILVGL	SEQ ID NO: 447	6	53	V527M
6	PDE7B	RMWDFDIFL	SEQ ID NO: 448	GMWDFDIFL	SEQ ID NO: 449	3	3	G113R
1	RASAL2	IMSSSLFNL	SEQ ID NO: 450	IMSPSLFNL	SEQ ID NO: 451	6	8	P637S
7	AKAP9	RLSDFSEQL	SEQ ID NO: 452	RLSDLSEQL	SEQ ID NO: 453	30	52	L974F

Hugo CHR	Symbol	MEL66A Exome VAF	MEL66A RNA VAF	MEL66A FPKM	MEL66D Exome VAF	MEL66D RNA VAF	MEL66D FPKM
7	LMBR1	66.07	95.59	133.906	31.17	64.38	32.8169
2	SH3BP4	51.72	38.56	24.5197	29.41	41.53	27.9068
1	ATP2B4	48.48	36.47	37.9108	25.81	35.89	36.7154
2	MGAT4A	48	17.12	34.4185	23.08	7.38	61.5058
X	PORCN	47.37	89.68	22.2618	8.86	78.2	17.7896
7	PHKG1	47.06	52.94	1.77883	17.86	34.78	1.61569
14	ATG2B	46.15	36.41	40.641	17.14	37.26	38.7526
12	CAMKK2	43.59	47.62	15.4478	14.89	19.78	14.1399
2	ZDBF2	42.22	89.47	7.94103	14.74	53.97	11.8555
11	EXT2	42	38.9	53.8156	10	40.85	37.7597
9	ZNF658	40.37	48.09	17.1165	20.83	33.77	13.9748
14	PLEKHH1	40	50.88	14.6035	46.67	41.96	25.1339
17	GAS7	38.48	19.74	10.3323	31.82	26.24	31.4939
20	SLC2A10	36.59	46.15	1.86998	21.43	63.33	2.29521
3	LMLN	36.17	45.45	7.56894	25.93	52.17	6.56604
2	CERS6	36.11	42.02	10.198	14.81	33.53	7.74818
6	CUL9	36	38.6	7.63523	22.58	26.88	13.4072
12	GDN1L1	34.78	33.67	38.6382	19.15	28.24	45.0198
20	SLC13A3	34	59.26	4.30641	15.94	62.79	5.58358
8	ARHGEF10	33.33	43.24	13.6682	19.57	35.42	14.6281
22	SF3A1	32.56	37.95	32.8032	15.58	32.72	56.3619
1	WDR63	31.82	46.82	41.4768	11.94	36.11	3.23577
14	SLC24A4	29.82	53.04	72.1497	11.54	56.82	3.81134
6	PDE7B	26.91	32.69	6.92805	14.29	34.88	6.604
1	RASAL2	33.33	31.23	21.9958	16.07	38.83	26.2991
7	AKAP9	71.05	86.04	60.8703	26.56	26.56	26.56

TABLE 13-continued

MEL 66 HLA A2

Hugo CHRSymbol	AAS-peptide	AAS-SEQID	wild-type peptide	WT SEQ ID	Predicted Affinity (nM) mutated	wild-type	Amino Acid Substitution (AAS)
14 AHNAK2	MPKFKMSSF	SEQ ID NO: 454	MPKFKMPSF	SEQ ID NO: 455	9	14	P3151S
4 DDX60	LPSMHRHQI	SEQ ID NO: 456	LPSMYRHQI	SEQ ID NO: 457	35	90	Y194H
19 TLE2	LPRAKKLIL	SEQ ID NO: 458	LPRAKELIL	SEQ ID NO: 459	14	40	E288K
9 DMRTA1	FSNYRRSRL	SEQ ID NO: 460	FPNYRRSRL	SEQ ID NO: 461	80	14	P338S
3 WDR52	QLILRTKAF	SEQ ID NO: 462	QPILRTKAF	SEQ ID NO: 463	38	41	P264L
7 FKBP3	YLKYHCNAS	SEQ ID NO: 464	YLKYHYNAS	SEQ ID NO: 465	62	32	Y449C
18 SOCS6	SLRSHHYSL	SEQ ID NO: 466	SLRSHHYSP	SEQ ID NO: 467	6	75	P134L
2 CHPF	FFSMHFQAF	SEQ ID NO: 468	FFPMHFQAF	SEQ ID NO: 469	20	49	P641S
2 DUSP2	LFRYKSISV	SEQ ID NO: 470	LFRYKSIPV	SEQ ID NO: 471	95	120	P223S
1 LRRC42	NLRYFAKSL	SEQ ID NO: 472	NLRYSAKSL	SEQ ID NO: 473	26	40	S85F
7 BRAF	LATEKSRWS	SEQ ID NO: 163	LATVKSRWS	SEQ ID NO: 164	24853	27478	V600E

Hugo CHRSymbol	MEL66A Exome VAF	MEL66A RNA VAF	MEL66A FPKM	MEL66D Exome VAF	MEL66D RNA VAF	MEL66D FPKM
14 AHNAK2	74.74	95.54	14.8985	35.24	93.66	40.6564
4 DDX60	41.51	30.09	35.1655	28.26	24.84	72.2322
19 TLE2	42	38.6	4.18558	27.59	42.86	2.88573
9 DMRTA1	31.25	29.61	16.3335	24.19	35.14	2.76312
3 WDR52	40	48.95	28.3206	22.22	26.32	12.81
7 FKBP3	40.19	45.63	210.808	19.42	44.71	167.962
18 SOCS6	39.13	27.48	30.9938	16.67	27.97	23.4984
2 CHPF	40	47.62	32.2709	15.73	48.12	27.2727
2 DUSP2	41.98	19.78	5.98827	14.63	15.14	19.9318
1 LRRC42	32.53	39.61	27.2896	12.05	36.05	25.2227
7 BRAF	66.67			33.33		

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 474

<210> SEQ ID NO 1
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 1

Lys Leu Met Asn Ile Gln Gln Lys Leu
1 5

<210> SEQ ID NO 2
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 2

Phe Val Ser Ala Leu Cys Met Phe Leu
1 5

<210> SEQ ID NO 3
<211> LENGTH: 9
<212> TYPE: PRT

-continued

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 3

Gln Leu Cys Glu Asp Ala Ser Thr Val
1 5

<210> SEQ ID NO 4
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 4

Leu Met Ser Ile Ile Ile Val Gly Val
1 5

<210> SEQ ID NO 5
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 5

Leu Ile Met Thr Cys Cys Val Ala Leu
1 5

<210> SEQ ID NO 6
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 6

Ala Leu Val Ser Gly Asn Gln Gln Leu
1 5

<210> SEQ ID NO 7
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 7

Tyr Ile Ser Lys Cys Trp Asp Tyr Ala
1 5

<210> SEQ ID NO 8
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 8

Phe Ile Met Gly Ile Ser Ile Leu Leu
1 5

<210> SEQ ID NO 9
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 9

Ile Gln Leu Ser Trp Val Leu Ile Ala
1 5

<210> SEQ ID NO 10
<211> LENGTH: 9

-continued

<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 10

Ile Leu Met Thr Trp Asn Leu His Ser
1 5

<210> SEQ ID NO 11
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 11

Tyr Ile Phe Leu Glu Asn Leu Ala Leu
1 5

<210> SEQ ID NO 12
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 12

Gln Leu Ser Cys Ile Ser Thr Tyr Val
1 5

<210> SEQ ID NO 13
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 13

Phe Leu Tyr Asn Leu Leu Thr Arg Val
1 5

<210> SEQ ID NO 14
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 14

Trp Met Ala Pro Glu Val Ile Leu Val
1 5

<210> SEQ ID NO 15
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 15

Gln Leu Asp Lys Cys Ser Ala Phe Val
1 5

<210> SEQ ID NO 16
<211> LENGTH: 9
<212> TYPE: PRT

-continued

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 16

Lys Leu Met Asn Ile Gln Gln Gln Leu
1 5

<210> SEQ ID NO 17
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 17

Phe Val Ser Ala Leu Arg Met Phe Leu
1 5

<210> SEQ ID NO 18
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 18

Gln Leu Arg Glu Asp Ala Ser Thr Val
1 5

<210> SEQ ID NO 19
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 19

Pro Met Ser Ile Ile Ile Val Gly Val
1 5

<210> SEQ ID NO 20
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 20

Leu Ile Met Thr Cys Tyr Val Ala Leu
1 5

<210> SEQ ID NO 21
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 21

Ala Pro Val Ser Gly Asn Gln Gln Leu
1 5

<210> SEQ ID NO 22
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 22

Tyr Ile Ser Lys Cys Trp Asp His Ala
1 5

<210> SEQ ID NO 23
<211> LENGTH: 9

-continued

<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 23

Phe Ile Thr Gly Ile Ser Ile Leu Leu
1 5

<210> SEQ ID NO 24
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 24

Ile Gln Leu Ser Gly Val Leu Ile Ala
1 5

<210> SEQ ID NO 25
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 25

Ile Leu Met Thr Gly Asn Leu His Ser
1 5

<210> SEQ ID NO 26
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 26

Tyr Ile Phe Leu Gly Asn Leu Ala Leu
1 5

<210> SEQ ID NO 27
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 27

Gln Leu Ser Cys Thr Ser Thr Tyr Val
1 5

<210> SEQ ID NO 28
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 28

Phe Leu Tyr Asn Pro Leu Thr Arg Val
1 5

<210> SEQ ID NO 29
<211> LENGTH: 9
<212> TYPE: PRT

-continued

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 29

Trp Met Ala Pro Glu Val Ile Leu Ala
1 5

<210> SEQ ID NO 30
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 30

Gln Leu Asp Gln Cys Ser Ala Phe Val
1 5

<210> SEQ ID NO 31
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 31

Ser Val Gly Gly Val Phe Thr Ser Val
1 5

<210> SEQ ID NO 32
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Rattus norvegicus

<400> SEQUENCE: 32

Ser Val Val Ser Thr Asp Asp Asp Leu Ala
1 5 10

<210> SEQ ID NO 33
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: West Nile virus

<400> SEQUENCE: 33

Ser Val Gly Gly Val Phe Thr Ser Val
1 5

<210> SEQ ID NO 34
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 34

Thr Gly Pro Ile Phe Lys Leu Met Asn Ile Gln Gln Lys Leu Met Lys
1 5 10 15

Thr Asn Leu Asn
20

<210> SEQ ID NO 35
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 35

Asn Leu Ser Gly Asn Thr Ala Leu Leu
1 5

-continued

<210> SEQ ID NO 36
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 36

Asp Leu Ser Gly Asn Thr Ala Leu Leu
1 5

<210> SEQ ID NO 37
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 37

Gln Thr Ile Asp Asn Ile Val Phe Leu
1 5

<210> SEQ ID NO 38
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 38

Gln Thr Ile Asp Asn Ile Val Phe Phe
1 5

<210> SEQ ID NO 39
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 39

Lys Met Ile Gly Asn His Leu Trp Val
1 5

<210> SEQ ID NO 40
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 40

Glu Met Ile Gly Asn His Leu Trp Val
1 5

<210> SEQ ID NO 41
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 41

Phe Thr Met Leu Ala Leu Gln Asp Leu
1 5

<210> SEQ ID NO 42
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 42

Phe Thr Met Leu Ala Leu Arg Asp Leu
1 5

-continued

<210> SEQ ID NO 43
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 43

Ser Leu Trp Asn Ala Ile Asp Phe Phe
1 5

<210> SEQ ID NO 44
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 44

Ser Leu Trp Asn Ala Ile Asp Phe Ser
1 5

<210> SEQ ID NO 45
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 45

Glu Leu Gln Asp Glu Val Tyr Thr Leu
1 5

<210> SEQ ID NO 46
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 46

Glu Leu Gln Asp Glu Ala Tyr Thr Leu
1 5

<210> SEQ ID NO 47
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 47

Leu Leu Ser Ile Val Pro Cys Thr Val
1 5

<210> SEQ ID NO 48
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 48

Leu Leu Ser Ile Val Leu Cys Thr Val
1 5

<210> SEQ ID NO 49
<211> LENGTH: 9
<212> TYPE: PRT

-continued

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 49

Ile Ile Gly Ala Gly Pro Ala Glu Leu
1 5

<210> SEQ ID NO 50
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 50

Ile Ile Gly Ala Gly Pro Ala Gly Leu
1 5

<210> SEQ ID NO 51
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 51

Asn Leu Phe Asn Arg Tyr Leu Ala Leu
1 5

<210> SEQ ID NO 52
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 52

Asn Leu Phe Asn Arg Tyr Pro Ala Leu
1 5

<210> SEQ ID NO 53
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 53

Trp Leu Thr Arg Asn Phe Tyr Phe Val
1 5

<210> SEQ ID NO 54
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 54

Trp Leu Thr Arg Asn Leu Tyr Phe Val
1 5

<210> SEQ ID NO 55
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 55

Met Leu Ser Ser Val Ala Cys Ser Leu
1 5

<210> SEQ ID NO 56
<211> LENGTH: 9

-continued

<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 56

Val Leu Ser Ser Val Ala Cys Ser Leu
1 5

<210> SEQ ID NO 57
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 57

Ile Leu Asn Pro Ala Asp Pro Thr Leu
1 5

<210> SEQ ID NO 58
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 58

Ile Leu Asp Pro Ala Asp Pro Thr Leu
1 5

<210> SEQ ID NO 59
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 59

Phe Leu Phe Leu Val Leu Leu Phe Val
1 5

<210> SEQ ID NO 60
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 60

Phe Leu Phe Ser Val Leu Leu Phe Val
1 5

<210> SEQ ID NO 61
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 61

Met Leu Leu Glu Ile Ser Glu Asn Ser
1 5

<210> SEQ ID NO 62
<211> LENGTH: 9
<212> TYPE: PRT

-continued

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 62

Met Leu Leu Glu Ile Pro Glu Asn Ser
1 5

<210> SEQ ID NO 63
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 63

Leu Leu Ser Ile Ile Phe Phe Pro Ala
1 5

<210> SEQ ID NO 64
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 64

Leu Leu Ser Ile Ile Ser Phe Pro Ala
1 5

<210> SEQ ID NO 65
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 65

Pro Leu Ala Asn Ser Ile Trp Asn Val
1 5

<210> SEQ ID NO 66
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 66

Pro Leu Ala Asn Pro Ile Trp Asn Val
1 5

<210> SEQ ID NO 67
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 67

His Ile Val Glu Ile Ser Thr Pro Val
1 5

<210> SEQ ID NO 68
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 68

His Ile Val Glu Ile Ser Thr Pro Val
1 5

<210> SEQ ID NO 69
<211> LENGTH: 9

-continued

<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 69

Ala Met Phe Trp Ser Val Pro Thr Val
1 5

<210> SEQ ID NO 70
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 70

Ala Met Phe Arg Ser Val Pro Thr Ser
1 5

<210> SEQ ID NO 71
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 71

Cys Leu Asn Glu Tyr His Leu Phe Leu
1 5

<210> SEQ ID NO 72
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 72

Cys Leu Asn Glu Tyr His Leu Phe Phe
1 5

<210> SEQ ID NO 73
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 73

Cys Leu Phe Pro Gln Thr Leu Ala Ala
1 5

<210> SEQ ID NO 74
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 74

Cys Leu Ser Pro Gln Thr Leu Ala Ala
1 5

<210> SEQ ID NO 75
<211> LENGTH: 9
<212> TYPE: PRT

-continued

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 75

Phe Leu Asn Cys Asn Ser Ser Arg Leu
1 5

<210> SEQ ID NO 76
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 76

Ser Leu Asn Cys Asn Ser Ser Arg Leu
1 5

<210> SEQ ID NO 77
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 77

Ser Leu Glu Gly Thr Ser Phe Ile Val
1 5

<210> SEQ ID NO 78
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 78

Pro Leu Glu Gly Thr Ser Phe Ile Val
1 5

<210> SEQ ID NO 79
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 79

Gly Met His Leu Leu Ile Thr Gly Leu
1 5

<210> SEQ ID NO 80
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 80

Gly Met His Leu Leu Ile Thr Gly Pro
1 5

<210> SEQ ID NO 81
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 81

Val Leu Ala Val Ser Val Leu Ala Ala
1 5

<210> SEQ ID NO 82
<211> LENGTH: 9

-continued

<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 82

Val Ser Ala Val Ser Val Leu Ala Ala
1 5

<210> SEQ ID NO 83
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 83

Phe Met Leu Leu Thr Gln Ala Arg Ile
1 5

<210> SEQ ID NO 84
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 84

Phe Met Leu Leu Thr Gln Ala Arg Leu
1 5

<210> SEQ ID NO 85
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 85

Ile Gln Tyr Phe Arg Asn His Asn Val
1 5

<210> SEQ ID NO 86
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 86

Ile Gln Tyr Phe Lys Asn His Asn Val
1 5

<210> SEQ ID NO 87
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 87

Ser Val Met Ile Met Ala Phe Ser Val
1 5

<210> SEQ ID NO 88
<211> LENGTH: 9
<212> TYPE: PRT

-continued

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 88

Ser Asp Met Ile Met Ala Phe Ser Val
1 5

<210> SEQ ID NO 89
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 89

Ser Ile Ser Lys Pro Leu Leu Pro Val
1 5

<210> SEQ ID NO 90
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 90

Ser Ile Pro Lys Pro Leu Leu Pro Val
1 5

<210> SEQ ID NO 91
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 91

Ile Ile Leu Val Ala Val Pro His Val
1 5

<210> SEQ ID NO 92
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 92

Ile Ile Leu Val Ala Val Gln His Val
1 5

<210> SEQ ID NO 93
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 93

Leu Met Leu Glu Ser Gly Tyr Ile Leu
1 5

<210> SEQ ID NO 94
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 94

Leu Met Leu Glu Ser Gly Tyr Ile Pro
1 5

<210> SEQ ID NO 95
<211> LENGTH: 9

-continued

<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 95

Ala Val Asp Asp Gly Lys Leu Thr Val
1 5

<210> SEQ ID NO 96
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 96

Ala Val Asp Gly Gly Lys Leu Thr Val
1 5

<210> SEQ ID NO 97
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 97

Ser Leu Leu Leu Leu Ser Val Ser Val
1 5

<210> SEQ ID NO 98
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 98

Ser Leu Leu Leu Leu Pro Val Ser Val
1 5

<210> SEQ ID NO 99
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 99

Tyr Met Ala Glu Leu Thr Val Thr Leu
1 5

<210> SEQ ID NO 100
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 100

Tyr Met Ala Lys Leu Thr Val Thr Leu
1 5

<210> SEQ ID NO 101
<211> LENGTH: 9
<212> TYPE: PRT

-continued

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 101

Lys Leu Ser Arg Glu Ile Lys Pro Val
1 5

<210> SEQ ID NO 102
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 102

Lys Leu Ser Arg Glu Ile Met Pro Val
1 5

<210> SEQ ID NO 103
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 103

Ala Val Ile Asp Ala Tyr Thr Glu Ile
1 5

<210> SEQ ID NO 104
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 104

Ala Val Ile Asn Ala Tyr Thr Glu Ile
1 5

<210> SEQ ID NO 105
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 105

Val Leu Leu Arg Ala Leu Pro Val Leu
1 5

<210> SEQ ID NO 106
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 106

Val Leu Leu Arg Ala Leu Pro Val Pro
1 5

<210> SEQ ID NO 107
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 107

His Leu Tyr Ala Ser Leu Ser Arg Ala
1 5

<210> SEQ ID NO 108
<211> LENGTH: 9

-continued

<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 108

His Pro Tyr Ala Ser Leu Ser Arg Ala
1 5

<210> SEQ ID NO 109
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 109

Phe Cys Phe Lys Leu Ser His Pro Leu
1 5

<210> SEQ ID NO 110
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 110

Phe Cys Phe Lys Leu Phe His Pro Leu
1 5

<210> SEQ ID NO 111
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 111

Met Leu Gly Glu Gln Leu Phe Pro Leu
1 5

<210> SEQ ID NO 112
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 112

Met Leu Gly Glu Arg Leu Phe Pro Leu
1 5

<210> SEQ ID NO 113
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 113

Phe Ile Trp Gly Asp Ala Pro Pro Thr
1 5

<210> SEQ ID NO 114
<211> LENGTH: 9
<212> TYPE: PRT

-continued

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 114

Ser Ile Trp Gly Asp Ala Pro Pro Thr
1 5

<210> SEQ ID NO 115
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 115

Arg Leu Leu Cys Pro Pro Ala Arg Ala
1 5

<210> SEQ ID NO 116
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 116

Arg Pro Leu Cys Pro Pro Ala Arg Ala
1 5

<210> SEQ ID NO 117
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 117

Lys Leu Ala Asn Pro Leu Pro Tyr Thr
1 5

<210> SEQ ID NO 118
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 118

Lys Leu Ala Lys Pro Leu Pro Tyr Thr
1 5

<210> SEQ ID NO 119
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 119

Ile Met Ala His Cys Ile Leu Asp Leu
1 5

<210> SEQ ID NO 120
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 120

Ile Ile Ala His Cys Ile Leu Asp Leu
1 5

<210> SEQ ID NO 121
<211> LENGTH: 9

-continued

<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 121

Ser Leu Ala Glu Thr Phe Leu Glu Thr
1 5

<210> SEQ ID NO 122
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 122

Ser Leu Ala Glu Thr Phe Trp Glu Thr
1 5

<210> SEQ ID NO 123
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 123

Phe Val Phe Cys Ala Leu Leu Leu Val
1 5

<210> SEQ ID NO 124
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 124

Phe Val Phe Arg Ala Leu Leu Leu Val
1 5

<210> SEQ ID NO 125
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 125

Phe Thr Gln Glu Lys Trp Tyr His Val
1 5

<210> SEQ ID NO 126
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 126

Phe Thr Gln Glu Glu Trp Tyr His Val
1 5

<210> SEQ ID NO 127
<211> LENGTH: 9
<212> TYPE: PRT

-continued

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 127

Val Leu Asp Gly Phe Ile Pro Gly Thr
1 5

<210> SEQ ID NO 128
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 128

Val Leu Asp Arg Phe Ile Pro Gly Thr
1 5

<210> SEQ ID NO 129
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 129

Lys Leu Ala Asp Tyr Leu Asn Val Leu
1 5

<210> SEQ ID NO 130
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 130

Lys Leu Ala Asp Tyr Leu Lys Val Leu
1 5

<210> SEQ ID NO 131
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 131

Tyr Ser Phe Leu Phe Leu Tyr Arg Leu
1 5

<210> SEQ ID NO 132
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 132

Tyr Ser Phe Leu Ser Leu Tyr Arg Leu
1 5

<210> SEQ ID NO 133
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 133

His Leu Gly Phe Leu Ser Pro Arg Val
1 5

<210> SEQ ID NO 134
<211> LENGTH: 9

-continued

<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 134

His Leu Gly Ser Leu Ser Pro Arg Val
1 5

<210> SEQ ID NO 135
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 135

Arg Val Val Phe Ile Gly Val Pro Val
1 5

<210> SEQ ID NO 136
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 136

Arg Val Val Ser Ile Gly Val Pro Val
1 5

<210> SEQ ID NO 137
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 137

Ser Met Ser Pro Gly Gln Pro Pro Leu
1 5

<210> SEQ ID NO 138
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 138

Ser Met Ser Pro Gly Gln Pro Pro Pro
1 5

<210> SEQ ID NO 139
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 139

Val Val Asp Phe Thr Glu Ser Ile Pro Val
1 5 10

<210> SEQ ID NO 140
<211> LENGTH: 10
<212> TYPE: PRT

-continued

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 140

Val Val Asp Ser Thr Glu Ser Ile Pro Val
1 5 10

<210> SEQ ID NO 141
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 141

Arg Leu Phe Gly Glu Ala Pro Arg Glu Leu
1 5 10

<210> SEQ ID NO 142
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 142

Arg Pro Phe Gly Glu Ala Pro Arg Glu Leu
1 5 10

<210> SEQ ID NO 143
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 143

Ala Leu Ala Ala Leu Gly Leu Ser Gly Ala
1 5 10

<210> SEQ ID NO 144
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 144

Ala Leu Ala Ala Leu Gly Leu Pro Gly Ala
1 5 10

<210> SEQ ID NO 145
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 145

Thr Ile Pro Ser Glu Ile Gln Ile Phe Val
1 5 10

<210> SEQ ID NO 146
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 146

Thr Ile Pro Ser Glu Ile Gln Val Phe Val
1 5 10

<210> SEQ ID NO 147
<211> LENGTH: 9

-continued

<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 147

Ile Leu Gly Ile Phe Asn Glu Phe Val
1 5

<210> SEQ ID NO 148
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 148

Ile Leu Gly Ile Ser Asn Glu Phe Val
1 5

<210> SEQ ID NO 149
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 149

Phe Val Gly Ala Leu Ser Phe Ser Ile
1 5

<210> SEQ ID NO 150
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 150

Phe Val Gly Val Leu Ser Phe Ser Ile
1 5

<210> SEQ ID NO 151
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 151

Tyr Val Leu Asp Leu Ala Asn Arg Leu
1 5

<210> SEQ ID NO 152
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 152

Tyr Val Leu Asp Leu Ala Asp Arg Leu
1 5

<210> SEQ ID NO 153
<211> LENGTH: 9
<212> TYPE: PRT

-continued

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 153

Phe Leu Phe Glu Leu Ile Pro Glu Pro
1 5

<210> SEQ ID NO 154
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 154

Phe Pro Phe Glu Leu Ile Pro Glu Pro
1 5

<210> SEQ ID NO 155
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 155

Gln Met Ile Tyr Ser Ala Ala Arg Val
1 5

<210> SEQ ID NO 156
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 156

Gln Met Ile Tyr Ser Ala Ala Arg Ala
1 5

<210> SEQ ID NO 157
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 157

Ser Leu Val Glu Glu Gln Ser Pro Ala
1 5

<210> SEQ ID NO 158
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 158

Ser Pro Val Glu Glu Gln Ser Pro Ala
1 5

<210> SEQ ID NO 159
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 159

Met Ala Phe Pro Glu Ala Pro Glu Ser Val
1 5 10

<210> SEQ ID NO 160
<211> LENGTH: 10

-continued

<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 160

Met Ala Ser Pro Glu Ala Pro Glu Ser Val
1 5 10

<210> SEQ ID NO 161
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 161

Ser Leu Val Arg Asp Val Phe Ser Ser Leu
1 5 10

<210> SEQ ID NO 162
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 162

Ser Leu Val Arg Asp Val Val Ser Ser Leu
1 5 10

<210> SEQ ID NO 163
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 163

Leu Ala Thr Glu Lys Ser Arg Trp Ser
1 5

<210> SEQ ID NO 164
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 164

Leu Ala Thr Val Lys Ser Arg Trp Ser
1 5

<210> SEQ ID NO 165
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 165

Tyr Leu Glu Pro Gly Pro Val Thr Ala
1 5

<210> SEQ ID NO 166
<211> LENGTH: 9
<212> TYPE: PRT

-continued

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 166

Ile Ile Gly Ala Gly Pro Ala Glu Val
1 5

<210> SEQ ID NO 167
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 167

His Leu Tyr Ala Ser Leu Ser Arg Val
1 5

<210> SEQ ID NO 168
<211> LENGTH: 57
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 168

cagctggagc tgatccagac gatagacaac atcgtgttcg tgcctgcaac tagtaag 57

<210> SEQ ID NO 169
<211> LENGTH: 57
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 169

aaagttttcg ctgtcttgct ctccattgtg ccgtgcacag tgacactttt tctccttt 57

<210> SEQ ID NO 170
<211> LENGTH: 57
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 170

aacaagagcg tgataattat aggagctggc ccagcagaag tggcagcagc tagacaa 57

<210> SEQ ID NO 171
<211> LENGTH: 57
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 171

gagatcgatg ctggactgct tagcataatc ttttttcctg cttttgcggt agaggat 57

<210> SEQ ID NO 172
<211> LENGTH: 63
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 172

gcgctggaag acctggctat gttttggtca gtgcccacag tgacagtctt ctacccttct 60

gat 63

<210> SEQ ID NO 173
<211> LENGTH: 57
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

-continued

<400> SEQUENCE: 173

cctgcagctc agacctgtct caacgagtat cacctgttcc tgcttctcac aggtgcc 57

<210> SEQ ID NO 174
<211> LENGTH: 57
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 174

gctgagggac cctccaaaat gataggtaac catctgtggg tatgtcggag tcgccat 57

<210> SEQ ID NO 175
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 175

actggcccta tttttaagct catgaatatc cagcaaaagc ttatgaaaac aaatctgaag 60

<210> SEQ ID NO 176
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 176

tttagcggaa aagattttgt gagcgcactc tgcatgtttc tcgagggatt caggctgcca 60

<210> SEQ ID NO 177
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 177

ctgcccagtc atgcgtgtct tttcccccaa actctggccg ctgaggagga gggcgaggtg 60

<210> SEQ ID NO 178
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 178

gatgtgccag aggagtttct ctataatctg cttacacgcg tctacggaga gccacaccgg 60

<210> SEQ ID NO 179
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 179

gctggattgc agcggcagct ggacaaatgc agcgcattcg taaatgagat cgaaaccata 60

<210> SEQ ID NO 180
<211> LENGTH: 60
<212> TYPE: DNA

-continued

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 180

atcctgccac tgctgcaact gtcttgcatt tctacctacg tgaatgaagt cgtggtcctc 60

<210> SEQ ID NO 181
<211> LENGTH: 42
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 181

tccgagatca gaccatacat tagcaagtgc tgggactatg cc 42

<210> SEQ ID NO 182
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 182

acagtggggg acattgtgct gctgcgagca ctgcccgtac ttcgagcaaa acacgtgaag 60

<210> SEQ ID NO 183
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 183

ggcacacggg acacacatct gtatgccagc ttgagccgcg cactccaaac acagtgctgc 60

<210> SEQ ID NO 184
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 184

caatgctccg gtatgatcat ggcccactgt atcctcgact tgttgggcag cagcgggccc 60

<210> SEQ ID NO 185
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 185

ccagaggacg cacaggcagt gatcgacgcc tacaccgaga taaacaagaa acattgctgg 60

<210> SEQ ID NO 186
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 186

gaatccctgg tcgagatcat cctggtagct gttccacatg tcgattacag ccttaggtgt 60

<210> SEQ ID NO 187
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 187

ggtgccgatg tcgaaaagct cgccaaccct ctcccttata cggaatcaag caaaaccgcg 60

-continued

<210> SEQ ID NO 188
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 188

ccacaggagc aaaaaatgtt gggcgaacaa ttgttcccgc tgattcaggc gatgcacccg 60

<210> SEQ ID NO 189
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 189

gtggtgacac acacctatct cgagccgggc cccgtgacag cccaggtagt tctgcaggcc 60

<210> SEQ ID NO 190
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 190

gcttgggatt tcgggagcgt gggtggcgtc ttcacatctg ttggcaaggc agtgcatcag 60

<210> SEQ ID NO 191
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 191

Cys Ala Ser Ser Gln Asp Leu Ser Gly Gly Val Tyr Tyr Gly Tyr Thr
1 5 10 15

Phe

<210> SEQ ID NO 192
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 192

Cys Ser Thr Leu Leu Ala Gly Gly Gly Asp Glu Gln Tyr Val
1 5 10

<210> SEQ ID NO 193
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 193

Cys Ala Ser Ser Pro Thr Gly Leu Gly Glu Thr Gln Tyr Phe
1 5 10

<210> SEQ ID NO 194
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 194

Cys Ser Ala Pro Pro Gly Pro Leu Ala His Thr Gln Tyr Phe
1 5 10

-continued

<210> SEQ ID NO 195
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 195

Cys Ala Ser Ser Phe Lys Gly Thr Gly Pro Asn Gln Pro Gln His Phe
1 5 10 15

<210> SEQ ID NO 196
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 196

Cys Ala Ser Ser Phe Gly Gly Pro Pro Asn Thr Gly Glu Leu Phe Phe
1 5 10 15

<210> SEQ ID NO 197
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 197

Cys Ala Ser Ser Ile Gly Pro Val Asn Thr Glu Ala Phe Phe
1 5 10

<210> SEQ ID NO 198
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 198

Cys Ala Ser Ser Val Ala Ala Ser Pro Ser Gly Asn Thr Ile Tyr Phe
1 5 10 15

<210> SEQ ID NO 199
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 199

Cys Ala Ser Ser Pro Tyr Arg Ala Gly Tyr Glu Gln Tyr Phe
1 5 10

<210> SEQ ID NO 200
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 200

Cys Ala Ser Ser Arg Thr Gly Ile Thr Asp Thr Gln Tyr Phe
1 5 10

<210> SEQ ID NO 201
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 201

Cys Ala Ser Ser Ile Ala Ser Gly Ile Tyr Glu Gln Tyr Phe
1 5 10

-continued

<210> SEQ ID NO 202
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 202

Cys Ala Ser Ser Ile Ser Ser Ser Glu Lys Leu Phe Phe
1 5 10

<210> SEQ ID NO 203
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 203

Cys Ala Ser Ser Leu Val Val Gly Leu Ala Leu Glu Gln Tyr Phe
1 5 10 15

<210> SEQ ID NO 204
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 204

Cys Ala Ser Ser Phe Trp Gly Leu Ser Thr Glu Ala Phe Phe
1 5 10

<210> SEQ ID NO 205
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 205

Cys Ala Ser Ser Ser Asp Leu Tyr Glu Gln Tyr Phe
1 5 10

<210> SEQ ID NO 206
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 206

Cys Ala Ser Ser Gln Glu Val Gly Ser Gly Asn Thr Ile Tyr Phe
1 5 10 15

<210> SEQ ID NO 207
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 207

Cys Ala Ser Ser Ser Ala Gly Gly Gly Gly Asn Thr Ile Tyr Phe
1 5 10 15

<210> SEQ ID NO 208
<211> LENGTH: 13
<212> TYPE: PRT

-continued

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 208

Cys Ala Ser Ser Ile Ala Gly Gly Tyr Glu Gln Tyr Val
1 5 10

<210> SEQ ID NO 209
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 209

Cys Ser Val Val Gly Gly Leu Leu Glu Ala Phe Phe
1 5 10

<210> SEQ ID NO 210
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 210

Cys Ala Ser Ser Ser Asp Trp Gly Leu Met Asn Thr Glu Ala Phe Phe
1 5 10 15

<210> SEQ ID NO 211
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 211

Cys Ala Ser Ser Ala Val Asp Arg Val Thr Ser Tyr Asn Glu Gln Phe
1 5 10 15

Phe

<210> SEQ ID NO 212
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 212

Cys Ala Ser Ser Leu Ile Ala Gly Asn Ser Asp Thr Gln Tyr Phe
1 5 10 15

<210> SEQ ID NO 213
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 213

Cys Ala Ser Arg Leu Thr Ala Gly Glu Tyr Gln Glu Thr Gln Tyr Phe
1 5 10 15

<210> SEQ ID NO 214
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 214

Cys Ala Ser Ser Leu Trp Asp Tyr Gly Tyr Thr Phe
1 5 10

-continued

<210> SEQ ID NO 215
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 215

Cys Ala Ser Ser Leu Trp Gly Val Gly Thr Glu Ala Phe Phe
1 5 10

<210> SEQ ID NO 216
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 216

Cys Ala Ser Ser Tyr Phe Gly Val Asn Ser Pro Leu His Phe
1 5 10

<210> SEQ ID NO 217
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 217

Cys Ala Thr Ser Ala Leu Ala Gly Gln Gly Arg Asp Glu Gln Phe Phe
1 5 10 15

<210> SEQ ID NO 218
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 218

Cys Ala Ser Ser Arg Leu Ala Gly Thr Asp Thr Gln Tyr Phe
1 5 10

<210> SEQ ID NO 219
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 219

Cys Ala Ser Ser Phe Pro Gly Tyr Gly Leu Asn Thr Glu Ala Phe Phe
1 5 10 15

<210> SEQ ID NO 220
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 220

Cys Ala Ser Ser Val Leu Ala Gly Gly Leu Asp Thr Gln Tyr Phe
1 5 10 15

<210> SEQ ID NO 221
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 221

Cys Ala Ser Ser Tyr Met Leu Gln Thr Phe Asn Thr Glu Ala Phe Phe
1 5 10 15

-continued

<210> SEQ ID NO 222
<211> LENGTH: 19
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 222

Cys Ala Ser Ser Pro Gly Leu Leu Ala Gly Gly Ser Ser Trp Glu Thr
1 5 10 15

Gln Tyr Phe

<210> SEQ ID NO 223
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 223

Cys Ala Ser Thr Ser Thr Pro Gly Gln Val Gly Gln Pro Gln His Phe
1 5 10 15

<210> SEQ ID NO 224
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 224

Cys Ala Ser Lys Gly Leu Ala Gly Ala Tyr Thr Asp Thr Gln Tyr Phe
1 5 10 15

<210> SEQ ID NO 225
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 225

Cys Ala Ser Ser Leu Gly Gly Asn Glu Gln Tyr Phe
1 5 10

<210> SEQ ID NO 226
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 226

Cys Ala Ser Ser Phe Thr Ala Gly Leu Asn Thr Glu Ala Phe Phe
1 5 10 15

<210> SEQ ID NO 227
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 227

Cys Ala Ser Ser Leu Val Trp Gly Leu Gly Thr Glu Ala Phe Phe
1 5 10 15

<210> SEQ ID NO 228
<211> LENGTH: 12
<212> TYPE: PRT

-continued

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 228

Cys Ala Ser Ser Leu Gly Leu Ser Gly Glu Ser Phe
1 5 10

<210> SEQ ID NO 229
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 229

Cys Ala Ser Ser Lys Leu Ala Gly Gly Leu Asp Thr Gln Tyr Phe
1 5 10 15

<210> SEQ ID NO 230
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 230

Cys Ala Ser Thr His Arg Thr Gly Leu Asn Thr Glu Ala Phe Phe
1 5 10 15

<210> SEQ ID NO 231
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 231

Cys Ala Ser Ser Ile Gly Gly Gln Glu Glu Thr Gln Tyr Phe
1 5 10

<210> SEQ ID NO 232
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 232

Cys Ala Ser Ser Leu Glu Ile Val Gly Glu Thr Glu Ala Phe Phe
1 5 10 15

<210> SEQ ID NO 233
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 233

Cys Ala Ser Ser Ile Ser Gly Gly Tyr Glu Gln Tyr Val
1 5 10

<210> SEQ ID NO 234
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 234

Cys Ser Ala Arg Thr Leu Ala Gly Phe Thr Asp Thr Gln Tyr Phe
1 5 10 15

<210> SEQ ID NO 235
<211> LENGTH: 13

-continued

<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 235

Cys Ala Ser Ser Asp Leu Leu Thr Gly Glu Leu Phe Phe
1 5 10

<210> SEQ ID NO 236
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 236

Cys Ala Ser Ser Ser Gly Leu Ala Gly Tyr Leu Met
1 5 10

<210> SEQ ID NO 237
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 237

Cys Ala Ser Ser His Arg Thr Thr Asp Glu Glu Thr Gln Tyr Phe
1 5 10 15

<210> SEQ ID NO 238
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 238

Cys Ala Ser Ser Tyr Pro Gly Tyr Gly Leu Asn Thr Glu Ala Phe Phe
1 5 10 15

<210> SEQ ID NO 239
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 239

Cys Ala Ser Ser Leu Asp Leu Tyr Glu Gln Tyr Phe
1 5 10

<210> SEQ ID NO 240
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 240

Cys Ala Ser Ser Trp Thr Gly Phe Gly Leu Asn Thr Glu Ala Phe Phe
1 5 10 15

<210> SEQ ID NO 241
<211> LENGTH: 15
<212> TYPE: PRT

-continued

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 241

Cys Ala Ser Ser Leu Ile Thr Gly Leu Ser Tyr Glu Gln Tyr Phe
1 5 10 15

<210> SEQ ID NO 242
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 242

Cys Ala Ser Ser Thr Trp Thr Gly Met Asn Thr Glu Ala Phe Phe
1 5 10 15

<210> SEQ ID NO 243
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 243

Cys Ala Ser Ser Glu Leu Trp Gly Ala Gly Asp Asn Glu Gln Phe Phe
1 5 10 15

<210> SEQ ID NO 244
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 244

Cys Ala Ser Ser Phe Ile Thr Gly Leu His Tyr Glu Gln Tyr Phe
1 5 10 15

<210> SEQ ID NO 245
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 245

Cys Ser Ala Gln Gln Gly Ile Gln Pro Gln His Phe
1 5 10

<210> SEQ ID NO 246
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 246

Cys Ala Ser Ser Leu Val Gly Gly Leu Ala Glu Thr Gln Tyr Phe
1 5 10 15

<210> SEQ ID NO 247
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 247

Cys Ala Ser Ser Phe Ser Gly Gly Leu Thr His Glu Gln Tyr Val
1 5 10 15

<210> SEQ ID NO 248
<211> LENGTH: 12

-continued

<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 248

Cys Ala Ser Ser Leu Gly Ala Gly Glu Gln Tyr Phe
1 5 10

<210> SEQ ID NO 249
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 249

Cys Ala Ser Ser Pro Ile Phe Gly Leu Thr Asn Glu Gln Tyr Phe
1 5 10 15

<210> SEQ ID NO 250
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 250

Cys Ala Ser Ser Tyr Phe Gly Gly Glu Gln Phe Phe
1 5 10

<210> SEQ ID NO 251
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 251

Cys Ala Ser Ser Gln Asp Trp Gly Leu Asn Tyr Glu Gln Tyr Phe
1 5 10 15

<210> SEQ ID NO 252
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 252

Cys Ala Ser Ser Thr Ser Gly Gly Tyr Glu Gln Tyr Phe
1 5 10

<210> SEQ ID NO 253
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 253

Cys Ala Ser Ser Arg Leu Ala Gly Gly Leu Asp Thr Gln Tyr Phe
1 5 10 15

<210> SEQ ID NO 254
<211> LENGTH: 13
<212> TYPE: PRT

-continued

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 254

Cys Ala Ser Ser Gly Leu Ile Thr Asp Thr Gln Tyr Phe
1 5 10

<210> SEQ ID NO 255
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 255

Cys Ser Ala Arg Glu Leu Ala Gly Phe Gln Glu Thr Gln Tyr Phe
1 5 10 15

<210> SEQ ID NO 256
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 256

Cys Ser Pro Ile Arg Gly Ile Glu Gln Tyr Val
1 5 10

<210> SEQ ID NO 257
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 257

Cys Ala Ile Gly Pro Gln Gly Gly Phe Tyr Glu Gln Tyr Phe
1 5 10

<210> SEQ ID NO 258
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 258

Cys Ala Thr Ser Ser Ala Ile Leu Ala Gly Val Lys Glu Thr Gln Tyr
1 5 10 15

Phe

<210> SEQ ID NO 259
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 259

Cys Ala Ser Ser Glu Gly Val Gly Leu Ala Phe Glu Gln Phe Phe
1 5 10 15

<210> SEQ ID NO 260
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 260

Cys Ala Ile Gly Leu Ala Gly Ala Tyr Glu Gln Tyr Phe
1 5 10

-continued

<210> SEQ ID NO 261
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 261

Cys Ala Ser Ser Ser Trp Thr Gly Leu Ser Leu Ser Phe Tyr Gly Tyr
1 5 10 15

Thr Phe

<210> SEQ ID NO 262
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 262

Cys Ala Ser Ser Glu Pro Gly Thr Val Glu Ala Phe Phe
1 5 10

<210> SEQ ID NO 263
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 263

Cys Ser Val Glu Glu Gly Ile Asp Glu Gln Tyr Phe
1 5 10

<210> SEQ ID NO 264
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 264

Cys Ala Ser Ser Leu Gly Ala Gly Glu Gln Phe Phe
1 5 10

<210> SEQ ID NO 265
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 265

Cys Ala Ser Ser Phe Gln Gly Gly Thr Gly Asn Thr Ile Tyr Phe
1 5 10 15

<210> SEQ ID NO 266
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 266

Cys Ala Ser Ser Leu Ala Leu Pro Tyr Glu Gln Tyr Phe
1 5 10

<210> SEQ ID NO 267
<211> LENGTH: 17
<212> TYPE: PRT

-continued

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 267

Cys Ala Ser Ser Pro Thr Gln Gly Leu Ala Ile Thr Gly Glu Leu Phe
1 5 10 15

Phe

<210> SEQ ID NO 268
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 268

Cys Ala Ser Ser Gln Thr His Pro Pro Gly Glu Leu Phe Phe
1 5 10

<210> SEQ ID NO 269
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 269

Cys Ala Ser Ser Ile Ser Ala Gly Tyr Glu Gln Tyr Val
1 5 10

<210> SEQ ID NO 270
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 270

Cys Ala Ser Ser Val Asp Gly Ala Tyr Asn Glu Gln Phe Phe
1 5 10

<210> SEQ ID NO 271
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 271

Cys Ala Phe Gly Val Asn Trp Asp Leu Pro His Ser Gly Asn Thr Ile
1 5 10 15

Tyr Phe

<210> SEQ ID NO 272
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 272

Cys Ala Ser Ser Phe Thr Trp Gly Leu Asn Thr Glu Ala Phe Phe
1 5 10 15

<210> SEQ ID NO 273
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 273

Cys Ala Ser Ser Tyr Phe Ser Tyr Glu Gln Tyr Phe
1 5 10

-continued

<210> SEQ ID NO 274
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 274

Cys Ala Ser Ser Ser Asp Arg Gly Leu Pro Ser Gly Asn Thr Ile Tyr
1 5 10 15

Phe

<210> SEQ ID NO 275
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 275

Cys Ser Ala His Glu Gly Leu Glu Gln Tyr Phe
1 5 10

<210> SEQ ID NO 276
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 276

Cys Ala Ser Ser Ala Ser Trp Thr Asp Tyr Tyr Gly Tyr Thr Phe
1 5 10 15

<210> SEQ ID NO 277
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 277

Cys Ala Ser Ser Thr Gly Thr Gly Ser Tyr Glu Gln Tyr Phe
1 5 10

<210> SEQ ID NO 278
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 278

Cys Ala Ser Ser Leu Trp Tyr Asn Gln Pro Gln His Phe
1 5 10

<210> SEQ ID NO 279
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 279

Cys Ala Ser Ser Pro Leu Ala Ala Pro Gly Ser Phe Glu Thr Gln Tyr
1 5 10 15

Phe

<210> SEQ ID NO 280
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

-continued

<400> SEQUENCE: 280

Cys Ala Ser Ser Val Asp Gly Asp Tyr Asn Glu Gln Phe Phe
1 5 10

<210> SEQ ID NO 281
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 281

Cys Ala Ser Ser Pro Thr Pro Ser Gly Leu Trp Trp Glu Leu Phe Phe
1 5 10 15

<210> SEQ ID NO 282
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 282

Cys Ala Ser Ser Thr Gly Thr Gly Leu Asn Thr Glu Ala Phe Phe
1 5 10 15

<210> SEQ ID NO 283
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 283

Cys Ala Thr Ser Ala Leu Pro Gly Gln Glu Thr Thr Asp Thr Gln Tyr
1 5 10 15

Phe

<210> SEQ ID NO 284
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 284

Cys Ala Ser Ser Leu Val Gly Gly Leu Ser Asn Gln Pro Gln His Phe
1 5 10 15

<210> SEQ ID NO 285
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 285

Cys Ala Ser Ser Gln Gln Ala Gly Gly Ile Thr Tyr Asn Glu Gln Phe
1 5 10 15

Phe

<210> SEQ ID NO 286
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 286

Cys Ala Ser Ser Tyr Ser Thr Ala Gly Gln Pro Gln His Phe
1 5 10

-continued

<210> SEQ ID NO 287
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 287

Cys Ala Ser Ser Pro Thr Gly Ala Gly Tyr Glu Gln Tyr Phe
1 5 10

<210> SEQ ID NO 288
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 288

Cys Ala Ser Ser Leu Leu Ser Gly Ser Thr Glu Ala Phe Phe
1 5 10

<210> SEQ ID NO 289
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 289

Cys Ala Ser Ser Tyr Gly Thr Ser Thr Asn Glu Gln Phe Phe
1 5 10

<210> SEQ ID NO 290
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 290

Cys Ala Ser Ser Gln Gly Asp Ser Gly Thr Asp Thr Gln Tyr Phe
1 5 10 15

<210> SEQ ID NO 291
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 291

Cys Ala Ser Ser Phe Ser Asn Gln Pro Gln His Phe
1 5 10

<210> SEQ ID NO 292
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 292

Cys Ala Ser Ser Gly Gly Gln Gly Thr Gln Pro Gln His Phe
1 5 10

<210> SEQ ID NO 293
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 293

Cys Ala Ser Ser Tyr Ser Gly Ala Gly Gln Pro Gln His Phe
1 5 10

-continued

<210> SEQ ID NO 294
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 294

Cys Ala Ser Ser Leu Leu Gln Gly Ala Glu Ser Pro Leu His Phe
1 5 10 15

<210> SEQ ID NO 295
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 295

Cys Ala Ser Ser Pro Gln Asp Arg Gly Pro Asn Tyr Gly Tyr Thr Phe
1 5 10 15

<210> SEQ ID NO 296
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 296

Cys Ala Ser Ser Phe Asp Tyr Ser Tyr Glu Gln Tyr Phe
1 5 10

<210> SEQ ID NO 297
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 297

Cys Ala Ala Gly Gly Val Asn Gln Pro Gln His Phe
1 5 10

<210> SEQ ID NO 298
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 298

Cys Ala Ser Ser Leu Leu Ala Gly Glu Leu Phe Phe
1 5 10

<210> SEQ ID NO 299
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 299

Cys Ala Ser Ser Pro Ser Ser Pro Tyr Glu Gln Tyr Phe
1 5 10

<210> SEQ ID NO 300
<211> LENGTH: 12
<212> TYPE: PRT

-continued

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 300

Cys Ala Ser Ser Glu Gly Thr Asp Thr Gln Tyr Phe
1 5 10

<210> SEQ ID NO 301
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 301

Cys Ala Ser Gly Ile Ser Asn Gln Pro Gln His Phe
1 5 10

<210> SEQ ID NO 302
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 302

Cys Ala Ser Ser Leu Asp Pro Pro Phe Asp Arg Gln Asn Tyr Gly Tyr
1 5 10 15

Thr Phe

<210> SEQ ID NO 303
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 303

Cys Ala Ser Ser Tyr Gly Asp Met Ala Tyr Asn Glu Gln Phe Phe
1 5 10 15

<210> SEQ ID NO 304
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 304

Cys Ala Thr Met Gly Thr Gly Gly Ser Leu Tyr Tyr Gly Tyr Thr Phe
1 5 10 15

<210> SEQ ID NO 305
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 305

Cys Ala Ser Ser Val Ser Asn Gln Pro Gln His Phe
1 5 10

<210> SEQ ID NO 306
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 306

Cys Ala Ser Ser Phe Thr Ser Gly Gly Tyr Asn Glu Gln Phe Phe
1 5 10 15

-continued

<210> SEQ ID NO 307
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 307

Cys Ala Ser Ser Leu Tyr Arg Ala Asn Thr Gly Glu Leu Phe Phe
1 5 10 15

<210> SEQ ID NO 308
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 308

Cys Ala Ser Ser Leu Thr Ser Leu Thr Asp Thr Gln Tyr Phe
1 5 10

<210> SEQ ID NO 309
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 309

Cys Ala Ser Ser Lys Ser Lys Gly Ser Pro Leu His Phe
1 5 10

<210> SEQ ID NO 310
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 310

Cys Ala Ser Ser Leu Ala Gly Gln Gly Pro Asn Ser Pro Leu His Phe
1 5 10 15

<210> SEQ ID NO 311
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 311

Cys Ala Ser Ser Pro Thr Gly Ala Gly Gln Pro Gln His Phe
1 5 10

<210> SEQ ID NO 312
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 312

Cys Ala Ser Ser Ser Gly Thr Ser Gly Ser Asp Thr Gln Tyr Phe
1 5 10 15

<210> SEQ ID NO 313
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 313

Cys Ala Ser Ser Phe Ser Gly Pro Arg Ser Pro Gln His Phe
1 5 10

-continued

<210> SEQ ID NO 314
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 314

Cys Ala Ser Asn Leu Gln Gly Leu Asp Tyr Glu Gln Tyr Phe
1 5 10

<210> SEQ ID NO 315
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 315

Cys Ala Ser Ser Leu Gly Gln Gly Asn Gln Pro Gln His Phe
1 5 10

<210> SEQ ID NO 316
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 316

Cys Ala Ser Ser Phe Trp Gly Ala Asn Glu Lys Leu Phe Phe
1 5 10

<210> SEQ ID NO 317
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 317

Cys Ala Ser Ser Tyr Ser Val Gly Val Asn Thr Glu Ala Phe Phe
1 5 10 15

<210> SEQ ID NO 318
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 318

Cys Ala Ser Arg Tyr Arg Ala Ala Pro Asn Gln Pro Gln His Phe
1 5 10 15

<210> SEQ ID NO 319
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 319

Cys Ala Ser Ser Gln Asp Ala Gly Gly Val Phe Gly Asn Thr Ile Tyr
1 5 10 15

Phe

<210> SEQ ID NO 320
<211> LENGTH: 13
<212> TYPE: PRT

-continued

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 320

Cys Ala Ser Ser Leu Tyr Ser Asn Gln Pro Gln His Phe
1 5 10

<210> SEQ ID NO 321
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 321

Cys Ala Thr Ala Pro Ile Asn Ser Pro Leu His Phe
1 5 10

<210> SEQ ID NO 322
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 322

Cys Ala Ser Ser Pro Pro Asn Gln Pro Gln His Phe
1 5 10

<210> SEQ ID NO 323
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 323

Cys Ala Ser Ser Phe Asn Asn Gln Pro Gln His Phe
1 5 10

<210> SEQ ID NO 324
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 324

Cys Ala Ser Gly Val Ser Asn Gln Pro Gln His Phe
1 5 10

<210> SEQ ID NO 325
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 325

Cys Ala Ser Ser Tyr Glu Ser Asn Tyr Gly Tyr Thr Phe
1 5 10

<210> SEQ ID NO 326
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 326

Cys Ala Ser Ser Leu Asp Val Ala Thr Asn Glu Lys Leu Phe Phe
1 5 10 15

<210> SEQ ID NO 327
<211> LENGTH: 13

-continued

<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 327

Cys Ser Asp Ser Ser Thr Gly Gly Ala Gly Phe Thr Phe
1 5 10

<210> SEQ ID NO 328
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 328

Cys Ala Ser Ser Glu Ser Gly Gly Gly Tyr Arg Trp Thr Glu Ala Phe
1 5 10 15

Phe

<210> SEQ ID NO 329
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 329

Cys Ala Ser Ser Glu Gly Pro Ser Gly Tyr Thr Phe
1 5 10

<210> SEQ ID NO 330
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 330

Cys Ala Ser Ser Pro Gly Leu Gly Glu Gln Tyr Phe
1 5 10

<210> SEQ ID NO 331
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 331

Cys Ala Ser Ser Leu Glu Gly Val Tyr Gly Tyr Thr Phe
1 5 10

<210> SEQ ID NO 332
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 332

Cys Ala Ser Thr Ile Gly Pro Gly Ile Thr Asp Thr Gln Tyr Phe
1 5 10 15

<210> SEQ ID NO 333
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 333

Cys Ala Ser Ser Pro Arg Asp Arg Gly Pro Arg Ser Pro Gln His Phe
1 5 10 15

-continued

<210> SEQ ID NO 334
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 334

Cys Ala Ser Ser Arg Thr Gly Ala Gly Glu Lys Leu Phe Phe
1 5 10

<210> SEQ ID NO 335
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 335

Cys Ala Ser Ser Leu Gly Ile Ala Gly Pro Tyr Asn Glu Gln Phe Phe
1 5 10 15

<210> SEQ ID NO 336
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 336

Cys Ala Gly Gly Leu Leu Asn Gln Pro Gln His Phe
1 5 10

<210> SEQ ID NO 337
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 337

Cys Ala Ser Ser Leu Gly Gln Gly Ala Gln Pro Gln His Phe
1 5 10

<210> SEQ ID NO 338
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 338

Cys Ala Ser Ser Pro Met Asn Thr Glu Ala Phe Phe
1 5 10

<210> SEQ ID NO 339
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 339

Cys Ala Ser Ser Leu Ser Ser His Gly Tyr Thr Phe
1 5 10

<210> SEQ ID NO 340
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 340

Cys Ala Ser Ser Phe Ala Thr Val Gly Glu Lys Leu Phe Phe
1 5 10

-continued

<210> SEQ ID NO 341
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 341

Cys Ala Ser Thr Leu Tyr Thr Gly Asp Asn Glu Gln Phe Phe
1 5 10

<210> SEQ ID NO 342
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 342

Cys Ala Ser Ser Tyr Ser Ala Gly Gly Tyr Tyr Gly Tyr Thr Phe
1 5 10 15

<210> SEQ ID NO 343
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 343

Cys Ala Ser Ser Tyr Gln Gln Gly Ser Gln Pro Gln His Phe
1 5 10

<210> SEQ ID NO 344
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 344

Cys Ala Ser Ser Pro Leu Asn Thr Glu Ala Phe Phe
1 5 10

<210> SEQ ID NO 345
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 345

Cys Ala Ser Ser Trp Ser Asn Gln Pro Gln His Phe
1 5 10

<210> SEQ ID NO 346
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 346

Cys Ala Ser Ser Pro Val Thr Gly Gly Asp Asn Ser Pro Leu His Phe
1 5 10 15

<210> SEQ ID NO 347
<211> LENGTH: 12
<212> TYPE: PRT

-continued

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 347

Cys Ala Ser Ser Ser Gly Asn Tyr Glu Gln Tyr Phe
1 5 10

<210> SEQ ID NO 348
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 348

Cys Ala Ser Ser Leu Gly Leu Ser Gly Ala Tyr Asn Glu Gln Phe Phe
1 5 10 15

<210> SEQ ID NO 349
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 349

Cys Ala Trp Ser Val Ala Ser Gly Asn Glu Gln Phe Phe
1 5 10

<210> SEQ ID NO 350
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 350

Cys Ala Ser Ser Trp Gly Gln Gly Gly Tyr Glu Gln Tyr Phe
1 5 10

<210> SEQ ID NO 351
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 351

Cys Ala Trp Ser Val Gly Val Ser Asn Gln Pro Gln His Phe
1 5 10

<210> SEQ ID NO 352
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 352

Cys Ala Ser Ser Leu Gly Gln Gly Gly Glu Leu Phe Phe
1 5 10

<210> SEQ ID NO 353
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 353

Cys Ala Ser Ser Leu Gly Asn Tyr Glu Gln Tyr Phe
1 5 10

<210> SEQ ID NO 354
<211> LENGTH: 15

-continued

<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 354

Cys Ala Trp Ser Ala Gly Thr Gly Gly Asn Glu Lys Leu Phe Phe
1 5 10 15

<210> SEQ ID NO 355
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 355

Cys Ala Trp Ser Val Ala Gly Gly His Glu Gln Tyr Phe
1 5 10

<210> SEQ ID NO 356
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 356

Cys Ala Ser Ser Leu Gly Gln Gly Tyr Glu Gln Tyr Phe
1 5 10

<210> SEQ ID NO 357
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 357

Cys Ala Ser Ser Phe Gly Gln Arg Glu Thr Glu Ala Phe Phe
1 5 10

<210> SEQ ID NO 358
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 358

Cys Ala Ser Ser Gln Gly Thr Gly Val Thr Glu Ala Phe Phe
1 5 10

<210> SEQ ID NO 359
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 359

Cys Ala Ser Ser Phe Gly Thr Gly Tyr Glu Gln Tyr Phe
1 5 10

<210> SEQ ID NO 360
<211> LENGTH: 12
<212> TYPE: PRT

-continued

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 360

Cys Ala Ser Ser Leu Asn Pro Asp Thr Gln Tyr Phe
1 5 10

<210> SEQ ID NO 361
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 361

Cys Ala Trp Ser Pro Gly Gln Gly Gly Thr Asn Glu Lys Leu Phe Phe
1 5 10 15

<210> SEQ ID NO 362
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 362

Cys Ala Trp Ser Ala Tyr Thr Gly Glu Leu Phe Phe
1 5 10

<210> SEQ ID NO 363
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 363

Cys Ala Trp Ser Val Gly Ala Gly Val Gly Glu Gln Tyr Phe
1 5 10

<210> SEQ ID NO 364
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 364

Cys Ala Trp Ser Gly Asp Arg Pro Leu Ala Phe Phe
1 5 10

<210> SEQ ID NO 365
<211> LENGTH: 19
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 365

Cys Ala Ser Ser Val Gly Leu Ser Glu Thr Thr Ala Leu Tyr Asn Glu
1 5 10 15

Gln Phe Phe

<210> SEQ ID NO 366
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 366

Cys Ala Ser Ser Leu Glu Val Val Gln Glu Thr Gln Tyr Phe
1 5 10

-continued

<210> SEQ ID NO 367
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 367

Cys Ser Ala Arg Asp Pro Ala Ser Trp Gly Glu Lys Leu Phe Phe
1 5 10 15

<210> SEQ ID NO 368
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 368

Cys Ala Ser Ser Val Ala Gly Leu Gln Gly Ala Glu Gln Tyr Phe
1 5 10 15

<210> SEQ ID NO 369
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 369

Cys Ala Ser Ser Tyr Glu Gln Gly Ser Tyr Glu Gln Tyr Phe
1 5 10

<210> SEQ ID NO 370
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 370

Cys Ala Ser Ser Phe Gly Pro Leu Gly Met Trp Ala Glu Ala Phe Phe
1 5 10 15

<210> SEQ ID NO 371
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 371

Cys Ala Ser Ser Tyr Leu Ser Val Gln Glu Thr Gln Tyr Phe
1 5 10

<210> SEQ ID NO 372
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 372

Cys Ala Ser Ser Leu Glu Thr Gly Tyr Gly Glu Gln Tyr Phe
1 5 10

<210> SEQ ID NO 373
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 373

Cys Ala Ser Ser Val Phe Gly Leu Ala Gly Ala Glu Gln Tyr Phe
1 5 10 15

-continued

<210> SEQ ID NO 374
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 374

Cys Ala Ser Ser Glu Phe Gly Gly Gly Ser Pro Asp Thr Gln Tyr Phe
1 5 10 15

<210> SEQ ID NO 375
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 375

Cys Ala Ser Ser Val Tyr Gly Gly Ala Glu Ala Phe Phe
1 5 10

<210> SEQ ID NO 376
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 376

Cys Ala Ser Ser Thr Tyr Gly Leu Ala Gly Glu Thr Gln Tyr Phe
1 5 10 15

<210> SEQ ID NO 377
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 377

Cys Ser Val Glu Asn Arg Val Ile Tyr Gly Tyr Thr Phe
1 5 10

<210> SEQ ID NO 378
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 378

Cys Ser Val Glu Asp Pro Thr Phe Tyr Gly Tyr Thr Phe
1 5 10

<210> SEQ ID NO 379
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 379

Cys Ala Ser Ser Leu Gly Ser Ser Gly Asn Thr Ile Tyr Phe
1 5 10

<210> SEQ ID NO 380
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 380

Cys Ser Val Glu Gly Gln Ile Ala Gly Lys Tyr Gly Tyr Thr Phe
1 5 10 15

-continued

<210> SEQ ID NO 381
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 381

Cys Ala Ser Ser Tyr Gly Thr Ser Gly Thr Glu Gln Phe Phe
1 5 10

<210> SEQ ID NO 382
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 382

Cys Ser Val Glu Asp Gly Ala Ala Lys Gln Ile Tyr Gly Tyr Thr Phe
1 5 10 15

<210> SEQ ID NO 383
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 383

Cys Ala Ser Ser Val Glu Tyr Ser Asn Gln Pro Gln His Phe
1 5 10

<210> SEQ ID NO 384
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 384

Cys Ser Val Glu Asp Arg Val Asn Tyr Gly Tyr Thr Phe
1 5 10

<210> SEQ ID NO 385
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 385

Cys Ala Ser Ser Gln Trp Ser Ser Thr Asn Glu Lys Leu Phe Phe
1 5 10 15

<210> SEQ ID NO 386
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 386

Cys Ala Arg Asn His Asp Arg Asp Arg Leu Tyr Glu Gln Tyr Phe
1 5 10 15

<210> SEQ ID NO 387
<211> LENGTH: 14
<212> TYPE: PRT

-continued

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 387

Cys Ala Ser Ser Ser Trp Gly Thr Ser Asp Glu Gln Tyr Phe
1 5 10

<210> SEQ ID NO 388
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 388

Leu Ser Ala Leu Thr Arg Cys Glu Lys
1 5

<210> SEQ ID NO 389
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 389

Leu Ser Ala Leu Thr Leu Cys Glu Lys
1 5

<210> SEQ ID NO 390
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 390

Leu Ser Ala Cys Asn Ser Pro Ser Lys
1 5

<210> SEQ ID NO 391
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 391

Leu Pro Ala Cys Asn Ser Pro Ser Lys
1 5

<210> SEQ ID NO 392
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 392

Lys Val Phe Glu His Val Gly Ser Arg
1 5

<210> SEQ ID NO 393
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 393

Lys Val Ser Glu His Val Gly Ser Arg
1 5

<210> SEQ ID NO 394
<211> LENGTH: 9

-continued

<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 394

Phe Ile Ser Asn Thr Val Phe Arg Lys
1 5

<210> SEQ ID NO 395
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 395

Phe Met Ser Asn Thr Val Phe Arg Lys
1 5

<210> SEQ ID NO 396
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 396

His Gln Cys Cys Ile Asp Asn Phe Lys
1 5

<210> SEQ ID NO 397
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 397

His Gln Cys Cys Ile Asp Asn Phe Lys
1 5

<210> SEQ ID NO 398
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 398

Ser Ser Ala Ala Gly Ser Phe Gly Tyr
1 5

<210> SEQ ID NO 399
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 399

Ser Ser Ala Ala Gly Ser Cys Gly Tyr
1 5

<210> SEQ ID NO 400
<211> LENGTH: 9
<212> TYPE: PRT

-continued

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 400

Lys Ile Tyr Arg Arg Gln Ile Phe Lys
1 5

<210> SEQ ID NO 401
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 401

Lys Ile Tyr Arg Arg Gln Val Phe Lys
1 5

<210> SEQ ID NO 402
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 402

Leu Leu Leu Leu Leu Cys Thr Ser Val
1 5

<210> SEQ ID NO 403
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 403

Leu Leu Leu Leu Leu Cys Thr Pro Val
1 5

<210> SEQ ID NO 404
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 404

Arg Leu Ile Gln Gly Phe Val Leu Leu
1 5

<210> SEQ ID NO 405
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 405

Arg Leu Ile Gln Asp Phe Val Leu Leu
1 5

<210> SEQ ID NO 406
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 406

Gln Leu Ile Val Ile Phe Ile Phe Val
1 5

<210> SEQ ID NO 407
<211> LENGTH: 9

-continued

<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 407

Gln Leu Ile Val Ile Phe Ile Leu Val
1 5

<210> SEQ ID NO 408
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 408

Ala Leu Ala Phe Ile Thr Phe Phe Leu
1 5

<210> SEQ ID NO 409
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 409

Ala Leu Ala Phe Ile Thr Ser Phe Leu
1 5

<210> SEQ ID NO 410
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 410

Leu Leu His Gly Phe Ser Phe Tyr Leu
1 5

<210> SEQ ID NO 411
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 411

Leu Leu His Gly Phe Ser Phe Tyr Leu
1 5

<210> SEQ ID NO 412
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 412

Thr Leu Phe Glu Asn Thr Pro Lys Ala
1 5

<210> SEQ ID NO 413
<211> LENGTH: 9
<212> TYPE: PRT

-continued

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 413

Ala Leu Phe Glu Asn Thr Pro Lys Ala
1 5

<210> SEQ ID NO 414
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 414

Lys Leu Asn Leu Val Cys Cys Glu Leu
1 5

<210> SEQ ID NO 415
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 415

Lys Leu Asn Pro Val Cys Cys Glu Leu
1 5

<210> SEQ ID NO 416
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 416

Tyr Leu Gly Met Glu Ser Phe Ile Val
1 5

<210> SEQ ID NO 417
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 417

His Leu Gly Met Glu Ser Phe Ile Val
1 5

<210> SEQ ID NO 418
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 418

Tyr Ile Leu Lys Tyr Ser Val Phe Leu
1 5

<210> SEQ ID NO 419
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 419

Tyr Ile Ser Lys Tyr Ser Val Phe Leu
1 5

<210> SEQ ID NO 420
<211> LENGTH: 9

-continued

<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 420

Val Leu Gln Glu Ala Thr Ile Cys Val
1 5

<210> SEQ ID NO 421
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 421

Val Leu Gln Glu Ala Thr Phe Cys Val
1 5

<210> SEQ ID NO 422
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 422

Gly Leu Tyr Asp Lys Ala Ile Cys Ile
1 5

<210> SEQ ID NO 423
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 423

Gly Leu Tyr Asp Lys Thr Ile Cys Ile
1 5

<210> SEQ ID NO 424
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 424

Tyr Leu Leu Lys Ile Gly Ser Gln Val
1 5

<210> SEQ ID NO 425
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 425

Tyr Leu Leu Lys Met Gly Ser Gln Val
1 5

<210> SEQ ID NO 426
<211> LENGTH: 9
<212> TYPE: PRT

-continued

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 426

Phe Leu Gly Glu Ala Trp Ala Gln Val
1 5

<210> SEQ ID NO 427
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 427

Ser Leu Gly Glu Ala Trp Ala Gln Val
1 5

<210> SEQ ID NO 428
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 428

Ser Leu Ser Ser Met Ala Cys Cys Ile
1 5

<210> SEQ ID NO 429
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 429

Ser Leu Ser Ser Met Ala Cys Cys Ile
1 5

<210> SEQ ID NO 430
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 430

Ser Leu Val Val Thr Leu Trp Pro Leu
1 5

<210> SEQ ID NO 431
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 431

Ser Leu Val Val Thr Leu Trp Leu Leu
1 5

<210> SEQ ID NO 432
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 432

Ser Met Trp Arg Phe Thr Phe Tyr Leu
1 5

<210> SEQ ID NO 433
<211> LENGTH: 9

-continued

<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 433

Ser Met Trp Arg Phe Ser Phe Tyr Leu
1 5

<210> SEQ ID NO 434
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 434

Cys Leu Leu Gln Leu Cys Pro Arg Leu
1 5

<210> SEQ ID NO 435
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 435

Arg Leu Leu Gln Leu Cys Pro Arg Leu
1 5

<210> SEQ ID NO 436
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 436

Ser Leu Leu Arg Ser Leu Glu Asn Val
1 5

<210> SEQ ID NO 437
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 437

Ser Leu Leu Arg Ser Pro Glu Asn Val
1 5

<210> SEQ ID NO 438
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 438

Phe Leu Ile Ser Ile Leu Tyr Ser Ala
1 5

<210> SEQ ID NO 439
<211> LENGTH: 9
<212> TYPE: PRT

-continued

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 439

Phe Leu Ile Ser Ile Pro Tyr Ser Ala
1 5

<210> SEQ ID NO 440
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 440

Tyr Leu Leu Arg Trp Ser Val Pro Leu
1 5

<210> SEQ ID NO 441
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 441

Tyr Leu Leu Lys Trp Ser Val Pro Leu
1 5

<210> SEQ ID NO 442
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 442

Met Leu Thr Thr Ala Ile Pro Lys Val
1 5

<210> SEQ ID NO 443
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 443

Met Leu Thr Thr Ala Ile Pro Lys Val
1 5

<210> SEQ ID NO 444
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 444

His Ile Leu Glu Ile Leu Trp Thr Leu
1 5

<210> SEQ ID NO 445
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 445

His Ile Leu Glu Ile Pro Trp Thr Leu
1 5

<210> SEQ ID NO 446
<211> LENGTH: 9

-continued

<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 446

Asn Met Phe Asp Ile Leu Val Gly Leu
1 5

<210> SEQ ID NO 447
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 447

Asn Val Phe Asp Ile Leu Val Gly Leu
1 5

<210> SEQ ID NO 448
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 448

Arg Met Trp Asp Phe Asp Ile Phe Leu
1 5

<210> SEQ ID NO 449
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 449

Gly Met Trp Asp Phe Asp Ile Phe Leu
1 5

<210> SEQ ID NO 450
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 450

Ile Met Ser Ser Ser Leu Phe Asn Leu
1 5

<210> SEQ ID NO 451
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 451

Ile Met Ser Pro Ser Leu Phe Asn Leu
1 5

<210> SEQ ID NO 452
<211> LENGTH: 9
<212> TYPE: PRT

-continued

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 452

Arg Leu Ser Asp Phe Ser Glu Gln Leu
1 5

<210> SEQ ID NO 453
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 453

Arg Leu Ser Asp Leu Ser Glu Gln Leu
1 5

<210> SEQ ID NO 454
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 454

Met Pro Lys Phe Lys Met Ser Ser Phe
1 5

<210> SEQ ID NO 455
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 455

Met Pro Lys Phe Lys Met Pro Ser Phe
1 5

<210> SEQ ID NO 456
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 456

Leu Pro Ser Met His Arg His Gln Ile
1 5

<210> SEQ ID NO 457
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 457

Leu Pro Ser Met Tyr Arg His Gln Ile
1 5

<210> SEQ ID NO 458
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 458

Leu Pro Arg Ala Lys Lys Leu Ile Leu
1 5

<210> SEQ ID NO 459
<211> LENGTH: 9

-continued

<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 459

Leu Pro Arg Ala Lys Glu Leu Ile Leu
1 5

<210> SEQ ID NO 460
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 460

Phe Ser Asn Tyr Arg Arg Ser Arg Leu
1 5

<210> SEQ ID NO 461
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 461

Phe Pro Asn Tyr Arg Arg Ser Arg Leu
1 5

<210> SEQ ID NO 462
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 462

Gln Leu Ile Leu Arg Thr Lys Ala Phe
1 5

<210> SEQ ID NO 463
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 463

Gln Pro Ile Leu Arg Thr Lys Ala Phe
1 5

<210> SEQ ID NO 464
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 464

Tyr Leu Lys Tyr His Cys Asn Ala Ser
1 5

<210> SEQ ID NO 465
<211> LENGTH: 9
<212> TYPE: PRT

-continued

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 465

Tyr Leu Lys Tyr His Tyr Asn Ala Ser
1 5

<210> SEQ ID NO 466
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 466

Ser Leu Arg Ser His His Tyr Ser Leu
1 5

<210> SEQ ID NO 467
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 467

Ser Leu Arg Ser His His Tyr Ser Pro
1 5

<210> SEQ ID NO 468
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 468

Phe Phe Ser Met His Phe Gln Ala Phe
1 5

<210> SEQ ID NO 469
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 469

Phe Phe Pro Met His Phe Gln Ala Phe
1 5

<210> SEQ ID NO 470
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 470

Leu Phe Arg Tyr Lys Ser Ile Ser Val
1 5

<210> SEQ ID NO 471
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 471

Leu Phe Arg Tyr Lys Ser Ile Pro Val
1 5

<210> SEQ ID NO 472
<211> LENGTH: 9

-continued

<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 472

Asn Leu Arg Tyr Phe Ala Lys Ser Leu
1 5

<210> SEQ ID NO 473
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 473

Asn Leu Arg Tyr Ser Ala Lys Ser Leu
1 5

<210> SEQ ID NO 474
<211> LENGTH: 12
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic dna

<400> SEQUENCE: 474

ctttgtgttt ga 12

1. A method of treating a cancer in a subject in need thereof, comprising:

providing a neoantigen peptide encoded in DNA of a tumor of the subject, wherein the neoantigen peptide consists of from 8 to 13 amino acids, binds in silico to an HLA class I molecule with an affinity of <500 nM and a stability>2 h and binds in vitro to an HLA class I molecule with an affinity of <4.7 log (IC50, nM);

transfecting at least one HLA class I positive cell with at least one tandem minigene construct comprising at least one sequence encoding the at least one neoantigen;

identifying a complex comprising the at least one HLA molecule and the at least ogre neoantigen peptide produced by the at least one HLA class I positive cell;

forming a vaccine comprising the at least one neoantigen; and

administering the vaccine to the subject, wherein at least one tumor cell of the cancer comprises at least one polypeptide comprising at least one amino acid substitution.

2. A method in accordance with claim **1**, wherein the at least one neoantigen peptide consists of 9 amino acids.

3. A method in accordance with claim **1**, wherein the at least one neoantigen binds in silico to an HLA class I molecule with an affinity of <250 nM.

4. A method in accordance with claim **1**, wherein the at least one neoantigen binds in vitro to an HLA class I molecule with an affinity of <3.8 log (IC50, nM).

5. A method in accordance with claim **1**, wherein the vaccine comprises at least seven neoantigen peptides.

6. A method in accordance with claim **1**, wherein the HLA class I molecule is selected from the group consisting of HLA-A*01:01, HLA-B*07:02, HLA-A*02:01, HLA-B*07:03, HLA-A*02:02, HLA-B*08:01, HLA-A*02:03, HLA-B*15:01, HLA-A*02:05, HLA-B*15:02, HLA-A*02:06, HLA-B*15:03, HLA-A*02:07, HLA-B*15:08, HLA-*03:01, HLA-B*15:12, HLA-A*11:01, HLA-B*15:16, HLA-A*11:02, HLA-B*15:18, HLA-A*24:02, HLA-B*27:03, HLA-A*29:01, HLA-B*27:05, HLA-A*29:02, HLA-B*27:08, HLA-A34:02, HLA-B*35:01, HLA-A*36:01, HLA-B*35:08, HLA-B*42:01, HLA-B*53:01, HLA-B*54:01, HLA-B*56:01, HLA-B*56:02, HLA-B*57:01, HLA-B*57:02, HLA-B*57:03, HLA-B*58:01, HLA-B*67:01 and HLA-B*81:01.

7. A method in accordance with claim **1**, wherein the HLA class I molecule is selected from the group consisting of an HLA-A*02:01 molecule, an HLA-A*11:01 molecule and an HLA-B*08:01 molecule.

8. A method in accordance with claim **1**, wherein the at least one HLA class I positive cell is at least one HLA class I positive melanoma cell.

9. A method in accordance with claim **1**, wherein the cancer is selected from the group consisting of skin cancer, lung cancer, bladder cancer, colorectal cancer, gastrointestinal cancer, esophageal cancer, gastric cancer, intestinal cancer, breast cancer, and a mismatch repair deficiency cancer.

10. A method in accordance with claim **1**, wherein the cancer is a melanoma.

11. A method in accordance with claim **1**, wherein the forming a vaccine comprises:

providing a culture comprising dendritic cells obtained from the subject; and

contacting the dendritic cells with the at least one neoantigen peptide, thereby forming dendritic cells comprising the at least one neoantigen peptide.

12. A method in accordance with claim **11**, further comprising:

administering to the subject the dendritic cells comprising the at least one neoantigen peptide;

obtaining a population of CD8+ T cells from a peripheral blood sample from the subject, wherein the CD8+ cells recognize the at least one neoantigen; and

expanding the population of CD8+ T cells that recognizes the neoantigen.

13. A method in accordance with claim **1**, wherein the identifying a complex comprises performing an assay selected from the group consisting of an LC/MS assay, a reverse phase HPLC assay and a combination thereof.

14. A method of treating a cancer in a subject in need thereof, comprising:

a) providing a sample of a tumor from a subject;

b) performing exome sequencing on the sample to identify one or more amino acid substitutions comprised by the tumor exome;

c) performing transcriptome sequencing on the sample to verify expression of the amino acid substitutions identified in b); and

d) selecting at least one candidate neoantigen peptide sequence from amongst the amino acid substitutions identified in c) according to the following criteria:

i) Exome VAF>10%;

ii) Transcription VAF>10%;

iii) Alternate reads>5;

iv) FPKM>1;

v) binds in silico to an HLA class I molecule with an affinity of <500 nM and a stability>2 h;

e) performing an in vitro HLA class I binding assay;

f) selecting at least one candidate neoantigen peptide sequence from amongst the amino acid substitutions identified in d) that bind HLA class one molecules with an affinity of <4.7 log (IC50, nM) in the assay performed in e)

g) transfecting at least one HLA class I positive cell with at least one tandem minigene construct comprising at least one sequence encoding the at least one neoantigen;

h) identifying a complex comprising the at least one HLA molecule and the at least one neoantigen peptide produced by the at least one HLA class I positive cell;

i) forming a vaccine comprising the at least one neoantigen; and

j) administering the vaccine to the subject, wherein at least one tumor cell of the cancer comprises at least one polypeptide comprising the one or more amino acid substitutions.

15. A method in accordance with claim **14**, wherein the in vitro HLA class I binding assay is selected from the group consisting of a T2 assay and a fluorescence polarization assay.

16. A method in accordance with claim **14**, wherein the forming a vaccine comprises:

providing a culture comprising dendritic cells obtained from the subject; and

contacting the dendritic cells with the at least one neoantigen peptide, thereby forming dendritic cells comprising the at least one neoantigen peptide.

17. A method in accordance with claim **16**, further comprising:

administering to the subject the dendritic cells comprising the at least one neoantigen peptide;

obtaining a population of CD8+ T cells from a peripheral blood sample from the subject, wherein the CD8+ T cells recognize the at least one neoantigen; and

expanding the population of CD8+ T cells that recognizes the neoantigen.

18. A method in accordance with claim **14**, wherein the identifying a complex comprising the at least one HLA molecule and the at least one neoantigen peptide comprises performing an assay selected from the group consisting of a LC/MS assay, a reverse phase HPLC assay and a combination thereof.

19. A method of treating a cancer in a subject in need thereof, comprising:

providing a neoantigen peptide encoded in DNA of a tumor of the subject, wherein the neoantigen peptide consists of from 8 to 13 amino acids, binds in silico to an HLA class I molecule with an affinity of <500 nM and a stability>2 h;

performing an in vitro HLA class I molecule binding assay to identify at least one neoantigen peptide which binds in vitro to an HLA class I molecule with an affinity of <4.7 log (IC50, nM);

transfecting at least one HLA class I positive cell with at least one tandem minigene construct comprising at least one sequence encoding the at least one neoantigen;

identifying a complex comprising the at least one HLA molecule and the at least one neoantigen peptide produced by the at least one HLA class I positive cell;

forming a vaccine comprising the at least one neoantigen; and

administering the vaccine to the subject, wherein at least one tumor cell of the cancer comprises at least one polypeptide comprising at least one amino acid substitution.

20. A method in accordance with claim **19**, wherein the in vitro HLA class I binding assay is selected from the group consisting of a T2 assay and a fluorescence polarization assay.

21. A method in accordance with claim **19**, wherein the identifying a complex comprising the at least one HLA molecule and the at least one neoantigen peptide comprises performing an assay selected from the group consisting of an LC/MS assay, a reverse phase HPLC assay and a combination thereof.

22. A method in accordance with claim **19**, wherein the forming a vaccine comprises:

providing a culture comprising dendritic cells obtained from the subject; and

contacting the dendritic cells with the at least one neoantigen peptide, thereby forming dendritic cells comprising the at least one neoantigen peptide.

23. A method in accordance with claim **22**, further comprising:

administering to the subject the dendritic cells comprising the at least one neoantigen peptide;

obtaining a population of CD8+ T cells from a peripheral blood sample from the subject, wherein the CD8+ cells recognize the at least one neoantigen; and

expanding the population of CD8+ T cells that recognizes the neoantigen.

* * * * *